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Cancer is a notorious affliction that knows no age, gender, ethnic, racial, or species bounds and is 
responsible for over 14% of annual worldwide human deaths. There is no universal cure and the 
treatments that exist have poor probabilities of success. Chemotherapy is often considered the 
staple for cancer treatment as it can enter areas of the body that are unsafe for surgery and can 
treat tumors that are too small to be detected, even with modern imaging techniques. However, 
chemotherapy can induce many harmful and fatal side-effects. It can also lose its therapeutic effect 
if the cancer mutates to become multi-drug resistant. These shortcomings can be linked to the poor 
selectivity and pharmacokinetics of conventional chemotherapy drugs. Modern research focusses on 
improving these aspects of existing chemotherapy regimens through the incorporation of drug 
delivery principles. This dissertation focusses on the development of a novel, polymeric, pH-
responsive drug delivery system for chemotherapy that incorporates the chemotherapeutic drug as 
well as a cell-penetrating peptide in a prodrug formulation. The system was designed to inhibit the 
release of its components into healthy tissues while selectively accumulating, through the enhanced 
permeability and retention effect, and releasing its payload, through reversible hydrolysis of imine 
bonds, within tumor tissues. Poly(L-lysine) was chosen as the cell-penetrating peptide since it is able 
to form imine bonds through its ε-amine functional groups on its residues. It was prepared by the 
primary amine-initiated ring-opening polymerization of Nε-(benzyloxycarbonyl)-L-lysine N-
carboxyanhydride at 0 °C and pressures lower than 1 mbar as these conditions allow for a 
controlled, living polymerization to occur. The benzyloxycarbonyl end-group was removed by 
acidolysis with HBr in a mixture of dichloromethane and 1,4-dioxane at 0 °C. The initiator used for 
the ring-opening polymerization was poly(N-vinylpyrrolidone) with a primary amine end-group, 
prepared by RAFT-mediated polymerization with O-ethyl-S-(phthalimidylmethyl)xanthate. This RAFT 
agent was shown to display slow pre-equilibrium kinetics which was linked to the lower relative 
stability of the phthalimidylmethyl radical compared to the poly(N-vinylpyrrolidone) propagating 
radical. The pre-equilibrium and main equilibrium kinetics of the RAFT polymerization were 
optimized by performing the polymerization in semi-batch mode. During the semi-batch 
polymerization, the monomer to RAFT agent ratio could be controlled by adjusting the monomer 
feed. This ratio was shown to be inversely proportional to the probability of radical transfer from the 
propagating radical to the phthalimidylmethyl radical. The phthalimide end-group could be 
converted to a primary amine both by reacting with hydrazine in methanol as well as reduction with 
sodium borohydride in water followed by hydrolysis in 1 M HCl at 60 °C. Doxorubicin and 




benzaldehyde could be conjugated, via imine bonds, to the poly(N-vinylpyrrolidone-block-L-lysine) 
copolymer spontaneously in methanol. Both types of conjugates would self-assemble into micelles 
when dispersed in water. However, the Doxorubicin conjugates were unstable, precipitating out of 
solution within 24 hours. The benzaldehyde conjugates were stable in water for over 24 hours. This 
suggested that a formulation of Doxorubicin and benzaldehyde conjugated to the block copolymer 


























Kanker is 'n berugte toestand wat geen ouderdom, geslag, etniese, ras- of spesiegrense ken nie en is 
verantwoordelik vir meer as 14% van die jaarlikse wêreldwye menslike sterftes. Daar is geen 
universele kuur vir hierdie siekte nie en die behandelings wat bestaan het swak waarskynlikhede van 
sukses. Chemoterapie is handig want dit behandel tumore waar operasies nie as veilig beskou word 
nie of as dit te klein is om te spoor, selfs met moderne beeldingstegnieke. Chemoterapie kan egter 
skadelike en dodelike newe-effekte tot gevolg hê. Dit kan ook die terapeutiese effek verloor as die 
kanker muteer en multi-middelweerstandig word. Hierdie tekortkominge kan gekoppel word aan die 
swak selektiwiteit en farmakokinetika van konvensionele chemoterapiemiddels. Moderne navorsing 
probeer om hierdie probleme op te los deur die inlywing van geneesmiddel-leweringsbeginsels. 
Hierdie proefskrif fokus op die ontwikkeling van 'n nuwe, polimeriese, pH-reaktiewe geneesmiddel-
leweringstelsel vir chemoterapie wat die chemoterapeutiese middel sowel as 'n sel-indringende 
peptied in 'n progeneesmiddel formulering inkorporeer. Die stelsel is ontwerp om die ophoping of 
vrystelling van die medikasie en die peptied in gesonde weefsel te inhibeer. Terselftertyd word die 
medikasie deur middel van gevorderde deurlatings en terughoudings in die tumor vrygestel deur 
omgekeerde hidrolise van die imienbindings. Poli (L-lisien) is gekies as die sel-indringerpeptied 
omdat dit imienbindings kan vorm deur middel van die ε-amien funksionele groep en ook omdat dit 
bioafbreekbaar is. Die reaksie is daargestel deur die primêre amien-geïnisieerde ring-
openingpolimerisasie van Nε-(bensieloksikarboniel)-L-lisien N-karboksianhidried. Die temperatuur is 
by 0 °C en die druk onder 1 mBar gehou aangesien hierdie omstandighede gekontroleerde lewende 
polimerisasie toelaat. Die bensieloksikarboniel eindgroep is verwyder deur middel van HBr in 'n 
mengsel van dichlorometaan en 1,4-dioksaan by 0 °C. Die inisieerder wat gebruik word vir die ring-
openingpolimerisasie is poli(N-vinielpirrolidoon) met 'n primêre amien eindgroep. Dit is berei deur 
RAFT-bemiddelde polimerisasie van N-vinielpirrolidoon met O-etiel-S-(ftalimidielmetiel)xantaat. 
Hierdie RAFT-agent het stadige voorewewig kinetika getoon as gevolg van die laer relatiewe 
stabiliteit van die ftalimidielmetielradikaal in vergelyking met die poli(N-vinielpirrolidoon) 
voortsettingsradikaal. Die voorewewig en hoofewewig kinetika van die RAFT-polimerisasie is 
geoptimaliseer deur die polimerisasie in ‘n semi-bondel manier uit te voer.  
 
Die monomeer / RAFT-agent verhouding kon deur die tempo van monomeertoevoeging beheer 
word. Hierdie verhouding is omgekeerd eweredig aan die waarskynlikheid van radikale oordrag van 




die voortsettingsradikaal aan die ftalimidielmetielradikaal. Die ftalimied eindgroep kon na 'n primêre 
amien omgeskakel word deur die reaksie met hidrasien in metanol sowel as deur die vermindering 
van natriumboorhidried in water, gevolg deur hidrolise met 1 M HCl by 60 °C. Doksorubisien en 
bensaldehied het spontaan imienbindings met poli-(N-vinielpirrolidoon-blok-L-lisien) kopolimeer in 
metanol gevorm. Altwee tipes konjugate sou self-omskakel in miselle wanneer hulle in water 
versprei word maar die doksorubisien konjugate was relatief onstabiel en het binne 24 uur 
neergeslaan in water. Die bensaldehied kojugaat was egter stabiel in water vir langer as 24 uur. Dit 
dui daarop dat ŉ oplossing van doksorubisien en bensaldehied gekonjugeer aan die blokkopolimeer 
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One of the cornerstones of civilization is the development of medicine to improve the average 
duration and quality of life. This is an endlessly changing and improving field of science as new 
diseases are emerging all the time.1 Also, there are still many known ailments that are either very 
difficult to cure or even untreatable with our current understanding. Cancer is one such disease that 
has notoriously plagued mankind physically and intellectually. It has been considered in the past as 
an incurable affliction2 due to the fact that it is, simply put, the patient’s own body turning against 
them. Formally, cancer is an unregulated growth of a group of genetically mutated cells within the 
patient. These cells usually cannot be recognized by the patient’s immune system and continue to 
grow until they overwhelm the body, causing death. This makes it very difficult to selectively treat 
the cancerous cells without affecting the patient. Another reason cancer is so difficult to treat is that 
symptoms often only emerge once the cancer has been well established.  
Unfortunately, cancer is not a rare affliction and was responsible for up to 14.6% of recent annual 
worldwide deaths.3-6 In developed countries, such as America, it is the second highest cause of 
death. Hence, there is a great demand for improvement in cancer treatment. 
 
1.2) Objectives 
The main objective of this research was to prepare a novel drug delivery system (DDS) that 
incorporates conventional chemotherapeutic compounds as well as a cell-penetrating peptide7-11 
(CPP) and transports them through the body, accumulating selectively within tumor tissues.12-14 
Doxorubicin was the model drug used in this study. A nano-sized block copolymer micelle with a size 
range of 10 – 150 nm is the basic architecture for the DDS. The hydrophobic core will be composed 
of poly(L-lysine) as this polypeptide has shown cell-penetrating properties7,8 and can bond to 
molecules containing aldehyde or ketone functional groups via reversible imine bonds. Doxorubicin 
is one such compound and will be used as the chemotherapeutic compound in this case. Imines 
were chosen as they are usually unstable under aqueous or acidic conditions,15 releasing the drugs 
and the cell penetrating peptide simultaneously, although they should be stable within the 
hydrophobic micelle core. The hydrophilic corona of the DDS was chosen to be composed of poly(N-




vinylpyrrolidone) (PVP) as this polymer offers excellent biocompatibility16-18 and has been researched 
extensively by our group.19-22 The PVP block will be prepared by a reversible addition-fragmentation 
chain transfer (RAFT) mediated radical polymerization.23 The RAFT agent used was chosen to allow 
for a primary amine to be incorporated into one of the polymer chain ends. In order to prepare the 
desired block copolymer, the amine-functionalized PVP will be used as a macroinitiator for the ring-
opening polymerization of Nε-(benzyloxycarbonyl)-L-lysine N-carbonxyanhydride.24-28 Subsequent 
deprotection of the lysine residues and incorporation of Doxorubicin should provide the desired 
DDS. 
The main aims of this research are: 
1) Determine if sufficiently stable micelles can be prepared by this route. The micelles need to 
have a very low critical micelle concentration (CMC) as they will be greatly diluted during 
blood circulation.29-31 They should also be stable under the physiological conditions of blood 
plasma for at least 24 hours. This translates to a necessity for a very slow hydrolysis rate of 
the imine linkages within the micelle core. If the polymer-drug conjugates are not 
sufficiently stable on their own then the addition of a cross-linker, modifier or a ternary 
stabilizing block will be investigated. 
2) Fine-tune the micelles to decompose readily under the physiological conditions of 
endosomes and lysosomes (pH ≈ 4 - 6).32,33 Tumor tissues also tend to be slightly acidic (pH ≈ 
6.5)34-36 and it would prove beneficial if the micelles could be optimized to be sufficiently 
stable in blood plasma but begin to decompose in tumor tissues. The drug could then be 
transported into the surrounding cells by the cell-penetrating peptide, provided a small 
fraction is still conjugated to it via the reversible imine bonds. 
3) Determine if the stability of Doxorubicin in neutral and slightly alkaline solutions is 
augmented when it is incorporated in the DDS. Doxorubicin is known to decompose 
increasingly rapidly in aqueous solutions with an increase in pH above 6.5.37 By incorporating 
the drug in a hydrophobic core of a micelle, this instability may be circumvented. 
4) Determine if there is a synergism occurring for the uptake of Doxorubicin and poly(L-lysine). 
Polycationic peptides are known to traverse through cell membranes by non-classical 
mechanisms.9,10,38 Poly(L-lysine) is one such peptide and since the imine linkages are 
reversible, some doxorubicin may still be conjugated to the peptide as it penetrates a tumor 
cell. This may improve the uptake of the drug within tumor tissues as well as the drug 
efficacy against multi-drug resistant cancer cells.    
 




1.3) Layout of Thesis 
1.3.1) Chapter 1: Prologue 
This chapter provides a description of the research proposal as well as the goals that the research is 
aiming to achieve. It also contains a breakdown of the thesis structure. 
 
1.3.2) Chapter 2: Literature Review 
This chapter contains the research topics that were reviewed and seen as beneficial or indicative 
towards the research focused on in this thesis. Each topic is discussed in a separate section although 
some sections inevitably deal with more than one of these topics. These are discussed in both 
sections with the emphasis being focused on the topic of the current section. The literature review 
avoids excessively covering the theory of the various analytical techniques applied as well as any 
fundamental mathematical or chemical background beyond what is unavoidable as the many 
existing textbooks already cover these topics sufficiently.  The topics covered in this review are on 
cancer, drug delivery, polymerization as well as controlled and living polymerization. 
 
1.3.3) Chapter 3: RAFT-Mediated Polymerization of N-vinylpyrrolidone with O-ethyl-S-
(phthalimidylmethyl)xanthate Performed in Batch-Mode  
This chapter covers the RAFT-mediated polymerization of NVP, why a protecting group is necessary 
to prepare an amine end-functional polymer by RAFT-mediated polymerization and describes some 
of the shortcomings of the RAFT agent used to incorporate this functional group. The most notable 
limitation of this RAFT agent was the slow pre-equilibrium kinetics that resulted in hybrid behavior 
occurring during the polymerization. 
 
1.3.4) Chapter 4: Designing a Semi-Batch RAFT-Mediated Polymerization of N-vinylpyrrolidone 
with O-ethyl-S-(phthalimidylmethyl)xanthate 
This chapter focusses on the slow pre-equilibrium kinetics of the RAFT agent used in this research 
and describes a method for overcoming this limitation as well as optimizing the control of the 
molecular weight and end-group functionality during the polymerization. 




1.3.5) Chapter 5: Deprotection of the Primary Amine α-End-Group on PVP 
This chapter focuses on the removal of the phthalimide protecting group from the PVP chain end by 
reacting it with hydrazine in methanol. It also discusses the incompatibility of the xanthate end-
group with strong nucleophiles and why this end-group needs to be removed or transformed before 
the deprotection can be carried out. It also covers a problem encountered when the simplest 
transformation is used that involves converting the xanthate to an alkene by thermolysis. 
 
1.3.6) Chapter 6: Hydrolysis of the Xanthate and Alkene End-Groups on PVP 
This chapter describes a kinetic analysis of the xanthate and alkene hydrolysis rates in D2O and 1 M 
DCl. It also investigates a novel method for removing the phthalimide end-group while 
simultaneously hydrolyzing and then reducing the xanthate end-group to an aldehyde and primary 
alcohol, respectively. 
 
1.3.7) Chapter 7: Preparation of Poly(N-vinylpyrrolidone)-block-poly(L-lysine) Copolymers by N-
Carboxyanhydride Ring-Opening Polymerization 
The preparation and ring-opening polymerization of Nε-(benzyloxycarbonyl)-L-lysine N-
Carboxyanhydride, using amine end-functional PVP as a macroinitiator is discussed in this chapter. 
The product was analyzed by cryo-TEM and DLS among the usual procedures to gauge the 
morphology that the block copolymer-conjugate would self-assemble into when dispersed in water. 
 
1.3.8) Chapter 8: Deprotecting the Nε-Amine of the Lysine Residues on PVP-block-poly(Nε-(CBZ)-L-
lys) 
This chapter covers the deprotection protocols investigated for the removal of the 
benzyloxycarbonyl (CBZ) protecting group. It also describes some of the pitfalls involved with the 








1.3.9) Chapter 9: Conjugation of Doxorubicin to PVP-block-poly(L-lysine) 
This chapter is a preliminary study of the preparation of PVP-block-poly(L-lysine)-Doxorubicin 
conjugates as well as their self-assembly and stability in water. It also investigates benzaldehyde as a 
possible modifier and proposes terephthalaldehyde as a possible cross-linker. 
1.3.10) Chapter 10: Epilogue 
A synopsis of the research is given, followed by some implications drawn from the research. This 
chapter concludes with the perceived future research that should be performed on this topic. 
 
1.3.11) Appendices 
This section contains all the derivations and calculations used during the research.   
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2.1) Cancer and Chemotherapy 
2.1.1) Overview of Cancer 
Cancer is the group of diseases that arise from unregulated cell growth. More specifically, when a 
cell becomes cancerous it begins to divide and grow uncontrollably. This forms new cancer cells, 
which eventually make up a cancerous tissue known as a tumor or malignant neoplasm. It is a 
disease that, if not treated rapidly, often has fatal consequences. To make matters worse, it can only 
be detected when a tumor mass reaches approximately 1 cm3 in volume. Cancer also often only 
produces notable symptoms late in its progression. This affliction is notoriously common (14% of 
worldwide deaths),1,2 has no age, ethnic, gender or racial bounds and can be as diverse as the 
individuals afflicted with it. 
The most crucial feature of a tumor is that it is malignant. This means that tumor cells can become 
detached from the tumor and enter the circulatory system where they can traverse throughout the 
body until they become lodged in another region, forming a new tumor. Benign tumors are not 
malignant hence are not considered cancerous but can still have negative effects to the body’s 
health3 and can become cancerous through tumor progression.4  
Many types of cancer exist - basically, any type of cell can become cancerous. The most common 
types of cancer encountered are different for men (lung and prostate cancer) and women (breast 
and cervical cancer.) The most common cancer-related fatalities are from lung, stomach, liver, colon 
and breast cancer.
1 
The causes of cancer are only partially understood and consist of complex as well as diverse 
mechanisms. The direct biochemical cause is a mutation of the proto-oncogenes of a cell that are 
responsible for stimulating cell division as well as the tumor suppressor genes. These genes regulate 
cell growth and division.5 There are five leading behavioral and dietary risks for developing cancer. 
These are high body mass index, low fruit and vegetable intake, lack of physical activity as well as 
tobacco and alcohol use. Of these, smoking has the highest risk factor.5,6 Exposure to carcinogens 
(compounds which have been linked to inducing cancer formation) as well as a genetic 
predisposition can also increase an individual’s risk of forming cancer. 




There are various methods of cancer treatment. They can be grouped into three main classes: 
• Physical resection of the afflicted tissue by surgery, transplantation, hyperthermia and 
cryotherapy. 
• Physically-stimulated necrosis of the afflicted tissue by radiation, ultrasound and laser 
therapy. 
• Chemically-stimulated necrosis of the cancerous cells by chemotherapy. 
The basis of this research is focused on chemotherapy and hence it will be the only treatment 
discussed in detail. More information on the other modes of treatment is available from Ko et al.5 as 
well as the World Health Organisation6 and National Cancer Institute7 websites. 
 
2.1.2) Concepts of Chemotherapy 
The main purpose of chemotherapy is to prevent cancerous cells from multiplying, invading, 
metastasizing and killing the patient. Since cancerous cells tend to multiply rapidly and 
uncontrollably, treating the patient with various cytotoxic or cytostatic agents usually results in a 
therapeutic effect. There are seven main classes of chemotherapeutic agents available these days.8,9  
These are: 
1. Alkylating agents 
2. Antimetabolites 
3. Anthracyclines 
4. Plant alkaloids 
5. Molecularly targeted agents, hormones and hormone antagonists  
6. Biologic response modifiers 
7. Miscellaneous agents 
Alkylating agents such as the nitrogen mustards, nitrosoureas and alkyl sulfonates react by adding an 
alkyl group to DNA residues. This inhibits DNA transcription and replication.8,9 Platinum-based 
chemotherapeutic drugs also damage DNA by forming stable coordination compounds with the 
residues.8,9 Antimetabolites like folic acid, pyrimidine and purine analogues mimic natural 
metabolites involved in DNA synthesis and either inhibit critical enzymes involved in nucleic acid 
synthesis or become incorporated into the nucleic acid sequence, which disrupts the genetic code 
and alters the gene’s function.8,9 Anthracyclines cause topoisomerase II-dependent DNA cleavage 




and intercalate with the DNA double helix. This also results in an inhibition of DNA transcription and 
replication.8,9 Many different plant alkaloids act as topoisomerase inhibitors though some also act as 
microtubule inhibitors or modulators.8,9 Targeting antitumor agents include enzymes, steroids and 
hormones, tyrosine kinase inhibitors and monoclonal antibodies. These affect certain metabolic 
pathways by interacting with specific cell receptors. The most common result is regulated or ceased 
cell proliferation.8,9 There are also other chemotherapeutic compounds with unclear modes of action 
that are grouped as miscellaneous compounds.  
Since rapid cell division is also an inherent process for many types of normal cells, chemotherapy is 
plagued by serious side-effects. They can range from relatively minor problems such as nausea, loss 
of hair and appetite, gastrointestinal distress, skin reactions and fatigue to more dangerous and 
even fatal adverse effects including depression of the immune system, vital organ failure and 
formation of secondary neoplasms.8,9 The side-effects usually arise from the toxicity of 
chemotherapy towards many vital cells, especially fast growing ones. This results in a 
characteristically narrow therapeutic window for chemotherapy that limits the achievable 
therapeutic effect and causes devastating collateral damage.8,9  
As the understanding of our body’s physiology on a molecular level expands, new methods of 
fighting cancer with chemotherapy have begun to emerge. These methods focus on stimulating or 
administering certain biological response modifiers, such as monoclonal antibodies and interferons8 
for immunotherapy, or changing the physiology of the tumor so that it is no longer self-sustainable, 
as is the case with antiangiogenic therapy. Gene therapy is being investigated as a method of 
reversing the mutation in the oncogenes or tumor suppressor genes.8,9 
However, even with this vast arsenal of chemotherapeutic agents, we still appear to be losing the 
war on cancer. Since the beginning of clinical chemotherapy, the average five-year survival rate for 
cancer patients has only increased by 5.7% in America.9 On the other hand, there has been an 
improvement in the number of successful treatments thanks to better diagnostic procedures 
resulting in more regular early detection and better tumor profiling.9 To understand this dilemma, 
both the virtues and pitfalls of chemotherapy need to be taken into account.  
To account for the benefits of chemotherapy, it is considered the first and last line of defense 
against malignant neoplasms. This is a result of the drugs being able to enter areas of the body that 
are unsafe for surgery as well as chemotherapy being able to treat metastatic cancer cells that are 
too small to be detected, even by state of the art diagnostic procedures. Chemotherapy is often 
administered as neoadjuvant therapy prior to surgery in order to shrink the tumor to a safe size for 




resection.10-14 This is especially important when the tumor is located in a vital organ such as the liver, 
kidneys or brain. It is also applied post-surgery to capture any remaining cancer cells that may have 
metastasized or have been dislodged during the operation.15,16 
Looking at the problems associated with chemotherapy, the most notable flaw is the less than 
adequate selectivity of the cytotoxic effects for aberrant cells. This results in a myriad of serious and 
potentially fatal side-effects. This, compounded with the low solubility issues for most 
chemotherapy compounds, usually limits the regimen to sub-optimal doses.8 As a tumor develops, 
heterogeneity forms among its cell populations. Most chemotherapy agents however only affect 
cells at a specific stage in their growth cycle. Many cells in larger tumors remain in the quiescent 
phase of the cell cycle because the poorly-developed vasculature in the tumor results in inadequate 
nutrient distribution throughout its tissues which permeates into formation of hypoxic, acidic and 
necrotic regions within the tumor.9 These cells are less responsive to cytotoxic and cytostatic 
compounds. The hypoxic as well as acidic environment (including other factors such as the 
chemotherapy regimen itself) where these cells are located also stimulates the expression of the 
multidrug resistance phenotype. Cancer cells which develop resistance to chemotherapy before 
initial treatments are said to have intrinsic drug resistance whereas cells that emerge with drug 
resistance after initial treatments are said to have acquired drug resistance. Intrinsic and acquired 
multidrug resistance is the highest obstacle for chemotherapy to overcome.17-23  
Multidrug resistance is a phenotype often displayed by some or all the cells in a neoplasm. This 
allows them to be much more resistant to chemotherapy than ordinary cells.4,24 A number of 
biochemical mechanisms are responsible for multidrug resistance. Changes in the cellular target of 
the respective drug by mutation will lower the binding efficiency of the drug and hence lower its 
therapeutic index. Alterations in enzymatic activation and detoxification mechanisms can increase 
the metabolism and clearance of a drug. Defective apoptotic pathways can prevent antigens or 
drugs from stimulating apoptosis. For example the mutation of the Fas gene as well as upregulation 
of Fas ligand secretion by tumors compromises immune responses.25,26 Membrane changes and 
expression of drug efflux pumps within them drastically increases drug clearance from the cell. Efflux 
pumps are the most notorious traits of the multidrug resistance phenotype. The most studied efflux 
pumps are P-glycoprotein,17,19,20,24 multiple resistance protein,18,21 and breast cancer resistance 
protein.22,23 These trans-membrane proteins belong to the ATP-binding cassette transporter family 
and actively expel chemotherapy drugs from the cytoplasm. Much effort is being focused on 
combinatorial chemotherapy, where compounds that inhibit the production or function of these 
efflux pumps are co-administered with the conventional cytotoxic compounds.17 




Another serious issue caused by the heterogeneity of a solid tumor is the poor accessibility of 
chemotherapy drugs to the hypoxic, acidic and necrotic regions within the tumor tissue.9 This is 
mainly due to the poorly developed vasculature of a tumor, which does not efficiently traverse its 
entire volume. The high osmotic pressure of the tissue (caused by an underdeveloped or non-
existent lymphatic system) as well as changes to the drug itself (such as protonation, hydrolysis or 
oxidation) caused by the harsh environment results in an insignificant amount of the drugs 
penetrating deep enough into the tumor to affect all the cancerous cells. 
From these observations, it is clear that traditional chemotherapy has many fundamental problems 
that would most likely not be solved by development of new chemotherapeutic compounds alone. 
Many of these issues are caused by the poor pharmacokinetics for the traditional drugs.  
 
2.1.3) Doxorubicin (Adriamycin) as a Chemotherapeutic Drug 
Doxorubicin is an anthracycline antibiotic prepared by semisynthesis from Daunomycin, which is 
extracted from the bacterium Streptomyces Peucetius. The molecular structure Doxorubicin is 
illustrated in Figure 2.1. 
 
Figure 2.1: A) Molecular Structure of Doxorubicin. B) Major Degradation Product at pH > 6.5. 
This compound has been used to treat many types of cancer including hematological malignancies, 
carcinomas and sarcomas.8 It unfortunately causes many side-effects including myelosuppression, 
diarrhea, nausea, vomiting, oral mucositis, oesophagitis, loss of hair, anaphylaxis, liver dysfunction 
and cardiomyopathy.8,27 According to Beijnen et al.28, it is usually formulated in acidic solutions as it 
decomposes increasingly fast as the pH is increased above 6.5. They also studied the temperature 
dependence of the degradation and revealed that Doxorubicin has a half-life over four and a half 
days at 37 °C and pH = 7.4. The major degradation product formed is depicted in Figure 2.1.B. 
Incorporation of the drug in an appropriate drug delivery system has aided in decreasing the 
observed side-effects and has allowed it to be administered in solutions at physiological pH = 7.4.29-31 




2.2) Drug Delivery 
2.2.1) Principles of Drug Delivery 
Drug design is a laborious (not to mention expensive) process involving target or disease 
identification, hit identification, hit optimization, lead selection and further optimization, candidate 
identification, and finally clinical trials of the candidate.32 In the past, new drugs were discovered by 
combinatorial chemistry. This involved screening tens of thousands of random compounds, though 
systematically different, to find a few hits (compounds that have a desired physiological effect on 
the target/disease.) After identification and optimization of their structure-activity relationships, 
even fewer candidates entered into clinical trials. During the clinical trials, many candidates that 
showed promising results in vitro could have completely different results in vivo. In the late 1980s, 
Prentis et al. determined that, based on data from seven UK-based pharmaceutical companies, 39% 
of candidate compounds in clinical trials were rejected due to poor pharmacokinetic properties in 
humans.32,33 On top of this, many of the other reasons for rejections were considered to be 
interrelated to the pharmacokinetics. Since the cost of clinical trials is far greater than that of the 
early developmental stages, new factors are now taken into account to determine the potential of a 
candidate. This new paradigm of drug discovery is known as rational design.34 With rational design, 
new drugs are not only synthesized based on knowledge of a biological target.  The 
pharmacokinetics, pharmacodynamics, toxicology and the compound’s metabolism are also taken 
into account as these play crucial roles in the final approval of a compound during clinical trials. 
Drug delivery deals mostly with the pharmacokinetics of a drug. This is the way a drug travels 
through the body and where it accumulates.32 In other words, it deals with the Absorption, 
Distribution, Metabolism and Elimination (ADME) of a drug. The focus is to optimize the transport of 
a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. 
There are two main types of drug delivery – site-specific targeting and controlled drug release. Site-
specific targeting aims to concentrate the drug in a specific region of the body while controlled drug 
release aims to control the concentration of the available drug in the body for a specific amount of 
time. 
There are several techniques that are very popular for optimizing drug delivery: 
• Formulations 
• Administration method 
• Prodrugs 
• Receptor-mediated targeting 




Often, several or all of these techniques are employed simultaneously when optimizing the 
pharmacokinetics of certain drugs. Recently, nanotechnology has imposed a great influence on the 
design of novel promising formulations for drug delivery.35 
 
2.2.2) Nanotechnology in Drug Delivery 
Nanotechnology is not bound to one strict, formal definition but the general idea remains the same. 
Simply stated, the concept of nanotechnology is the exploitation of materials with structural 
features at the intermediate range between the molecular and the macroscopic scale i.e. that at 
least one of the dimensions are in the nanometer length scale.36,37 Nanomaterials differ from bulk 
systems by their surface-related properties as well as their quantum properties.38 
The surface properties of nanomaterials are different because of the fact that their surface-to-
volume ratios are generally larger than for larger objects of similar dimensions. For instance, the 
surface area to volume ratio for a cube is: 
cd = 6 × hihj = 6h 
Where 
S = Surface area of the cube 
V = Volume of the cube 
L = length of each of the sides of the cube 
This simple equation indicates that as the length of the sides of the cube decrease, the surface to 
volume ratio will increase. On the other hand, any shape can be approximated by a linear 
combination of different-sized cubes. The total surface area and volume of the shape can then also 
be formulated as such a linear combination. Corrections made to take into account the fraction of 
the area of each cube that is exposed can be made by multiplying S for each cube by an appropriate 
coefficient. This also affects the dependence of each cube’s surface to volume ratio. Thus the surface 
to volume ratio depends inversely on the cube dimensions as well as the sum of the coefficients.  
The atoms or molecules at the surface of a material can display different properties than those 
within the bulk due to a reduced coordination number.35 This usually has an effect on the physical 
behavior of those atoms/molecules as well as their chemical properties. 




Atoms/molecules at the surface of a nanoparticle tend to display liquid-like characteristics that can 
affect its glass transition temperature, melting point and other phase transitions as well as its 
solubility. The nucleation and growth of particles is also governed by the thermodynamics at their 
surface, most notably their surface (or interfacial) energy.  Many chemical properties of a 
nanomaterial display a transition from that of the bulk material towards quantum mechanical 
behavior due to the electrons in a nanosystem being confined to dimensions within the order of 
molecules. This causes the material’s electronic structure to be more discrete, which can affect its 
electrical conductivity, magnetic and optical properties. 
The various physiological barriers within the body portray an additional property of nanomaterials: 
the selective permeation of nanomaterials of a certain size and/or composition through them.35 
Further discussion of this phenomenon can be found in Section 2.2.6. 
The ability to fine-tune a material’s physicochemical properties through nanotechnology as well as 
the evolution of unique phenomena for nanomaterials and nanoarchitectures is an intensely 
researched field in modern medicine. Such innovations include selective distribution through certain 
biochemical barriers,39 unique light absorption and scattering characteristics40 as well as 
superparamagnetism.41 These innovations have been implemented in drug delivery,9,32,35,42 gene 
therapy,43 tissue and bone engineering44,45  as well as in imaging techniques such as computed 
tomography46 and magnetic resonance imaging.41 
 
2.2.3) Stimuli-Responsive Polymers in Drug Delivery 
Synthetic polymers that can mimic the behavior of certain biopolymers towards various 
environmental stimuli are beyond fascination and offer a broad potential spectrum of applications in 
the biomedical and industrial fields. Plenty of research has been focused on developing such stimuli-
responsive polymers and applications of these materials is seen in tissue engineering,47 hydrophobic 
interaction chromatography,48 size exclusion chromatography,49 affinity chromatography,50 ion 
exchange chromatography,51 smart membranes,52-55 lithography,56 molecular imprinting57  and drug 
delivery.47,58-61  
Stimuli-responsive polymers are defined as polymers that undergo relatively large and abrupt, 
physical or chemical changes in response to small external changes in the environmental 
conditions.62 Stimuli-responsive polymers can be arranged into two major groups according to the 
stimulus that causes their reaction. Both physical and chemical stimuli-responsive materials exist. 
Physical stimuli include temperature, light, electric and/or magnetic fields as well as mechanical 




stress. Chemical stimuli include pH, ionic factors as well as chemical agents. The various structures 
that are of particular interest to construct from stimuli-responsive polymers are cross-linked and 
reversible hydrogels, micelles, modified surfaces and membranes as well as conjugated polymer 
solutions.62 Stimuli-responsive hydrogels have been applied in sustained drug release.63,64 
Amphiphilic copolymers with one or more stimuli-responsive polymer blocks have been used to 
prepare stimuli-responsive micelles58-62,65,66  or polymersomes60,67 for site-specific drug delivery. 
Nanoparticles and bioconjugates containing stimuli-responsive polymers have also been investigated 
for various drug delivery applications.65,68 
Due to the ability to control and optimize the pharmacokinetics of drugs through the incorporation 
of stimuli-responsive polymers in the design of drug delivery systems, they are among the most 
intensively researched topics in current cancer research and development.58,65,69-71 The fundamental 
idea behind stimuli-responsive drug delivery systems is to encapsulate the drug and prevent it from 
interacting with the physiological environment until the appropriate stimulus is applied. The sudden 
or sustained release of the drug is then initiated. This methodology is closely related to that 
surrounding prodrug design, vide infra. 
Poly-L-histidine and chitosan are two pH-responsive cationic polymers that are useful as 
components for drug delivery systems since they undergo their transition from neutral to cationic 
when the pH drops below that of blood plasma.66,72,73 
 
2.2.4) Prodrugs  
Prodrugs are drugs that are biologically inactive while in the initial form that they are administered 
in. They are converted into their active state within the body only once they have reached a specific 
region such as an organ, tissue, cell or organelle. There are two main types of prodrugs:74 
• Bioprecursor Prodrugs 
• Carrier Prodrugs 
A bioprecursor prodrug enters a metabolic pathway to release the active form of the drug, 
sometimes releasing a small metabolite along with it. A carrier prodrug is a molecule/aggregate that 
incorporates the drug through a labile linker. Various linkers have been developed that can be 
cleaved either by enzymatic reactions or specific physiological conditions.32,35,74,75 




The main difference between the two types of prodrugs is that carrier prodrugs are generally larger 
than the free drug or bioprecursor prodrug and may not necessarily target a metabolic pathway for 
release of the drug. 
The major benefits of employing a prodrug over a free drug include improvement in the absorption 
and transport of the drug through cell membranes and other physiological barriers, improving 
patient compliance, inducing site-specific release or sustained release and minimizing the drug’s side 
effects.32 
 
2.2.5) Polymeric Prodrugs 
In 1975, Helmut Ringsdorf proposed a novel class of carrier prodrugs based on using synthetic 
polymers as the carrier molecule.76,77 In the general model, the polymer is functionalized with three 
types of functional groups attached to the polymer backbone.  
The first type is a solubilizing group, which allows for modification of the pharmacokinetics of the 
conjugate. These are usually functional groups on the repeating units of the polymer. In the case of a 
copolymer, there may be more than one type of solubilizing group. Block copolymers with different 
solubility properties can be designed to self-assemble into polymeric micelles or vesicles in aqueous 
solution. They usually exhibit much lower critical micelle concentrations and greater stability than 
small molecule surfactant micelles or vesicles.32 They can also incorporate the ability to be cross-
linked, which increases their stability even more. 
The second is the conjugated drug. The drug is usually attached to the polymer chain by a cleavable 
linker. Modern polymeric prodrugs also consider physical interactions, such as hydrophobic or 
electrostatic interactions, and coordination chemistry for incorporating the drug.32,43,78 The linkers 
are often categorized by their cleavage mechanism. For instance, enzymatically cleavable linkers are 
substrates, such as oligopeptides, for certain metabolic enzymes. The oligopeptide glycine-
phenylalanine-leucine-glycine (GFLG) is the most common one employed.32 Some esters, α-
acyloxyalkyl esters, alkoxycarbonyloxyalkyl esters, carbonates and carbamates can also be substrates 
for certain esterase enzymes.32 Other linkers are reduced by certain enzyme-coenzyme systems. The 
most common is the reduction of disulfides by the glutathione-glutathione reductase system.79 
Other linkers have been designed to decompose when exposed to a specific physical stimulus. 
Linkers sensitive to stimuli such as temperature,67,69,70 light,80 and pH9,32,70,81 have been developed. 
Temperature and pH-responsive linkers are among the most researched. Thermoresponsive 
polymers have been used to prepare reversible amphiphilic block copolymers that can self-assemble 




into micelles or vesicles in an aqueous environment. Drugs can be loaded into a micelle core or 
encapsulated within a vesicle. When local hyperthermia or hypothermia is induced in a patient 
receiving the treatment, the drug delivery system will disintegrate at that site resulting in site-
specific drug administration.70 pH-responsive linkers are stable at a certain pH range but are readily 
hydrolyzed when there is either a significant increase or decrease in the pH. Some examples of these 
type of linkers include imine, hydrazone, acyl hydrazone, ketal, acetal, cis-aconityl, and trityl bonds.9 
There has been significant research on developing an acid-labile linker that reversibly binds an amine 
to a substrate.32,82 However, very few practical applications of this type have been achieved since the 
linkages tend to be too unstable towards hydrolysis.32 Imines, oxazolidines and thiazolidines seem to 
be the only viable linkers of this type and of these, only imines require just an amine and an 
aldehyde/ketone for the drug-linker conjugation. Imine stability under physiological conditions is 
improved when the nitrogen-carbon double bond is conjugated to an aromatic, lipophilic carbonyl 
compound because the pKa of the protonated imine is lowered.32,83 Various types of linkers have 
been developed that can bind to many different types of functional groups. The most common 
functional groups targeted for binding are amines, thiols, carboxylic acids, alcohols, aldehydes or 
ketones, alkenes and alkynes. 
The final component of the Ringsdorf model is a targeting moiety, which helps to improve the 
selective localization of the prodrug to a specific region within the body. All kinds of compounds 
have been used for this purpose. Substrates for certain cell surface receptors such as fatty acids, 
glycans, peptides, antibodies, vitamins and various antigens have all been used as targeting ligands 
in drug delivery systems for chemotherapy.8,9 The selectivity of these ligands depends on the 
selectivity of their binding to a specific receptor as well as the distribution of the receptor 
throughout the different cells of the body. Targeting can also be a passive process such as the 
enhanced permeability and retention effect (EPR) that results in localization of molecules and 
aggregates of a specific size from the bloodstream into the tissue of a solid tumor.9 This occurs due 
to a poorly developed basement membrane and lymphatic system within tumor tissue resulting in 
particles with a diameter 10 – 150 nm passing through the leaky vasculature and accumulating due 
to the absence of a functional lymphatic system. They would not do so in healthy blood vessels. 
 
2.2.6) Targeted Drug Delivery 
The poor selectivity of conventional chemotherapy drugs for tumor tissues is the cause for most of 
the serious side effects of chemotherapy and is also a limiting factor in the therapeutic effect of the 




regimen due to the constraints of sub-optimal dosage being necessary for safety. This makes 
improving a drug’s selectivity for tumor tissues an intensively investigated topic in cancer research. 
Over one hundred years ago, Dr. Paul Ehrlich, the father of chemotherapy, conceptualized a therapy 
for infectious diseases whereby the treatment would affect the afflicted areas only and leave healthy 
tissues alone. This idea was termed the magic bullet concept.84 A hundred years later, Dr. Ehrlich’s 
dream is becoming a reality through the development of targeted drug delivery. Targeted drug 
delivery involves optimization of a drug delivery system’s pharmacokinetics and pharmacodynamics 
in order to achieve selective accumulation and release of the drug at a specific site within a 
body.8,9,32,35 There are two main methods of targeting tumor tissues. 
The first method is known as passive targeting and is caused by the enhanced permeability and 
retention effect (EPR.)8,9,39 This phenomenon is defined as the selective accumulation of 
macromolecules, with a mass of 40 to 800 kDa, within tumor tissues. The cause of EPR is the poorly 
formed vasculature of tumor tissues that can have pore sizes in the range of 100 – 1200 nm.9 
Nanoparticles with a diameter smaller than these pores while larger than the pore diameters of 
normal vascular tight junctions (usually 2 nm)9 can permeate into the tumor tissue whereas the tight 
junctions of normal vasculature prevent this. The lack of a well-developed lymphatic system or even 
its entire absence within tumor tissues also prevents the clearance of the accumulated 
macromolecules. Thus the incorporation of chemotherapy drugs into nanoscale drug delivery 
systems allows for an inherently more selective therapy. The EPR effect seems to only be sensitive to 
the size of the drug delivery system rather than the composition and all types of materials have been 
exploited for delivering therapeutics or imaging agents. EPR arises in most types of tumors though it 
may be less expressed for heterogeneous tumors. In larger tumors, the vascular network does not 
cover the entire tissue resulting in hypoxic, acidic and necrotic regions forming. The chemotherapy 
drugs and their associated drug delivery systems have difficulty reaching those regions.9,85 In order 
to augment the EPR effect in hypovascular regions, angiotensin II has been used to induce 
hypertension during the infusion process.86-88 Nitric oxide releasing agents, which act as vasodilators, 
have also been used to augment EPR.89,90 The role of nitric oxide as a tumor suppressor has also 
been demonstrated.91,92 Other vascular modulators such as angiotensin II-converting 
enzyme/bradykinin inhibitors,93 prostaglandin I2 agonists94 and carbon monoxide95 have been 
investigated for EPR augmentation.  
Another obstacle that has been encountered for the EPR effect is the polyethylene glycol (PEG) 
dilemma.9,96 The improved circulation time and EPR of PEGylated macromolecular drug delivery 
systems has been shown to be counteracted by the poor cellular uptake and endosomal escape due 




to the polar, hydrated PEG layer impeding contact of the PEGylated particle to the cell surface 
receptors. In addition to this, it has been demonstrated that certain PEG-specific IgM antibodies are 
formed after several administrations of a PEGylated particle into a rat. These antibodies cause the 
rapid elimination of the particle from the blood by the formation of an IgM antibody complex that is 
cleared by the liver or macrophages.97 A new method to increase the plasma half-life of small drugs, 
peptides or imaging agents with a size below the renal clearance threshold involves conjugating the 
compounds to serum albumin or Immunoglobulin G (or analogues that retain the FcRn-binding 
affinity at endosomal pH). Such fused compounds have shown superior circulation times due to 
FcRn-mediated recycling while still benefiting from the EPR effect.98-102  
The second method of targeting tumors is known as active targeting. This involves the incorporation 
of rationally designed targeting ligands to a drug or drug delivery system. The targeting ligands bind 
with a certain selectivity and affinity to a specific target. The target may be a cell surface receptor, 
tumor endothelial cell surface receptor or a specific extracellular matrix. The ligands can be 
proteins,103-106 peptides,107-112 glycopeptides,113 peptidomimetics,114 small molecules115 or nucleic acid 
aptamers.116,117 Humanized and chimeric monoclonal antibodies are among the most promising of 
these candidates and have also been shown to induce chemotherapeutic effects.9,93,103 The use of 
antibodies in antibody-directed enzyme prodrug therapy is an indirect method to actively target 
tumor tissues.9 The procedure involves administration of an exogenous enzyme conjugated to a 
monoclonal antibody targeting ligand. It is allowed to accumulate into the tumor tissue by both 
passive and active targeting before a chemotherapy prodrug, with an enzymatic activation specific to 
that enzyme, is administered. 
The major benefit of incorporating an active-targeting motif to a drug delivery system is that, in 
addition to improving the selectivity of the drug, the targeting ligands can act as agonists or 
antagonists in a certain biochemical process. Cytokines and monoclonal antibodies have been 
discovered and designed that can directly induce apoptosis or rally an immune response such as 
phagocytosis, complement dependent cytotoxicity or antibody-dependent cellular cytotoxicity.103,104 
Growth factor receptor ligands, such as those that target EGFR and VEGFR, can also act as 
antagonists providing a cytostatic action.105,118 The targeting ligands can initiate active assimilation of 
the drug delivery systems into the target cells. For instance, certain arginine-glycine-aspartic acid 
(RGD) peptides have been shown to induce integrin-mediated endocytosis.111,112 
There are limitations in developing targeting ligands for chemotherapy. To date, there are no distinct 
receptors on a cancer cell’s surface that are exclusive to it. Hence there is always some inherent 
affinity of the targeting ligands for normal cells. It is only through targeting receptors that are 




overexpressed or mutated at crucial sites in the primary structure that a higher affinity for cancer 
cells can be achieved.9 The targeting ligands will have an induced toxicity if they can induce a toxic 
reaction or stimulate endocytosis. Genetic polymorphisms and mutations of a tumor cell receptor 
can also cause a reduced affinity of a specific targeting ligand in individual patients compared with 
results from clinical trials.119 If the targeting ligand is composed of biological subunits, then it may be 
susceptible towards metabolic degradation and may need chemical modification to increase its 
lifetime within the body. Incorporation of smaller targeting ligands into an appropriate drug delivery 
system is often also necessary to improve their pharmacokinetics. 
  
2.2.7) Cell-penetrating Peptides and Drug Delivery 
Polycationic polymers have been used as non-viral gene transvectors due to their affinity for DNA 
and RNA.35,43,120 Certain cationic amphipathic polypeptides have also shown antimicrobial 
capability.121,122 The cell-penetrating peptides (CPPs) such as trans-activating transcriptional activator 
(Tat)123 and  penetratin are also polycationic peptides and their non-classical cell-penetrating ability 
usually depends on their degree of cationic residue functionalization as well as the basicity of the 
residue’s conjugate base.124 For instance, increasing the number of arginine residues on a CPP 
improves the cell-penetrating ability of the peptide more than adding lysine residues,125 which in 
turn have a greater effect than adding histidine residues.9,126 The multidentate and pi interaction of 
arginine residues with the cell membrane also plays a role. The addition of hydrophobic and 
aromatic residues can further improve the cell-penetrating ability of the peptide.126 Tyrosine and 
tryptophan have shown the highest synergistic potential for increasing the cell-penetrating ability of 
the peptide. However, histidine is the only natural aromatic amino acid residue that displays pH-
responsive behavior under physiological conditions. 
The use of cell-penetrating peptides for drug delivery systems in chemotherapy has been 
investigated as a means to both sensitize multidrug resistant cancer cells to the drugs by 
counteracting drug efflux9,127-132 as well as to aid in the dispersion of the drugs to the hypoxic and 
acidic regions of solid tumors.9,128,129 Cell-penetrating peptides are able to transport 
chemotherapeutic drugs across the blood-brain barrier, making it possible to treat certain brain 
cancers that cannot be surgically removed or treated with conventional chemotherapy.127,133 Some 
cell-penetrating peptides also have demonstrated intrinsic antineoplastic activity.134-137 




In addition to conventional cytotoxic and cytostatic drugs, cell-penetrating peptides have also been 
conjugated with various other cargos. These include antibodies, peptides, fluorescent dyes and 
oligonucleotides as well as their analogs.9 
 
2.3) Radical Polymerization 
2.3.1) Overview of Radical Polymerization  
Radical polymerization is a chain polymerization process whereby vinyl monomers are connected to 
each other sequentially to the end of a growing polymer chain. It is extensively used in industry for 
preparing commercial materials due to its robust nature. Unlike ionic chain polymerization, it is 
tolerant to a vast number of functional groups as well as impurities. Unlike condensation 
polymerization, high molecular weights can be achieved even at low monomer conversions. 
Reaction temperatures also play a less crucial role for radical polymerization than for ionic 
polymerization. Overall, less stringent reaction conditions are required. Due to the fact that the 
backbone is composed of carbon-carbon bonds, depolymerization is also seldom a problem. 138-140 
Like all chain reaction mechanisms, the kinetic model for radical polymerization involves three basic 
steps. These are initiation, propagation and termination.138-140 
The initiation step involves the formation of an active radical species within the polymerization 
mixture, usually by the homolytic decomposition of a suitable initiator. There are many types of 
initiators and they are classed according to the stimulus by which they are induced to form radicals. 
Such stimuli include thermal, photolytic and electrochemical. Some initiation methods can act 
directly on a monomer present in the reaction mixture. These include thermal, ionizing radiation and 
ultrasound-stimulated self-initiation. Once the initiating radical is formed it can react with a 
monomer in the reaction mixture or it can undergo any number of side reactions that do not result 
in a growing polymer chain (propagating radical.) The initiator efficiency is the fraction of initiator-
derived radicals that form a propagating radical.138-140 
The propagation step is described as the successive addition of monomer units to the end of a 
propagating radical. With each addition, the propagating radical is retained at the propagating end 
of the polymer chain.138-140  
The termination step involves the reaction of two radical species to form stable products. There are 
two ways in which the radicals can do this, via combination or via disproportionation. Termination 




by combination results in the two radicals being bonded together by a sigma bond to form a single 
compound. Termination by disproportionation results in the formation of two separate, stable 
compounds.138-140 
There is another step that can occur during radical polymerization and it can have pronounced 
effects on the product properties. This is known as a transfer step. It is a process whereby a radical is 
transferred from a propagating chain to another molecule. Hence one chain is terminated but no 
radicals are destroyed in the process. If the newly formed radical is capable of initiating 
polymerization, a new polymer chain is formed.138-140 
The reaction of radicals with monomers and with each other during these steps depends on four 
factors. These are polar, steric, stabilization and thermodynamic effects. Polar effects are observed 
through nucleophilic radicals reacting more readily with electrophilic monomers and vice versa. 
Steric effects are observed by the almost complete incorporation of functional monomers in a head-
to-tail manner. In other words, reaction between the propagating radical and monomer occurs at 
the less sterically hindered end on the vinyl group of the monomer. The much lower reactivity of 1,2-
substituted vinyl monomers is also evidence of the contribution of steric effects in radical 
propagation.  Stabilization effects arise when delocalization of the unpaired electron is possible 
within the radical. If the reactant radical is stabilized by delocalization, it will be less reactive than an 
analogous radical that does not exhibit delocalization. On the other hand, if a reaction were to result 
in the formation of a radical that is stabilized by delocalization, it will be more favorable than an 
analogous reaction that does not form a product radical that is stabilized by delocalization. 
Thermodynamic effects arise from differences in the relative energies of the reactants and products, 
which contribute to the magnitude of the reaction barrier. 139,140 
The kinetics of radical polymerization is not a trivial matter and has been the subject of much 
research. There are numerous coupled processes involved that can complicate things greatly. 
However, the overall process can be divided into a simplified set of fundamental reactions, with 
varying degrees of accuracy. These are initiator decomposition (if a chemical initiator is being used), 
chain initiation, chain propagation, chain transfer and chain termination. Each of these reactions can 
be described by an associated rate law. The real difficulty lies in the melding of the effects of chain 
length on the rates of these reactions into the fundamental equations. This is especially tricky for the 
propagation and termination rate coefficients as they tend to display non-linear changes with chain 
length that can also depend on parameters such as viscosity of the reaction mixture, polarity of the 
solvent, pressure and rigidity of the polymer backbone.139,140 




Various polymers prepared by radical polymerization have been applied as biomedical materials. 
Some important examples include polyvinyl chloride, polytetrafluoroethylene, poly(methyl 
methacrylate), poly(methyl methacrylamide), poly(N-vinylpyrrolidone) (PVP) and polyvinylalcohol 
(prepared from polyvinylacetate).138-140  
 
2.3.2) PVP as a Biomaterial 
PVP is a hydrophilic polymer that has been used in the pharmaceutical industry for over a hundred 
years. Its main application in this regard is as an excipient and a disintegrant. It was used during the 
Second World War as a blood plasma enhancer. When mixed with iodine, the formulation better 
known as Betadine or Pyodine serves as a broad spectrum topical antiseptic. It has also been used as 
an adhesive, emulsifier and thickening agent, as well as a component of water purification 
membranes and as a liquid-phase dispersion-enhancing agent in DOSY NMR. The similar properties 
to PEG, when in aqueous solutions, make PVP and 2-(hydroxypropyl) methacrylamide (HPMA) 
suitable alternative hydrophilic polymers for drug delivery purposes. The fact that PVP and HPMA 
are synthesized by free radical polymerization, while PEG is prepared by anionic ring-opening 
polymerization, makes their large-scale production less stringent. They may require more stringent 
purification though. PVP bioconjugates have also shown longer circulation times compared to the 
analogous PEG conjugates.141 However, the inherent lack of control associated with conventional 
radical polymerizations results in polymers with broad molecular weight distributions (i.e. large 
dispersity) and poorly defined end-groups.  
PVP with a molecular weight above the renal clearance threshold accumulates in the patient 
permanently and can trigger an immune response over time.142-144 Many components of nanoscale 
drug delivery systems also need to have low dispersities in order to achieve the desired architecture 
that exhibits the optimum pharmacokinetics. The use of a chain transfer agent can aid in controlling 
the molecular weight of the product, but does not lower its dispersity significantly. The use of a 
controlled radical polymerization process can provide control of both of these properties. Hence, the 
polymerization of PVP by controlled radical polymerization processes has been greatly studied.  
Nitroxide-mediated polymerization of NVP was unsuccessful, yielding polymers with large 
dispersities.145  
ATRP has also proven to be inadequate since the reversibility of the deactivation by the metal center 
depends on the stability of the propagating radical as well as the stabilizing ligands.146 An unstable 
propagating radical would require a metal complex with highly stabilizing ligands for the reaction to 




be significantly reversible but, under those conditions, propagation would dominate over 
deactivation. Regardless, PVP with dispersities between 1.2 and 1.4 and number-average molecular 
weights below 5000 g/mol have been prepared by ATRP.147  
Organostibine-mediated polymerization of PVP has been investigated by Yamago et al. 148 as well as 
Ray et al.149 The organostibine acts as a degenerative chain transfer agent during the polymerization 
process. The reaction times they published are substantially shorter than those published in the 
literature for other free radical polymerizations of NVP to similar conversions.148,149 This was due to a 
higher concentration of initiator being used for the organostibine-mediated polymerization. Yamago 
et al. also polymerized NVP using analogous organotellurium chain transfer agents.150 While these 
chain transfer agents show unprecedented control of the dispersity, they are limited in the sense of 
incorporating end-group functionality for the polymer chains and often require stringent purification 
protocols for the removal of antimony or tellurium from the product.  
Reversible addition-fragmentation chain transfer (RAFT) polymerization has also been applied to 
control NVP polymerization with significant success as reported by Moad et al.,151,152 Kowollik et 
al.
153 and Pound et al.154,155 Though the conversion rates were slower and the dispersities slightly 
higher than those for organostibine and organotellurium-mediated polymerizations, the process is 
more tolerant to various functionalized monomers, and allows for greater control of the end-groups 
formed by these processes. Another perk of RAFT-mediated polymerization is that the synthesis of 
most RAFT agents is usually rather simple and, with a few exceptions, the products tend to be quite 
stable under general storage conditions.153 
 
2.3.3) Controlled Radical Polymerization and RAFT Polymerization 
One of the major drawbacks of radical polymerization is the lack of control of the rate of 
propagation relative to the rate of initiation. By approximating the formation of a polymer chain as a 
random walk process, a broad distribution of the polymer chain lengths is possoble even at low 
monomer conversions. Other issues include lack of control of functionality with respect to the chain 
ends and the rapid termination of propagating radicals, making the synthesis of block copolymers 
and other macromolecular architectures only achievable by grafting techniques. The chemical 
linkage of two macromolecules at their end groups is only efficient when click chemistry techniques 
are employed.156,157 Grafting techniques employed for coupling macromolecules are problematic, 
mostly due to termination reactions and the difficulty in separating byproducts. The synthesis of 




gradient copolymers is also not possible since the gradient will be distributed among the polymer 
chains produced at different monomer conversions. 
These limitations spurred a large amount of research that began with the emergence of living vinyl 
polymerization techniques, such as anionic polymerization, almost 60 years ago140 and has 
culminated in the development of controlled radical polymerization. One of the most notable of 
these early techniques is nitroxide-mediated polymerization (NMP.) 140,145 Another more recent 
example is atom transfer radical polymerization (ATRP.) 140,146,147 Both these techniques depend on 
the persistent radical effect to reduce the rate of propagation relative to initiation and minimize the 
rate of irreversible termination by allowing a reversible termination reaction to dominate. In 1998, 
the Commonwealth Scientific and Industrial Research Organization (CSIRO) introduced a newly 
invented controlled radical polymerization technique known as the reversible addition-
fragmentation chain transfer (RAFT) polymerization.151,153 What makes RAFT polymerization stand 
out from NMP and ATRP is that it does not rely on the persistent radical effect to achieve control of 
the polymerization kinetics, but rather it is a degenerative chain transfer of the propagating radical 
between the polymer chains that induces a means of controlling the polymerization. This means that 
the RAFT process displays quasi-identical rates of polymerization and any deviations are usually 
caused by the chain length dependence of the rate coefficients. Hence, synthesis time tends to be 
almost identical to the analogous conventional radical polymerization. The process itself is also 
relatively simple, usually only requiring the addition of a special transfer agent, known as a RAFT 
agent. The basis of a RAFT agent is a thiocarbonylthio functional group as depicted in Figure 2.2. 
 
Figure 2.2: Fundamental Structure of a RAFT Agent. 
 
Z in Figure2.2 represents a stabilizing group and plays a role in the reactivity of the RAFT agent. R is a 
leaving group. Its purpose is to re-initiate polymerization, making the number of polymer chains in 
the final product approximately equal to the number of RAFT agent molecules initially added to the 
reaction mixture. It can also be used to add functionality to the α-end of the polymer chains.  
The mechanism of a general RAFT polymerization follows that of a conventional radical 
polymerization with two equilibrium reactions imposed during the propagation step. Scheme 2.1 
illustrates this. 







Scheme 2.1: General Mechanism for a RAFT Polymerization. 
 
The first equilibrium, also known as the pre-equilibrium or initialization, involves the addition of the 
propagating radical to the RAFT agent to form the intermediate adduct radical 2. This is followed by 
fragmentation of 2 into either the reactants or a thiocarbonylthio-terminated polymer chain 3 (poly-
RAFT agent) and the leaving group radical (R●). The leaving group is usually chosen to be such that 
fragmentation of 2 favors the formation of products. Hence R● needs to be more stable than the 
propagating radical but still able to reinitiate polymerization.  
The second equilibrium is known as the main equilibrium and involves the degenerative transfer of 
the propagating radical between the dormant polymer chains 3. No radicals are lost or formed by 
the RAFT equilibria though termination and initiation still occur as in a conventional radical 
polymerization. Hence, an initiator must be added to allow for polymerization to occur but the 
radical concentration must be kept low to minimize the rate of termination of the higher molecular 
weight radicals. 151,153 




There are four main classes of RAFT agents, based on the type of Z-group they have, each of which is 
capable of controlling a specific monomer class. Alkyl and aryl dithioesters are very reactive and 
hence are used for RAFT polymerization of more activated monomers such as acrylates, acrylamides, 
styrene and acrylonitrile. These RAFT agents cause inhibition if used for polymerization of less 
activated monomers as the adduct radical intermediate is more stable than the propagating radicals. 
Trithiocarbonates can also be used for more activated monomers and tend to cause retardation or 
inhibition during polymerization of less activated monomers. Dithiocarbonates, also known as 
xanthates, and dithiocarbamates are not reactive enough to provide sufficient control for the more 
activated monomers but work well for less activated monomers such as vinyl pyrrolidone and vinyl 
acetate. The switchable RAFT agents, such as N-(4-pyridinyl)-N-methyldithiocarbamates, have 
demonstrated control over polymerizations of both more-activated monomers, when protonated, 
and less-activated monomers, when deprotonated.158 Fluorodithioformates have been proposed as 
universal RAFT agents though their applications and success has been limited so far.153,158 
Thanks to the development of such controlled radical polymerization techniques, a vast array of 
polymer architectures can now be easily synthesized. These include block, star, gradient and brush 
copolymers. Controlling the dispersity of the polymer chains is also achievable even for high 
molecular weight polymers. 
 
2.4) N-Carboxyanhydrides and their Ring-Opening Polymerization 
2.4.1) Overview of Ring-Opening Polymerization 
Ring-opening polymerization (ROP) is a form of chain-growth polymerization that involves the 
conjugation of cyclic monomers to the end of a propagating chain by breaking a bond that is part of 
the ring structure. The propagating center can be cationic, anionic or radical in nature. It has been 
used to prepare polymers from cyclic alkanes, alkenes, ethers, acetals, esters (lactones, lactides, and 
carbonates), anhydrides, polysulfur, sulfides, polysulfides, amines, amides (lactams), imides, N-
carboxyanhydrides, 1,3 - oxaza derivatives, phosphates, phosphonates, phosphites, phosphines, 
phosphazenes, siloxanes, silaethers, carbosilanes and silanes.159 Thus ring-opening polymerization 
provides a method to prepare polymers with functionality incorporated into the polymer backbone, 
similar to condensation polymerization. However, since it is a chain polymerization process, it allows 
for high molecular weight polymers to be prepared at lower monomer conversions as well as 
incorporating more control over the polymerization process than possible for condensation 
polymerizations - not taking into account sequential condensation polymerization as that is not 




practical for high molecular weight polymer synthesis. To date, ROP is the most efficient way to 
prepare certain types of biopolymers and biodegradable polymers in large quantities.159-161 
 
2.4.2) Overview of N-Carboxyanhydrides 
Peptides and proteins are fundamental structural components of life due to their ability to form 
complex shapes and interactions under the appropriate conditions. For this reason, they have been 
extensively studied as biomaterials for biomedical engineering, drug delivery systems and 
therapeutic compounds. Traditional peptide synthesis techniques involve sequential addition of 
protected amino acid residues to one another in solution with isolation and deprotection steps in 
between. Solid phase peptide synthesis involves the immobilization of the initial amino acid residue 
onto an appropriate resin, optimizing the product isolation after each step. Solid phase peptide 
synthesis still becomes complicated and expensive for the preparation of significantly large peptide 
sequences. 
2,5-Dioxo-1,3-oxazolidines, also known as N-carboxanhydrides (NCAs), were first discovered in 1906 
by Hermann Leuchs when he tried to distill N-methoxycarbonyl amino acid chlorides.160,162 NCAs 
have the general structure depicted in Figure 2.3. 
 
Figure 2.3: General Structure of α-Amino Acid N-Carboxyanhydrides. 
These amino acid derivatives are unique as they are simultaneously protected at the α-nitrogen and 
activated at the α-carboxyl group. They can readily react with nucleophiles without 
isomerization.160,163 However, they have a tendency to oligomerize since the carbamic acid 
intermediate that is formed after reaction with a nucleophile is unstable and decomposes to free the 
α-amino group, liberating carbon dioxide. They also tend to isomerize in the presence of bases such 
as trialkylamines and even in pyridine in high enough concentrations.164 The mechanism involves 
deprotonation of the amino nitrogen in the heterocyclic ring. Another issue with NCAs is their 
competitive reactivity. More precisely, NCAs can act as electrophiles by adding a nucleophile at the 
α-carboxyl group. They can also act as acids, liberating a proton from their α-nitrogen to form an 
NCA anion that is a sufficiently strong nucleophile to react with NCAs. This makes their use in 




peptide synthesis complicated as addition of more than one residue is difficult to control. Some 
success has been achieved using a biphasic aqueous buffer-acetonitrile system with rigorous control 
over the pH.164,165 The preparation of urethane-protected NCAs (UNCAs) has improved their use in 
sequential peptide synthesis. However, UNCAs can still isomerize in the presence of a base.163-165 
 
2.4.3) NCAs as Monomers for Ring-Opening Polymerization 
NCAs are well suited for homopolymerization of amino acids. The mechanism by which they 
polymerize falls under the category of Ring-Opening Polymerization. There are two classical 
initiation mechanisms which can be active during their polymerization. They are known as the 
normal amine mechanism and the activated monomer mechanism. Scheme 2.2 depicts these 
initiation mechanisms for NCA polymerization. 
Scheme 2.2: Mechanisms of Initiating NCA Polymerization. 
Looking at the two mechanisms for NCA initiation, it is evident that the normal amine mechanism 
has characteristics of a living polymerization while the activated monomer mechanism has many 
termination and transfer reactions that would suggest very little control is possible for the polymers 
formed when this mechanism is active. This is the major obstacle towards preparing well-structured 
polymeric materials from NCAs as both mechanisms are active under normal conditions.167,168 To 




complicate the process further, it has been shown that trace impurities in the reaction mixture can 
also have dire consequences for the products formed.161,165,167,168 
Optimization of the conventional method that uses a primary amine as an initiator has been 
achieved by applying a high vacuum and low temperatures during the polymerization.168-170 It is 
believed that the reduced concentration of impurities, especially water, under high vacuum 
conditions provides a better control of the polymerization by minimizing the possible termination 
reactions. A higher activation energy barrier for the Activated Monomer Mechanism as opposed to 
that for the Normal Amine Mechanism is what makes NCA polymerization more controlled at lower 
temperatures.169 
Development of zerovalent transition metal initiators, most notably Co(0) and Ni(0) complexes, 171-173 
has also allowed the living polymerization of NCAs without competing side reactions. This procedure 
has been employed in the synthesis of random, block and gradient copolypeptides as well as hybrid 
materials. The mechanism is illustrated by Scheme 2.3 and involves the consecutive formation of 5 
metallocycle intermediates, starting with an oxidative addition of an NCA to the metal center. The 
forth intermediate essentially undergoes the first propagation step and the consecutive propagation 
steps occur in a similar manner, though they are better depicted as the fifth intermediate. 171  
 
Scheme 2.3: NCA Polymerization Using Zerovalent Transition Metal Initiators. 
The metallocycle can be removed easily by dialysis with mild acid.173 In order to control the 
functionality at the C-terminus of the polypeptide, the appropriately functionalized amido-amidate 




metallacycle intermediate 4 can be prepared by tandem oxidative addition of 
allyloxycarbonylaminoamides to the metal center as depicted by Scheme 2.4.174 
 
Scheme 2.4: Preparation of Functionalized Transition Metal Initiators. 
The use of amine hydrochloride salts as initiators results in living polymerization of NCAs to be 
achieved by a reversible deactivation mechanism analogous to ATRP while also negating any side 
reactions caused by the formation of NCA anions.168 The reaction is quite slow however and only the 
single monomer adduct is formed at ambient temperatures. 
N-(Trimethylsilyl)amine (TMS-amine) initiators can control NCA polymerization via a ring-opening 
metathesis mechanism as shown in Scheme 2.5.175 
 
Scheme 2.5: Initiation Using TMS-amine Initiators. 
The reaction proceeds with similar control as the other methods, but polymerization is faster than 
low temperature polymerization with amine initiators or polymerization at elevated temperatures 
with amine hydrochloride initiators. However, the TMS-carbamate intermediates are degraded in 
the presence of air or moisture. 
Polypeptides prepared by NCA polymerization are attractive for use as biomedical materials since 
they are composed of biological building blocks that can be decomposed by the body. They can also 
adopt similar secondary or tertiary structures as those of natural proteins and exhibit stimuli-
responsive behavior. For instance, polyglutamic acid shows a conformational change from α-helix to 
random coil in aqueous media when the pH is raised from below 5.5 to a higher value.176,177 
Polyglutamic acid hydrazone conjugates with hydrophobic drugs release their payload in an acidic 




environment.178 Polyhistidine is hydrophobic at physiological pH, but becomes soluble in water when 
the pH is below 7.66 Poly(L-lysine) is a commercially important polypeptide, prepared by NCA 
polymerization.165 It is used as an attachment factor that improves cell adherence in tissue culture179 
and in non-viral gene transvectors as it forms polyionic complexes with the phosphate groups of 
DNA and RNA.43  
 
2.5) Brief Deduction of the Researched Literature 
The incorporation of nanotechnology in medicine, coupled with state-of-the-art diagnostic and 
imaging techniques has improved our understanding of the pharmacokinetics and 
pharmacodynamics of chemotherapy drugs.32,42,46 It has also provided a better description of the 
development, growth and spread of cancer within the body. This combined knowledge has indicated 
that many conventional chemotherapy regimens are unable to completely treat the afflicted tissue 
due to poor pharmacokinetics of the drugs throughout the body and their even poorer 
pharmacokinetics within a tumor.9 The development of the multidrug resistance phenotype within 
tumor tissues intensifies this issue.17,18,20 Since a drug’s efficacy is strongly dependent on its 
selectivity for its intended target as well as its distribution within the body, modern chemotherapy 
research aims at improving drug delivery of existing chemotherapeutic compounds instead of 
developing novel drugs.  
Most cancer drug delivery systems are nanostructures as these tend to accumulate within tumors by 
the Enhanced Permeability and Retention Effect.39 Various targeting ligands have been attached to 
the drug delivery systems to further increase their selectivity for tumor tissue. However, this is 
difficult as most cell surface receptors of cancerous cells are identical or almost identical to those 
found in healthy tissues. Certain targets can stimulate synergistic responses, such as 
endocytosis.111,112,118 
In order to achieve selective release of the drugs at the target site, various stimuli-responsive 
materials have been developed.58-65,69-71,73 These can respond to either physical stimuli, such as heat 
and light, or chemical stimuli, such as pH or ionic strength. Various labile linkers have also been 
developed, which can be designed to cleave under conditions specific to the target region. There has 
been limited success for developing a reversibly labile linker for an amine that releases its payload 
under the mildly acidic conditions of an endosome or lysosome.32,73,82,83,179 Imines can provide such a 
linker but they tend to be too labile in aqueous conditions. Confining the imine bond to a 
hydrophobic region within a drug delivery system can improve its stability by both reducing the 




concentration of water available as well as decreasing the pKa of the protonated imine. There has 
been work done on PEG conjugates with hydrophobic drugs, via an imine bond, to form 
micelles.83,180 
Such a linker could prove beneficial for preparing a prodrug based on poly(L-lysine). This polypeptide 
has shown cytotoxic activity, via membrane disruption, as well as a cell-penetrating ability125 under 
acidic pH. It has been shown that cell-penetrating peptides can improve the penetration of 
chemotherapy drugs within a tumor and even aid them in crossing the blood-brain barrier.9  
Many hydrophilic polymers are used as components in drug delivery systems, PEG being the most 
common. Their main purpose is to provide solubility to the drug delivery system. Their steric 
hindrance and inert composition also provides the system with stealth properties against the body’s 
reticuloendothelial system (RES).32,96,96,141 There are a few disadvantages to using PEG. Firstly, it is 
prepared by anionic ring-opening polymerization, which requires extremely stringent reaction 
conditions. Secondly, it gradually becomes detectable by the RES with time.96 For these reasons, 
other hydrophilic polymers have been developed for drug delivery systems. Poly(N-(2-
hydroxypropyl)methacrylamide) and poly(N-vinylpyrrolidone) are two such polymers. They can be 
prepared by radical polymerization or RAFT-mediated polymerization. PVP has been shown to have 
longer circulation times than PEG.141 
No literature has been found for the preparation of PVP-block-poly(L-lysine) block copolymers, for 
their behavior in aqueous solutions, the conjugation of chemotherapeutic compounds to them via 
imine bonds or their cell-penetrating ability. There have been some papers dealing with PEG-poly(L-
lysine) block copolymers though their focus was on polyionic complex micelles for gene 
delivery.43,181,182 An article also mentioned the use of these copolymers as carriers for MRI contrast 
agents by modifying the lysine residues with chelating agents.183 There is also the pioneering work of 
Ringsdorf et al. that involved functionalizing some of the lysine residues of a PEG-poly(L-lysine) block 
copolymer with palmitic acid, via amide bond formation, to imbue sufficient hydrophobicity to the 
block so as to form micelles in aqueous solutions. They loaded these micelles with a 
cyclophosphamide-sulfido derivative prodrug and were able to fine-tune its release rate from 
minutes to hours.182,184 Current methodologies for formulating prodrugs of CPPs involve 
incorporation of the CPPs as an intermediate phase between the hydrophilic and hydrophobic 
phases of polymeric micelles or within the core of a nanoparticle.9 The CPPs are exposed when a 
labile linker connecting the hydrophilic polymer to the CPPs is cleaved or when the nanoparticle 
disintegrates. However, such ternary block copolymers usually require stringent and complicated 
synthesis procedures and these are limited by the compatibility of the functional groups on the CPP 




and polymer chains. The only reports found of imine bonds being used in prodrug formulations are 
for crosslinking chitosan microcapsules with terephthalaldehyde73 and for the conjugation of 
Doxorubicin to an aldehyde end-functional PEG via its daunosamine residue179 as well as to the 
benzaldehyde residues of poly(1,2:3,4-di-O-isopropylidene-6-O-(2’-formyl-4’-vinylphenyl)-D-
galactopyranose-co-5,6-benzo-2-methylene-1,3-dioxepane).184 Thus this work will incorporate imine 
bonds to both the ketone and amine functional groups of Doxorubicin in order to maximize its 
hydrophobicity and prevent its oligomerization via Schiff base linkages.  
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RAFT-Mediated Polymerization of N-vinylpyrrolidone with O-ethyl-S-
(phthalimidylmethyl)xanthate Performed in Batch-Mode 
 
3.1) Introduction 
This chapter focuses on the preparation of PVP with a low dispersity (Ð) and a free primary amine α-
end-group by a RAFT-mediated polymerization. Amines are not compatible with RAFT agents as they 
readily attack the thiocarbonyl carbon, resulting in elimination of the R-group thiol and, in the case 
of xanthates, formation of an O-thiocarbamate.1 By using a protecting group that masks the 
nucleophilicity of the amine, the RAFT-mediated polymerization with a protected amine-
functionalized RAFT agent is feasible and the desired amine-functionalized polymer could be 
obtained by removal of the protecting group. This was attempted using a RAFT-mediated 
polymerization of NVP with O-ethyl-S-(phthalimidylmethyl)xanthate (XA2).2 The phthalimide-
functionalized R-group of this RAFT agent can be converted to a primary amine by reacting with 
hydrazine in methanol.3,4 Alternatively, it can be removed by a two-step process that involves 
reduction with sodium borohydride and subsequent acidic or basic hydrolysis of the O-
hydroxymethylbenzamide.4-6 The amine α-end-group functionalized PVP was intended for use as a 
macroinitiator during the ring-opening polymerization of Nε-(benzyloxycarbonyl)-L-lysine N-
carboxyanhydride. 
In order to get a fundamental idea of the kinetic parameters for the XA2-mediated polymerization of 
NVP, several trials were performed at different monomer to RAFT agent ratios. An in-situ 1H-NMR 
polymerization was carried out for the trial with the lowest monomer to RAFT agent ratio. 
The RAFT-mediated polymerization of NVP with XA2 was first described by Postma et al.2 Polymers 
with number-average molecular weights (Mn) over 13,000 g/mol were obtained using a monomer to 
RAFT agent ratio (
klmni = R) of 517. These had a dispersity (Ð) around 1.5, indicating inadequate 
control of the polymerization. Their second highest monomer to RAFT agent ratio was 92. The 
polymers obtained by these trials had Mn between 5,000 g/mol and 9,000 g/mol with Ð around 1.2.  
Two trials, using R = 117 and R = 196, were performed by our group in order to better assess if PVP 
with Mn above 10,000 g/mol and Ð < 1.3 could be obtained by a RAFT-mediated polymerization of 
NVP with XA2. 




3.2) Materials and Experimental Methods 
N-Vinylpyrrolidone (NVP) was purchased from Merck and vacuum distilled over 5% ground 
potassium hydroxide before use. Azobisisobutyronitrile (AIBN) was purchased from Merck and 
recrystallized from methanol before use. Potassium O-ethyldithiocarbonate, anhydrous calcium 
chloride, anhydrous magnesium sulfate, anhydrous calcium sulfate, potassium hydroxide pellets, 
concentrated sulfuric acid (95 – 97%) and sodium metal were purchased from Merck and used as 
received. A seven inch Wilmad® quick pressure valve medium wall NMR tube with a 5 mm diameter, 
N-(bromomethyl)phthalimide, benzophenone, N,N-dimethylacetamide (DMAC, Chromosolv® Plus, 
for HPLC ≥ 99.9%), butylated hydroxytoluene (BHT) 99% (GC)  and chloroform-d 99.8 atom % were 
purchased from Sigma Aldrich and used as received. Benzene-d6 (99.6 atom %) was purchased from 
ACROS Organics and used as received. Methanol, chloroform (CHCl3), dichloromethane (DCM) and 
diethyl ether were purchased from KIMIX. Methanol was fractionally distilled before use. Chloroform 
and dichloromethane were washed with concentrated sulfuric acid followed by 5% sodium 
bicarbonate solution and finally water before being dried over calcium chloride and fractionally 
distilled from calcium sulfate. Diethyl ether was distilled from sodium and benzophenone. Lithium 
chloride ≥ 98% was purchased from Riedel-de Haën and used as is. 0.45 μm Glass fiber prefilters 
were purchased from PALL Life Sciences.  
 
3.2.1) Synthesis of XA2 
XA2 was synthesized as published by Postma et al.2 Potassium O-ethyldithiocarbonate (5.15 g, 
3.21×10-2 mol) was suspended in 200 mL chloroform and N-(bromomethyl)phthalimide (5.00 g, 
2.08×10-2 mol) was added. The solution was stirred at room temperature for 14 hours overnight. The 
solution was then filtered, washed with 2×50 mL de-ionized water followed by 50 mL saturated 
calcium chloride solution and dried over magnesium sulfate. After filtering the solution, the solvent 
was removed by rotary evaporation. Product yield: 5.56 g (95%). 1H-NMR (300 MHz, CDCl3): δ = 1.46 
(tr, 7.1 Hz, 3H), 4.68 (q, 7.1 Hz, 2H), 5.33 (s, 2H), 7.75 (m, 2H), 7.85 (m, 2H). 
 
3.2.2) RAFT-Mediated Polymerization of NVP with XA2 – R = 196 
NVP (2.0 g, 1.8×10-2 mol), XA2 (0.025 g, 8.89×10-5 mol) and AIBN (0.003 g, 1.83×10-5 mol) were 
placed in a Schlenk tube which was capped with a rubber septum. This ratio should give a monomer 
to XA2 ratio (R) of 202. R was confirmed by 1H-NMR to be 196. Three freeze-pump-thaw cycles were 




performed. The Schlenk tube was back-filled with argon and placed in an oil bath which was 
regulated at 65 °C by a thermocouple. Samples for NMR and SEC were taken using a syringe that had 
been purged with argon. The samples were taken after reaction times of 120 minutes, 240 minutes 
and 345 minutes. 
The polymer was isolated from the reaction mixture by precipitation in diethyl ether. 
Dichloromethane was used as a solvent to aid in the precipitation process. The precipitate was 
separated by centrifugation at 2500 rpm for 3 minutes, washed with a small portion of diethyl ether, 
separated again by centrifugation and dried under vacuum.  
 
3.2.3) RAFT-Mediated Polymerization of NVP with XA2 – R = 117 
NVP (2.000 g, 1.80×10-2 mol), XA2 (0.042 g, 1.49×10-4 mol) and AIBN (0.0034 g, 2.07×10-5 mol) were 
placed in a Schlenk tube which was capped with a rubber septum. R = 117 according to NMR. Three 
freeze-pump-thaw cycles were performed. The Schlenk tube was back-filled with argon and placed 
in an oil bath which was regulated at 65 °C by a thermocouple. Samples were taken for NMR and SEC 
analysis after 50 minutes, 110 minutes, 185 minutes and 245 minutes. Isolation of the polymer from 
the reaction mixture was performed as described in Section 3.2.2. 
 
3.2.4) 1H-NMR In-situ Polymerization of NVP with XA2 – R = 5 
NVP (0.300 g, 2.7×10-3 mol), XA2 (0.152 g, 5.4×10-4 mol) and AIBN (0.009 g, 5.48×10-5 mol) were 
added to 0.5 mL benzene-d6. R = 5 for this reaction. The volume of the solution was measured (0.89 
mL.) 0.7 mL of the solution was placed in a Wilmad® quick pressure valve NMR tube and three 
freeze-pump-thaw cycles were performed on the sample. The tube was back-filled with argon and 
placed in a Varian 400 MHz Inova NMR spectrometer. A spectrum of the initial conditions was taken 
at 25 °C before switching the variable temperature flow gas to nitrogen, removing the sample from 
the spectrometer and raising the temperature to 65 °C. The polymerization was performed at 65 °C 
as this was the temperature at which the calculated half-life of AIBN was 10 hours (see Section 4.2). 
Once the temperature had stabilized, the sample was inserted. The time required for shimming the 
magnetic field and adjusting the deuterium feedback loop was recorded. 




The spectrometer was programmed to take an array of spectra, recording a scan every 5 minutes for 
10 hours. Each scan was taken using 4 transients, with an acquisition time of 4 seconds and 
relaxation delay of 1 second. The pre-acquisition delay between scans was set to 280 seconds. 
 
3.2.5) SEC Analysis 
Each SEC sample was prepared by dissolving approximately 2 mg of the isolated polymer in 1.5 mL of 
dimethylacetamide (HPLC grade) containing 0.05% (w/v) BHT and 0.03% (w/v) lithium chloride. The 
samples were filtered through a 0.45 μm glass fiber prefilter before analysis. A Waters 717 Plus 
autosampler connected to a Shimadzu LC-10AT pump was used with the following column 
configuration: 1×PSS GRAM analytical precolumn (10 μm particle size, 8.0×50 mm), 1×PSS GRAM 
analytical column (10 μm particle size, 100 Å pore size, 8.0×300 mm), 2×PSS GRAM analytical 
columns (10 μm particle size, 3000 Å pore size, 8.0×300 mm.) A Waters 2487 dual wavelength 
absorbance detector and a Waters 410 differential refractometer were connected in series. The 
dwell time between the detectors was 18 seconds. The temperature of the column oven was set to 
40 °C and the flow rate was 1 mL per minute. The instrument was calibrated using peak position 
calibration with narrow, linear poly(methyl methacrylate) (PMMA) standards. 
 
3.2.6) NMR Analysis 
Unless otherwise stated, both the reaction mixture and the isolated polymer samples were analyzed 
using 1H-NMR spectroscopy. CDCl3 was used as the solvent. All NMR spectra were taken using a 
Varian 300 MHz VNMRS, Varian 400 MHz Inova or Varian 600 MHz Unity spectrometer. 1H-NMR 
analysis of the reaction mixtures taken at different time intervals was used to determine the NVP 
and XA2 conversions with reaction time. 1H-NMR analysis of the isolated polymer samples was used 
to confirm that the phthalimide and xanthate functionalities were incorporated into the polymer as 
well as compare their relative abundance. Unless otherwise stated, all PVP samples were dissolved 








3.3) Results and Discussion 
3.3.1) Analysis of Polymers Prepared in Sections 3.2.2 and 3.2.3 
NMR Analysis 
Figure 3.1 shows the 1H-NMR spectra of the reaction mixture at A) 0% and B) 50% monomer 
conversion for the trial with R = 196. 
By normalizing the peaks for the aromatic phthalimide protons of XA2 (a and b) to 4.00, the change 
in signal intensity could be computed for the vinyl protons of the monomer (f) as well as for the 
methylene protons on XA2 (d). 
[NVP] at each time interval was calculated using Equation 3.1: 
kl kl = i×o p(q)rqstu.wxstu."yz×o p(q)rqst{.|}st{.x|                                                                                                                                   (3.1) 
[XA2] at each time interval was computed using Equation 3.2: 
mni mni = i×o p(q)rqstw.~{stw."}o p(q)rqst{.|}st{.x|                                                                                                                                   (3.2) 
Figure 3.2 shows the 1H-NMR spectrum for the polymer isolated from the sample taken at 50 
percent monomer conversion for the trial with R = 196. Since the phthalimide protons of the R-
group could only be present after isolation of the polymer if they were part of the polymer chain, 
they could be used as an internal reference for the number of polymer chains. However, isolation of 
the polymer from the reaction mixture could affect Mn by partial fractionation of the low molecular 
weight chains into the non-solvent. Hence, Mn,NMR was calculated from the crude polymer samples. 
The conversion of XA2 had to be taken into account. 
The degree of polymerization (DP) in the samples of the reaction mixture was calculated using 
Equation 3.3. 
 = ×o p(q)rqstu."st".} o p(q)rqstu.wxstu."x j×o p(q)rqst{.|}st{.x| ×D.×o p(q)rqstw.~|stw.~"                                                                                                 (3.3) 
 





Figure 3.1: 1H-NMR Spectra for the Reaction Mixture of the Trial with R = 196. A) Initial Conditions. B) 50% Monomer 
Conversion. 





Figure 3.2: 1H-NMR Spectrum for the Isolated Polymer from the Trial with R = 196 at 50% Monomer Conversion 
(Presaturation of the DCM Solvent Peak at δ = 5.31 ppm). 
The backbone protons peak at δ = 2.9 - 4.2 ppm in Figure 3.1.B is overlapped with the NVP protons 
peak at δ = 3.47 - 3.60 ppm. The intensity of this peak should however be equal (or very close) to 
that for the vinyl protons peak at d = 4.26 - 4.56 ppm. Hence, by subtracting the integral for the vinyl 
protons from the integral for d = 2.9 - 4.2 ppm, the interference from the NVP protons is removed. 
Mn,NMR could then be calculated using Equation 3.4. 
M,kz =  × 111.14. + 281.34.                                                                              (3.4) 
The theoretical Mn (Mn,theory) for an ideal RAFT-mediated polymerization could also be calculated by 
using Equation 3.5. 
M, =  × 1 − kl kl × 111.14. + 281.34.                                                 (3.5) 
NVP conversion, XA2 conversion Mn and Mn,theory for the samples obtained by the experiments 
described in Sections 3.2.2 and 3.2.3 are given in Table 3.1. 




There were still traces of XA2 detected in the reaction mixture at the end of both reactions. The 
singlet at δ = 5.27 ppm in Figure 3.1.B was from DCM, most likely introduced by vapors from a 
contaminated pipette bulb. The number-average molecular weights (Mn) for the samples taken at 
low monomer conversions were significantly larger than predicted for an ideal RAFT-mediated 
polymerization. These properties are characteristic of hybrid behavior.7,8 This suggests that the 
phthalimidylmethyl radical is a poor leaving group relative to the PVP propagating radical. 
Table 3.1: Results for RAFT-mediated Polymerizations of NVP with XA2 as described in Section 3.2.2 and 3.2.3. (a) – 
Measured using the isolated polymer samples. 













196 120 25 72 87a 5900 7800 17900 1.54 
196 240 46 93 82a 10300 10300 17600 1.26 
196 345 53 ca. 99 73a 11800 10900 18700 1.24 
117 50 23 55 ca. 100 3300 5600 8200 1.30 
117 110 42 84 ca. 100 5700 6800 9600 1.27 
117 185 61 95 ca. 100 8200 8700 11100 1.24 
117 245 71 97 ca. 100 9900 9500 12900 1.24 
 
A large increase in viscosity of the reaction mixture was noted when the monomer conversion was 
over 60%. A loss of xanthate functionality relative to phthalimide functionality was noted for the 
isolated polymer samples, as noted by the data in Table 3.1 for the trial with R = 196. Some alkene-
terminated polymer chains also began to form (δ = 6.88 – 7.07 ppm in CDCl3 – only detectable in 
isolated samples), though their quantification proved difficult by NMR alone. The relatively low 
concentration (compared to the sensitivity of the instrument), residual monomer in the isolated 
samples, the broad nature of the peak and a relatively long longitudinal relaxation time (T1) of vinyl 
protons in general were the major interferences. It was unclear what was causing the loss of 
xanthate chain ends but the formation of alkene-functionalized chains would suggest a slow 
thermolytic β-scission of the xanthate-functionalized polymer was occurring.1-3 Termination by 
disproportionation could also be the cause of alkene-functionalized chain ends. However, this has 
not been observed during the NRP of NVP.9 Hydrolysis of the xanthate end-group into a thiol (and its 
subsequent oxidation into a disulfide) or a hydroxyl end-group (see Chapter 6 for more information) 
could also cause the relative abundance of xanthate end-groups to decrease. The resonance of the 
α-proton of the disulfide is overlapped by the polymer backbone resonance in the 1H-NMR 
spectrum, making it impossible to confirm this by NMR alone. The hydroxyl end-group also cannot 




be detected by NMR though the α-proton resonates at δ = 5.21 – 5.54 ppm in CDCl3. This is a very 
broad peak and is difficult to detect at low concentrations. It is only clearly detected for low 
molecular weight polymers with a high degree of end-group conversion. 
To be able to make a more accurate assessment of the situation, the number of alkene end-groups 
as well as the presence of disulfides, thiols or hydroxyl end-groups needs to be quantified. A more 
accurate measurement of the xanthate end-groups is unfortunately not possible with MALDI-TOF 
MS as they are photolytically labile even when embedded in the matrix. Gruendling et al.10 used ESI 
MS to study the end-group degradation of poly(methyl methacrylate) and polystyrene prepared by 
RAFT-mediated polymerization. This type of analysis could prove useful in this case but, due to time 
constraints, it was not performed. 
The thermolysis of RAFT agents by β-scission has been documented1,7 and its mechanism is depicted 
in Scheme 3.1. 
 
Scheme 3.1: Thermolysis of a RAFT agent from a Polymer Chain. 
According to the literature, this can be a problem for xanthates at temperatures below 100 °C, but it 
depends on the R-group of the RAFT agent as well as on the polarity of the surrounding solution.7 It 
was shown that acrylate R-groups seem to confer the most destabilizing effect while phenylacetate 
R-groups stabilize the thiocarbonyl thio group against thermolysis. As a general rule, the carbon–
sulfur single bond is the most labile bond and factors that affect its strength include strongly 
electron-donating Z-groups, such as dithiobenzoates, as well as a high-energy penalty for the 
formation of breakdown products, like methylbenzene carbocations. 
Thus to avoid excessive loss of the xanthate end-groups during polymerization, the reaction 
temperature should be kept as low as possible. This can be achieved by substituting AIBN with an 
initiator that has a 10-hour half-life at a lower temperature. In our work however, we simply applied 
rigorous control of the reaction temperature to ensure that the amount of xanthate functionality 
that was lost was kept sufficiently low. 
Determination of the fraction of xanthate-functionalized chains relative to phthalimide-initiated 
chains by using the 1H-NMR spectrum of the crude reaction mixture was difficult due to the presence 
of multiple interferences. The most significant interference came from the carbon satellite peaks for 




the vinyl protons (f - Figure 3.1.A) overlapping with the methylene protons (e - Figure 3.2) of the 
xanthate-functionalized chains. This was accounted for by subtracting 0.55% (natural abundance of 
13C = 1.1%) of the integral value for the vinyl protons peak (f) from the integral of the methylene 
protons peak (e) (Figure 3.1.B). This proved difficult for high concentrations of monomer and 
polymer coupled with low concentrations of xanthate as the base of the vinyl protons peak (f - 
Figure 3.1.A) and the polymer backbone peak (c - Figure 3.1.B) also began to overlap with the 
xanthate methylene protons peak. This made baseline correction difficult in that region. This analysis 
proved most difficult for the samples from the polymerization with R = 196. Optimized shimming of 
the axial and radial shims as well as presaturation of the 13C nuclei could improve the analysis 
conditions. Using an instrument with a larger static magnetic field strength would also aid in 
providing better resolution between the monomer peak’s carbon satellites as well as the polymer 
backbone peak from the methylene protons peak of the xanthate.  
 
SEC Analysis 
SEC was performed for the isolated polymer samples obtained as described in Sections 3.2.2 and 
3.2.3. The instrument was calibrated using peak position calibration with narrow, linear poly(methyl 
methacrylate) (PMMA) standards. Thus the distribution measurements for PVP on this system are 
relative to PMMA. Fortunately, both PVP and PMMA are linear polymers. That means the major 
divergences in the measured distribution parameters of the PVP samples from their actual values 
when using the PMMA calibration curve will be due to the differences in the hydrodynamic volume 
of the polymers in the mobile phase. Einstein’s viscosity law states that the product of a polymer 
chain’s molecular weight and intrinsic viscosity in a solution is directly proportional to the 
hydrodynamic volume of an equivalent sphere.11 Thus the solvation properties of a polymer chain in 
a solution can affect its hydrodynamic volume, the key parameter controlling the separation process 
in SEC. One relation between the intrinsic viscosity of a polymer and its molecular weight (MN) is 
given by the Mark-Houwink equation.11 
 = MN                                                                                                                                                    (3.6) 
Where  and  are the Mark-Houwink parameters that vary with polymer chemistry, architecture, 
solvent and temperature. This means that as long as the differences in hydrodynamic volume 
between the calibrant and the analyte are only due to their different solvation properties, the 
differences between their intrinsic viscosities in a particular solution can be calculated. There is a 
large collection of Mark-Houwink constants for many different polymers in various solutions11,12 




though caution is advised when using these values to attempt a universal calibration without an on-
line viscometer. For more information on the caveats of Mark-Houwink calibrations, the reader is 
referred to Striegel.11 The main causes for inaccuracies in Mark-Houwink calibrations include the 
great uncertainty in the published Mark-Houwink parameters, the necessity for corresponding 
architectures as well as molecular weight range of the two polymers being compared.11,12 A much 
simpler approach would be to recalibrate the system using PVP standards, to directly determine the 
absolute molecular weight of the eluting fractions using a light scattering detector or to use 
universal calibration by connecting an on-line viscometer.11 
The SEC traces were normalized according to the method described in Appendix A1 and plotted 
according to molecular weight in Figure 3.3. 
 
Figure 3.3: Normalized Molar Mass Distributions for RAFT-mediated Polymerizations with A)  = 196, B)	 = 117 at 
Different Monomer Conversions.  
Mn,SEC and ÐSEC for each sample were calculated from the results in Figure 3.3 and are displayed in 
Table 3.1. Generally, Mn,SEC was larger than Mn,theory or Mn,NMR. However, the trend did not seem to 
follow an exponential deviation with molecular weight, as predicted by the Mark-Houwink equation, 
and was larger than predicted for the samples isolated at low monomer conversions. A universal 
calibration based on the Mark-Houwink parameters could help determine the magnitude of this 
deviation and it could be performed post-analysis. Unfortunately, the Mark Houwink parameters for 
either polymer in DMAC could not be found nor was there access to an on-line viscometer. 
Comparison of the published Mark-Houwink parameters for PMMA13 and PVP14 in DMF indicated 
that PMMA has a smaller hydrodynamic volume compared to PVP in mobile phases similar to DMAC. 
This would result in a positive error when calculating the molecular weight of PVP using PMMA 
standards but this does not help to account for the deviation from the expected values of Mn,SEC at 
low monomer conversion.   




The larger than expected Mn,SEC for the polymerizations with R = 117 and R = 196 at low conversions 
could be explained by the theory that there is an inefficient pre-equilibrium phase for the RAFT-
mediated polymerization of NVP with XA2, as indicated by the NMR data. The larger dispersity of the 
synthesized polymers would result in a greater weight fraction of higher molecular weight polymer 
chains. This would cause a greater positive error when calculating Mn,SEC and Mw,SEC due to the 
greater difference in hydrodynamic volume of the calibrant and the analyte at larger molecular 
weights. One reason for a slow pre-equilibrium phase can be that the leaving group (R-group) radical 
of the RAFT agent is less stable than the propagating radical. Fragmentation of the adduct radical 
would then favor formation of the propagating radical and propagation of the polymer chains would 
be significant before complete conversion of RAFT agent is achieved. Calculating the apparent 
transfer constant (Ctr) for XA2 with a monomer to RAFT agent ratio of 196, as described by Kowollik 
et al.,7 gave a value of 3.26. This signifies that XA2 is not a very efficient RAFT agent for the 
polymerization of NVP. 
 
3.3.2) Pre-Equilibrium Kinetics Study by In-Situ 1H-NMR 
Since O-ethyl xanthates are sufficient stabilizing groups for RAFT agents intended to control the 
polymerization of less activated monomers such as NVP and vinyl acetate,7,15-20 the low apparent Ctr 
for XA2 may be due to the phthalimidylmethyl radical being less stable than the propagating radical. 
This would make it less likely to fragment from the adduct-radical intermediate compared to the 
propagating radical. The resulting lower rate of RAFT agent consumption would affect Ð for the final 
product since new dormant chains would be formed for a longer period during the polymerization 
while the pre-existing dormant chains would be able to propagate. 
In order to accurately assess the pre-equilibrium kinetics for the RAFT-mediated polymerization of 
NVP with XA2, 1H-NMR in-situ polymerization was performed. The kinetic data obtained was used to 
calculate the probability of radical transfer from a propagating radical to the R-group on the RAFT 
agent as a function of reaction time and composition. This would help to quantify the relative rates 
of fragmentation of the R-group radical and the propagating chain radicals from the adduct-radical 
intermediate during the pre-equilibrium phase of the reaction. 
A relatively high concentration of RAFT agent to monomer was used for the kinetic study in order to 
extend the pre-equilibrium phase of the RAFT process as well as to be able to accurately quantify the 
relative amount of monomer and RAFT agent in the reaction mixture by NMR. The spectral array, 
obtained as described in Section 3.2.4, was used to calculate the change in [NVP] and [XA2] during 




the reaction. Figure 3.4 is a plot of [NVP] and [XA2] with respect to reaction time during the in-situ 
NMR experiment. 








































Figure 3.4: Plot of [XA2] and [NVP] During In-situ 1H-NMR Polymerization with R = 5. 
An exponential function was fitted from the data using least squares approximation to give [XA2] 
and [NVP] as functions of time. The least squares approximations for [NVP] and [XA2] were obtained 
using OriginPro 8. These functions are given in Appendix A2.1. 
The probability that a propagating radical or initiator-derived radical would transfer their radicals to 
the phthalimidylmethyl leaving group of XA2 instead of continuing to propagate at a specific time 
during the reaction could be calculated using Equation 3.7. 
P(T) = " "                                                                                                                                        (3.7) 
P(T) for the 1H-NMR in-situ polymerization was plotted in Figure 3.5: 
 
Figure 3.5: P(T) for the 1H-NMR In-situ Polymerization with R = 5. 




There was an increase in P(T) after 16700 seconds that correlated with an increase in [XA2]/[NVP] 
to a value greater than the initial value of 0.2. However, 
rmr  was close to 0 from that time onwards, 
meaning that there may be large errors involved with its approximation in this region. Also, the 
reaction of initiator-derived radicals with XA2 may be significantly affecting P(T) at this stage. Figure 
3.6 is a plot of [XA2]/[NVP] as a function of reaction time: 
 
Figure 3.6: [XA2]/[NVP] as a Function of Time for the 1H-NMR In-situ Polymerization. 
P(T) less than 0.5 suggests that propagation is favored over radical transfer to the R-group. A 
decrease in P(T) can be ascribed to the cumulative effects of the decreasing RAFT agent 
concentration as well as an increase in poly-RAFT agent concentration. Pound et al.17 performed a 
similar kinetic study for the RAFT-mediated polymerization of NVP with O-ethyl-S-
(cyanoisopropyl)xanthate (X1). They reported on the quantitative conversion of the RAFT agent to a 
single-monomer adduct before any further propagation of the dormant polymer chains took place. 
They claimed this effect was due to the greater stability of the cyanoisopropyl radical compared to 
the propagating radical of PVP. By comparing the change in P(T) as a function of RAFT agent 
conversion for the two experiments, the effect that the poly-RAFT agent concentration has on P(T) 
for each leaving group could be assessed. The calculations are given in Appendix A2.3. P(T) for X1 
was found to be 0.484 and did not change significantly until all of X1 was consumed. This indicated 
that the concentration of poly-RAFT agent did not affect P(T)	and hence fragmentation of the 
cyanoisopropyl R-group was greatly favored over that for the propagating radical. The monomer 
conversion was only 17% after all the detectable RAFT agent was converted to a poly-RAFT agent. In 
contrast, despite having a higher initial RAFT agent concentration, P(T) for XA2 was only 0.254 
initially and decreased to 0.085 at 72% XA2 conversion. The monomer concentration was only 0.6 M 
(77% conversion) at this stage, drastically reducing the rate of propagation.  




Even though the lower stability of the phthalimidylmethyl radical relative to the PVP propagating 
radical makes it a poor choice as a leaving group for a RAFT-mediated polymerization of NVP, this 
issue seems to only be a problem at low monomer conversions and low initial RAFT agent 
concentrations, as noted by the results of the polymerization with R = 196 in Table 3.1. The RAFT-
mediated polymerization with R = 117 in Section 3.2.2 gave a polymer with Mn,NMR = 9500 g/mol and 
a dispersity of 1.24. While this is within the bounds for a controlled polymerization, decreasing the 
dispersity of the product as much as possible would be beneficial. It would not only allow for a 
greater control of the aggregate architecture of the drug delivery system but it would also decrease 
the mole fraction of high molecular weight polymer chains. Since PVP is not biodegradable, it is 
essential that the polymer used for parenteral infusions does not have any polymer chains with a 
molar mass greater than the renal excretion threshold.21,22 This has been estimated to a value of 
25,000 g/mol by Gärtner et al.21 and, in practice, pharmaceutical grade PVP with a K-value of 17 (Mw 
= 10,000 g/mol) is the limit allowed for parenteral formulations.23 
The probability of adduct radical formation depends on the frequency of collision of a propagating 
radical with a RAFT agent as well as the relative stability of the adduct radical compared to the 
propagating radical, an increase in the probability of transfer can be obtained by using a higher initial 
RAFT agent concentration. 
P(T) for the polymerizations described in Sections 3.2.2 and 3.2.3 was calculated in order to 
measure the change in P(T) with initial RAFT agent concentration. The least squares approximations 
for [NVP] and [XA2] for the trials in Section 3.2.2 and 3.2.3 were obtained using OriginPro 8. These 
functions are given in Appendix A2.2. P(T) was parameterized with respect to monomer conversion 
in each case and the results were plotted in Figure 3.7. 
 
Figure 3.7: P(T) for the Polymerizations with Different Initial Monomer to RAFT Agent Ratios (R). A) R = 117 and B) R = 196. 
C) Comparison of P(T) for the Polymerizations with R = 5, 117 and 196. 
Since the approximations were made with only one data set for each monomer to RAFT agent ratio, 
nothing can be said about their accuracy. Also, the data sets for the polymerizations with R = 117 




and R = 196 consisted of only 5 and 4 data points, respectively. Thus the accuracy of these 
approximations is more questionable. Some qualitative information could still be extracted from the 
results though. 
From Figure 3.7.C, it is clear that P(T) tends to be greater throughout the reaction for lower initial 
monomer to RAFT agent ratios. Thus P(T) for the RAFT-mediated polymerization of NVP with XA2 
could be maximized by performing the polymerization with a high initial concentration of XA2. These 
conditions should also increase the concentration of poly-RAFT agent forming during the reaction. 
That would improve the probability of radical transfer between the propagating and dormant 
polymer chains of a specific molecular weight during the main equilibrium. However, in order to 




Polymerization of NVP with XA2 to prepare heterotelechelic linear polymers with a phthalimide α-
end-group and a xanthate ω-end-group was achieved as described by Postma et al.2 Analysis by 1H-
NMR and SEC revealed that the polymerization was well controlled in terms of α-end-group 
functionality, but there was a substantial loss of xanthate functionality in the isolated polymers. This 
was as high as 21% in some cases. There was also hybrid behavior observed due to the relatively 
poor radical stability of the phthalimidylmethyl radical compared to the propagating radicals of PVP. 
This caused the probability of a successful radical transfer from a propagating radical to a 
phthalimidylmethyl radical to decrease with poly-RAFT agent concentration. However, it was 
confirmed experimentally that this probability increased with an increase in the ratio of RAFT agent 
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For the preparation of high molecular weight polymers by RAFT-mediated polymerization in a batch 
reactor, the ratio of monomer to RAFT agent has to be sufficiently large. On the other hand, the 
probability of radical transfer from a propagating chain to the R-group of the RAFT agent at any 
given moment during the pre-equilibrium (P(T))	is inversely proportional to the ratio of NVP to 
RAFT agent for XA2. In Chapter 3, the dispersity of the polymer formed during the batch-mode RAFT-
mediated polymerization of NVP with XA2 decreased with an increase in P(T) for a particular 
molecular weight. Thus in order to synthesize PVP with a high molecular weight and the lowest 
possible dispersity by RAFT-mediated polymerization with XA2, the ratio of NVP to XA2 should be 
kept as low as possible during the polymerization. This can be achieved by performing the RAFT-
mediated polymerization in a semi-batch reactor. By this methodology, an initially large 
concentration of RAFT agent will ensure a high P(T) for the initial stages of the polymerization. P(T) 
can be optimized by gradually feeding more monomer and initiator into the reactor at a rate that 
keeps the monomer concentration at a level that allows propagation to take place, while 
maintaining a relatively high ratio of (poly)RAFT agent to monomer throughout the polymerization in 
order to end up with a narrow molecular weight distribution. 
The monomer concentration should also not be too low in order to avoid the rate of propagation 
from becoming diffusion controlled1-3 as well as to keep other parameters such as solution viscosity 
and reaction time in check. The initial RAFT agent concentration should not be too high so as to 
avoid any retardation or inhibition periods. During the initial stages of a RAFT-mediated 
polymerization, a larger fraction of propagating radicals are oligomeric in size than is the case during 
the initial stages of an NRP. Since termination is diffusion-controlled, the rate of termination during 
the initial stages of a RAFT-mediated polymerization is abnormally high.4 This could lower the 
fraction of phthalimide-functionalized dormant polymer chains present at the later stages of the 
polymerization unnecessarily as well as affect the polymer dispersity.	




In order to optimize the semi-batch process we first need to describe how the monomer should be 
fed into the reactor in order to control the monomer conversion profile for a particular set of initial 
conditions. It would also be helpful to deduce the evolution of Mn with reaction time. The 
concentration profile for the monomer in a semi-batch process can be calculated by solving Equation 
4.1.   
rr = − ( )" r r + ¡¢()( ) r r − £¤M¥¦! § ( )                                                                                (4.1) 
Where 
     M = monomer concentration (mol.dm-3) 
      MD = initial number of moles of monomer in the reaction mixture (mol) 
       dD = initial volume of the reaction mixture (dm3) 
         ¨	= total volume added to the reaction mixture from t0 to t	(dm3)	
«(C)	= concentration of monomer in the feed at time t	(mol.dm-3)	
							£¤	= propagation rate constant (mol-1.dm3.s-1) 
         ¬	= efficiency factor for the thermal initiator used (-) 
       £r = rate constant for initiator decomposition (s-1) 
        ­D = initial number of moles of initiator in the reaction mixture (mol) 
       £ = termination rate constant (mol-1. dm3.s-1) 
 
The derivation for Equation 4.1 can be found in Appendix A3. 
This is a non-linear first-order ordinary differential equation of three functions (M(t) ,	«(C)	and ¨(C)) of one variable (C). Hence two more equations are required to be able to simultaneously solve 
the system of differential equations. For instance, if the monomer concentrations in the reactor and 
the monomer feed are kept constant, the equation becomes: 
r r = ®¡¡¢ ¯(°±)²¥
¦! §( ) ∗  ; ¨(0) = 0                                                                                       (4.2) 





 = the constant concentration of monomer in the reaction mixture 
 
Equation 4.2 provides the rate at which the monomer feed needs to be added to the reactor during 
the reaction. 
Approximate solutions to the initial value problem can be obtained via numerical methods such as 
Euler’s Method, Predictor-Corrector or Runge-Kutta Methods. This will be useful in order to 
determine the total volume of the reaction mixture, and thus the concentration of the RAFT agent, 
with time. Knowing that would allow us to use Equation 3.5 to calculate Mn,theory. For a more 
accurate approximation of Mn, the RAFT agent conversion needs to be taken into account. However, 
the RAFT agent conversion in a semi-batch process should occur more rapidly due to the increase in 
P(T) hence any deviations of Mn,theory from Mn should only occur in the early stages of the 
polymerization. 
Evaluation of Equation 4.2 suggests that the rate at which the volume of monomer is fed into the 
reactor with time is directly proportional to the rate of propagation, the concentration of monomer 
in the feed and the desired concentration to be maintained in the reactor. This means that if a 
higher monomer conversion (lower monomer concentration) is maintained, the rate of monomer 
addition will be slower. This is intuitive since a lower monomer concentration would result in a 
slower rate of propagation. Also, the concentration of monomer in the feed must be greater than 
the maintained concentration in the reactor in order to overcome the dilution effect. 
The rate of chain growth in the reaction mixture can be approximated by Equation 4.3. 
r³lr ≈ ¤µm × − rr ¶ %                                                                                                                      (4.3) 
The concentration of poly-RAFT agent in the reactor with time depends on the total volume of the 
reaction mixture as well as the initial concentration of RAFT agent used. Since the concentration of 
poly-RAFT agent in a semi-batch RAFT-mediated polymerization will be greater than that for a 
conventional batch-mode synthesis until near the end of the reaction, the rate of chain growth of a 
polymer by a dead-end continuous semi-batch process (d-CSB) will be slower. The term “dead-end” 
implies that the loss of initiator with time will impose an upper limit for Mn. The rate of 
decomposition of the initiator is only dependent on the amount of initiator in the reactor and the 
initiator decomposition rate constant. It is not dependent on the volume of the reaction mixture 




hence it can be easily calculated and compensated for by adding more initiator with the feed, at a 
rate equal to the initial rate of initiator decomposition. This steady continuous semi-batch process 
(s-CSB) would not only be faster than a d-CSB but it also enables the synthesis of polymers with Mn 
larger than the upper limit for the d-CSB, provided that the rate of termination is kept sufficiently 
low. 
The real issue is that competing side-reactions of the xanthate (such as Chugaev elimination,5 
thermolysis4,6,7 or hydrolysis4,7-9) as well as the continuous initiation and termination of the 
propagating radicals during the reaction would affect the composition of end-groups in the final 
product as well as Ð. Thus an optimization of the semi-batch process that accounts for reaction time, 
composition and P(T) is necessary in order to achieve a product with the most desirable properties. 
From Equation 4.2, increasing 
r r would increase [M], provided « > . The concentration profile of 
poly-RAFT agent in the reactor can be determined by Equation 4.4, provided that the poly-RAFT 
agent and the initial RAFT agent do not undergo any side reactions. 
¸ = m( ) − ¸                                                                                                                                     (4.4) 
The change in [PX] with time can be calculated using Equation 4.5. 
rlmr = − m( )" r r − rr  m  = − m( )" r r − ( ) rmr + m( )" r r                                             (4.5) 
From Equation 4.5, increasing 
¹¨¹C causes [PX] and [X] to decrease more rapidly. This would result in a 
more rapid decrease in the probability of transfer for the pre-equilibrium phase. Thus, to avoid 
unnecessary dilution,  should be as high as possible i.e. neat monomer should be used as the 
feed. This may cause viscosity and mixing problems, limiting the maximum monomer conversion 
achievable between intervals. Also, the polarity of the reaction medium can affect the propagation 
rate constant beneficially.10 Knowledge about the change in P(T)	with a change in RAFT agent, poly-
RAFT agent and monomer concentrations is required in order to balance the increase in reaction 
rate with the decrease in P(T). Obtaining this information would require several experiments with 
varying initial monomer, RAFT agent and poly-RAFT agent concentrations. A simpler approach for 
gauging the behavior of P(T)	with respect to these parameters would be to perform semi-batch 
polymerizations that vary the dilution profile for [PX] and assess the differences in the composition 
of end-groups as well as Ð in the final products. The initial RAFT agent concentration was another 
variable parameter considered and its effect on the reaction time as well as the end-group 
composition was calculated. In order to avoid solvent effects as well as reduce the reaction times, 




the initial monomer concentrations in the reactor as well as in the feed were those for the undiluted 
monomer. The monomer conversion in the reactor was kept below 60% for the trials as large 
increases in viscosity began to occur beyond this conversion. A discrete semi-batch process was 
considered for the experiments since automated machinery was not required for the monomer 
additions, making the process mechanically simpler than a continuous semi-batch process. This 
process allows propagation to take place in batch mode until a specific monomer conversion is 
reached. The reaction is then stopped, a discrete amount of monomer and initiator is added and the 
reaction is continued. If Đ does not decrease significantly with a decrease in the rate of dilution of 
[PX], it would indicate that a continuous semi-batch process may have little noticeable effect other 
than increasing the reaction time. 
 
4.2) Simulating the Convergent Discrete Semi-Batch Process 
The rate of propagation for the time interval CO ≤ C < CO, between monomer additions, can be 
described by the kinetics for a batch process. Hence the concentration of monomer at any given 
time during the intervals can be determined by the piecewise function in Equation 4.6. 
M = i® ¥¼ ∗ ( ! ¼)"  − 1% + MO			¬½	CO ≤ C < CO                                                   (4.6) 
The derivation of Equation 4.6 can be found in Appendix A4. 
By rearranging Equation 4.6 to Equation 4.7, the reaction time required to reach a certain monomer 
conversion can be calculated. 
CO − CO = − i 	¾1 + i®  ∗¼¥¼  ¼°y¼ ¿                                                                                          (4.7) 
Ideally, the length of each time interval does not depend on the absolute values of MO  and MO 
but rather the desired monomer conversion as well as ­O. However, MO and MO should not be 
lower than certain critical values since £¤ becomes greatly affected by monomer concentration at 
high monomer conversions or high solution viscosities. This is due to the rate of propagation 
becoming diffusion controlled.1,2  From the experiments in Section 3.2, a distinct increase in viscosity 
of the reaction mixture was noted as the monomer conversion passed 60%.  
In order to find the fraction of R-group initiated chains as well as xanthate-functionalized chains at 
the end of the discrete semi-batch polymerization, various parameters need to be given. Firstly, it is 




assumed that the thiocarbonylthio end-group doesn’t undergo any side reactions. The amount of 
initiator that decomposed during the reaction interval will be replenished, keeping the RAFT agent to 
monomer concentration at 10:1. This way, the propagation rate will only decrease due to the 
dilution of initiator and will not be significantly affected by the initiator decomposition during each 
interval. The limit of monomer conversion for each reaction interval will be 60% in order to optimize 
P(T) for each interval while avoiding excessive viscosity increases. If the amount of monomer added 
at the end of each interval is kept constant, this discrete semi-batch process will converge to a 
continuous semi-batch process as the number of reaction intervals approaches infinity. This process 
will be referred to as a convergent discrete semi-batch process (CDSB.)  
The length of each time interval can be calculated using Equation 4.8. 
CO − CO = − i lnÁ
Â1 + i®² ∗
¼Ã¥¼  ¾ 
¼Ã~°"¼"Ã ¿Ä
Å                                                                        (4.8) 
The derivation of Equation 4.8 can be found in Appendix A6. 
The number of initiator-derived chain ends that form during the interval CO to CO can be calculated 
by equation 4.9. 
Æ­> = 2¬­>(1 − ¦−£¹(C>+1−C>§)                                                                                                                    (4.9) 
If it is assumed that the RAFT agent was completely converted to poly-RAFT agent at the end of the 
reaction and no side reactions took place, the mole fraction of R-group-functionalized polymer 
chains can be calculated using Equation 4.10. 
ÇÈÉ = m(∑ kË¼)Ì¼t m                                                                                                                                         (4.10) 
Where 
¸D = Number of moles of RAFT agent used  
If the RAFT agent conversion is known, the fraction of R-group-functionalized polymer chains for 
each interval can be calculated by multiplying Equation 4.10 by the fraction of RAFT agent 
conversion. The number of polymer chains that underwent termination by combination during each 
reaction interval can be calculated by Equation 4.11. Its derivation is in Appendix A7. 
ÍO = ¬­D(1 − ((¼°y¼)))                                                                                                                    (4.11) 




Thus the fraction of dormant chains after n intervals (ÇÎ) can be computed by Equation 4.12. 
ÇÎ = m(∑ lÏ¼)Ì¼t m                                                                                                                                       (4.12) 
Where 
ÍO = the number of terminated chains formed during interval >   
 
If it is assumed that all of the RAFT agent is consumed after interval >, the theoretical Mn of the 
dormant polymer chains can be approximated by a modified version of Equation 3.5. 
M, =  ¼ÃÐm × 0.6 × 111.14. + 281.34/                                           (4.13) 
After extensive evaluation of the literature, very few publications were found which contained the 
propagation and termination rate constants for NVP at 65 °C in the bulk phase.10-13 The variation in 
the values for the reported rate constants was quite broad, making it difficult to determine which of 
these values were accurate. The work by Stach et al.12 appears to be the most accurate as they 
worked with pulsed-laser polymerization and repeated their measurements for each parameter 
many times. They report an average £¤  = 2536 L.mol-1.s-1 for polymerization of neat NVP at 60 °C. 
No reports on the efficiency factor of AIBN in NVP could be found. To simplify our computations and 
remove the necessity for assumptions, the observed rate constant (&) at 65 °C in neat NVP was 
calculated from the polymerization data. 
This was done by rearranging Equation 4.6 to the following form: 
   = ®"¥ ∗   ( ! )"  − 1%                                                                                              
                 = &  ( ! )"  − 1%                                                                                                        (4.14) 
£r = 2.1 × 10Ò for AIBN at 65 °C was determined by least squares approximation of the data 
published in the Polymer Handbook14 to obtain an Arrhenius plot. The observed rate constant (&) 
was calculated from the slope of    versus   ( ! )"  − 1%, for each of the 
polymerizations performed in Section 3.2, as well as 4.5.1.  




The fraction of phthalimide-functionalized chain ends (ÇÈÉ) and dormant polymer chains (ÇÎ) 
during a CDSB were plotted as functions of Mn,theory	for different initial monomer to RAFT agent 
ratios (R0) in Figures 4.1.A and 4.1.B, respectively. The observed rate constant was parameterized to & = 0.250 L0.5.mol-0.5.s-0.5 (See Section 4.6.1 and Appendix A5 for the calculation.) The reaction time 
required to reach a particular Mn,theory	for the different initial RAFT agent concentrations is plotted in 
Figure 4.2. 
From Figure 4.2, a higher initial RAFT agent concentration results in a longer reaction time required 
to reach a desired Mn. A longer reaction time would result in more initiator-derived chains as well as 
more terminated chains forming, as illustrated in Figure 4.1. However, this difference was not more 
than 7% for for  ÇÈÉ and 5.5% for ÇÎ . 
 
Figure 4.1: Calculated Mole Fractions of A) Phthalimide-Functionalized Chain Ends and B) Dormant Polymer Chains for the 
RAFT-Mediated Polymerization of NVP with XA2 by the CDSB. 
 
Figure 4.2: Reaction Time Required to Reach a Specific Mn During the CDSB. 
 




4.3) Simulating the Steady Discrete Semi-Batch Process 
Another discrete semi-batch process was considered. In this process, the degree of dilution of the 
thiocarbonyl thio functionality was kept constant. This was achieved by keeping 
Ó¼  for each interval 
constant. This process will be referred to as a steady discrete semi-batch process (SDSB) as it does 
not converge to a continuous semi-batch process. 
The initial parameters, including the initial rate of dilution, were kept identical to those for the CDSB. 
Hence, the first two reaction intervals were identical. The length of each reaction interval, after the 
first, could be determined by Equation 4.15. Its derivation can be found in Appendix A8. 
CO − CO = − i  Ô1 + Õ¼ (0.5714)Ø                                                                                       (4.15) 
Where 
dO = dD + ∑ ÙOÚ                                                                                                                                          (4.16) 
ÙO = 2ÙO							∀	> > 1, > ∈ ℕ						(	Ù = dD)                                                                                              (4.17) 
 
ÇÈÉ, ÇÎ  and Mn,Theory	at the end of each reaction interval can be calculated by using Equations 4.10 
to 4.13 and 4.15. 
ÇÈÉ  and ÇÎ  for different R0 during the SDSB were plotted as functions of Mn,theory	in Figures 4.3.A 
and 4.3.B, respectively. The reaction time required to reach a particular Mn,theory	for the different R0 
is plotted in Figure 4.4. 
The results in Figures 4.1 – 4.4 indicate that there is only a maximum difference of 3% for ÇÈÉ of the 
CDSB compared to the SDSB at a specific R0. The difference in ÇÎ  between the two processes is 
only 2% at most. Their main difference is in the reaction times required to reach a specific molecular 
weight. The SDSB is less affected by the initial RAFT agent concentration as well as the desired 
molecular weight. 





Figure 4.3: Calculated Mole Fractions of A) Phthalimide-Functionalized Chain Ends and B) Dormant Polymer Chains for the 
RAFT-Mediated Polymerization of NVP with XA2 by the SDSB. 
 
Figure 4.4: Reaction Time Required to Reach a Specific Mn During the SDSB. 
The CDSB would take fourteen hours to reach Mn,Theory	= 10,000 g/mol if R0 = 10 while the SDSB 
would only take eleven and a half hours. The difference in Đ for the polymers prepared by a CDSB 
and a SDSB would indicate if a significant improvement in the transfer probability during the main 
equilibrium would be achieved by a continuous semi-batch process or if the reaction time would be 
unnecessarily extended after the pre-equilibrium phase is complete. In order to determine if there is 
a significant difference in ÇÈÉ, ÇÎ  and reaction time for a particular Mn,Theory, these parameters 








4.4) Simulating the Continuous Semi-Batch Process 
For a d-CSB with the monomer conversion being kept constant at 60%, the rate of monomer 
addition for the RAFT-mediated polymerization of NVP with XA2 at 65 °C can be calculated by 
modification of Equation 4.2 to use the observed rate constant &. This is illustrated in Equation 4.18. 
The reaction time required for the monomer conversion to reach 60% was calculated using Equation 
4.19. 
r r = Õ¡i¡¢ ¯(°±)Ü£r­D()(dD + ¨) ; ¨(0) = 0                                                                       (4.18) 
CD = − i ln	1 + ln	(0.4) Õ  %                                                                                                       (4.19) 
In order to improve the limiting molar mass plateau for the d-CSB, the amount of initiator consumed 
to reach 60% monomer conversion was replenished at the beginning monomer feeding stage. 
Mn,theory	can be calculated by Equation 4.20. 
M, = m × (dD + ¨) × 0.6 × 111.14. + 281.34/                                           (4.20) 
ÇÈÉ  can be calculated by Equation 4.21. 
ÇÈÉ = mmi¥¦! §i¥¦!( ! )§                                                                                             (4.21) 
ÇÎ  can be calculated by Equation 4.22. 
ÇÎ = mm¥(! )¥(!( ! ))	                                                                                                (4.22) 
ÇÈÉ  and ÇÎ  for different R0 during the d-CSB were plotted as functions of Mn,theory	in Figures 4.5.A 
and 4.5.B, respectively. The reaction time required to reach a particular Mn,theory	for different R0 is 
plotted in Figure 4.6. 





Figure 4.5: Calculated Mole Fractions of A) Phthalimide-Functionalized Chain Ends and B) Dormant Polymer Chains for the 
RAFT-Mediated Polymerization of NVP with XA2 by the d-CSB. 
 
Figure 4.6: Reaction Time Required to Reach a Specific Mn During the d-CSB. 
For an s-CSB, the amount of initiator is kept constant during the monomer feeding stage. Thus the 
rate of monomer addition can be calculated using Equation 4.23. 
r r = Õ¡i¡¢ ¯(°±)Ü£r­D(dD + ¨) ; ¨(0) = 0                                                                                         (4.23) 
Equations 4.19 and 4.20 still hold for the SDSB and once the volume ¨ required to reach Mn,theory	= 
10,000 g/mol is known, the time required for the reaction to be completed can be calculated from 
Equation 4.23. 
ÇÈÉ  can be calculated by Equation 4.24 and ÇÎ  can be calculated by Equation 4.25. Their derivation 
can be found in Appendix A9. 
ÇÈÉ = mmi¥()                                                                                                                                  (4.24) 




ÇÎ = mm¥()	                                                                                                                                  (4.25) 
ÇÈÉ  and ÇÎ  for different R0 during the s-CSB were plotted as functions of Mn,theory	in Figures 4.7.A 
and 4.7.B, respectively. The reaction time required to reach a particular Mn,theory	for the different R0 
is plotted in Figure 4.8. 
 
Figure 4.7: Calculated Mole Fractions of A) Phthalimide-Functionalized Chain Ends and B) Dormant Polymer Chains for the 
RAFT-Mediated Polymerization of NVP with XA2 by the s-CSB. 
 
Figure 4.8: Reaction Time Required to Reach a Specific Mn During the s-CSB. 
Comparing the results for the simulations of the continuous semi-batch processes to the discrete 
semi-batch processes, two important observations were made. ÇÈÉ and ÇÎ  for the d-CSB were 
similar to the CDSB for R0 = 10 and R0 = 20, the s-CSB had the lowest ÇÈÉ and ÇÎ . These were more 
than 10% lower for R0 = 10. Also both the continuous semi-batch processes would take considerably 
longer to reach the desired molecular weight than the discrete semi-batch processes. The d-CSB 
taking days longer for R0 = 10 and R0 = 20. 




4.5) Materials and Experimental Methods 
N-Vinylpyrrolidone was purchased from Merck and vacuum distilled from 5% ground potassium 
hydroxide before use. Azobisisobutyronitrile (AIBN) was purchased from Merck and recrystallized 
from methanol before use. Sodium metal, concentrated sulfuric acid (95 - 97%), anhydrous calcium 
chloride, potassium hydroxide pellets, sodium hydrogen carbonate (ACS reagent grade) and 
anhydrous calcium sulfate were purchased from Merck and used as received. Benzophenone, 
butylated hydroxytoluene (BHT) 99% (GC), dimethylacetamide (Chromosolv® Plus, for HPLC ≥ 99.9%) 
and chloroform-d 99.8 atom % were purchased from Sigma Aldrich and used as received. 4Å 
molecular sieves (8 – 12 mesh) were also purchased from Sigma Aldrich, dried in a vacuum oven at 
165 °C for 5 hours and allowed to cool to room temperature under vacuum before use. Methanol, 
dichloromethane and diethyl ether were purchased from KIMIX. Methanol was fractionally distilled 
before use. Dichloromethane was washed with concentrated sulfuric acid followed by 5% sodium 
bicarbonate solution and finally water before being dried over calcium chloride and fractionally 
distilled from calcium sulfate before use. Diethyl ether was distilled from sodium and 
benzophenone. Lithium chloride ≥ 98% was purchased from Riedel-de Haën and used as is. 0.45 μm 
Glass fiber prefilters were purchased from PALL Life Sciences. O-Ethyl-S-
(phthalimidylmethyl)xanthate (XA2) was prepared as described in Section 3.2.1. 
 
4.5.1) Determining the Observed Rate Constant for the Polymerization of NVP with XA2 
The data from the polymerizations in Sections 3.2.2 to 3.2.4 were used to determine & for R = 196, 
R= 117 and R = 5 respectively. For R =  20, the data from the first reaction interval of the CDSB and 
SDSB in Sections 4.5.2 and 4.5.3 was used. The first measurement was performed as described 
below. Degassed NVP (1 g, 9.0×10-3 mol) was transferred to a Schlenk tube along with XA2 (0.1265 g, 
4.5×10-4 mol) and AIBN (9.0×10-3 g, 5.5×10-5 mol). A magnetic stirrer bar was added and 3 freeze-
pump-thaw cycles were performed before back-filling with nitrogen. The sample was polymerized at 
65 °C for 1 hour and 50 minutes. Another two trials were performed though the reaction time was 
increased to 2 hours and 5 minutes in each case. 
 
4.5.2) Polymerization of NVP with XA2 by the Convergent Discrete Semi-Batch Process 
Degassed NVP (1 g, 9.0×10-3 mol) was transferred to a Schlenk tube (reactor) along with XA2 (0.1265 
g, 4.5×10-4 mol) and AIBN (9.0×10-3 g, 5.5×10-5 mol). A magnetic stirrer bar was added and 3 freeze-




pump-thaw cycles were performed before back-filling with nitrogen. The sample was polymerized at 
65 °C for 2 hours and 5 minutes. A sample of the crude reaction mixture was taken for NMR analysis. 
The reaction mixture was degassed by three freeze-pump-thaw cycles, before back-filling with 
nitrogen. The polymerization was re-initiated and polymerized for 10 hours and 5 minutes in total, 
with the reaction being stopped to take a sample and add more monomer at specific times. The 
reactant feed times and quantities are tabulated in Table 4.1. Crude and isolated polymer samples 
were taken at the end of each reaction interval and prepared as described in Section 3.2.2. From the 
third interval onwards, the reaction mixture became too viscous to be stirred by a magnetic stirrer 
alone. From then on, the reaction was stopped between intervals and the monomer feed was mixed 
in by hand using a Pasteur pipette. The reaction mixture was degassed by 3 freeze-pump-thaw cycles 
and back-filled with nitrogen before the polymerization was continued. 
Table 4.1: Monomer and AIBN Feed Profile for CDSB. 
Time (minutes) Volume of NVP added (mL) Mass of AIBN Added (mg) 
125 1.0 0 
245 1.0 0 
355 1.0 2.8 
435 1.0 0 
515 1.0 0 
 
4.5.3) Polymerization of NVP with XA2 by the Steady Discrete Semi-Batch Process 
10 mL of NVP was distilled. Degassed NVP (1 g, 9.0×10-3 mol), XA2 (0.1265 g, 4.5×10-4 mol) and AIBN 
(9.0×10-3 g, 5.5×10-5 mol) were placed in a Schlenk tube. A magnetic stirrer bar was added and 3 
freeze-pump-thaw cycles were performed. The Schlenk tube was back-filled with nitrogen and a 
drop was taken for NMR analysis of the initial conditions. The reaction mixture was polymerized at 
65 °C for 8 hours and 50 minutes. The reaction was stopped at specific time intervals, a sample of 
the reaction mixture was taken for analysis and a specific amount of degassed monomer as well as 
AIBN were carefully transferred to the reaction mixture. The reaction mixture was then degassed by 
three freeze-pump-thaw cycles and back-filled with nitrogen before continuing the polymerization. 








Table 4.2: Monomer and AIBN Feed Times for SDSB. 
Time (minutes) Volume of NVP added (mL) Mass of AIBN added (mg) 
125 1.0 0 
245 2.0 2.5 
380 4.0 0 
 
4.6) Results and Discussion 
4.6.1) Calculating the Observed Rate Constant for the Polymerization of XA2 with NVP  
The observed rate constant (&) was calculated from the slope of    as a function of 
  ( ! )"  − 1%, for each of the polymerizations performed in Section 3.2, as well as 4.5. 
The slope between each adjacent data pair was calculated to check for a linear correlation. This was 
equal to & for that time interval. The data for the trial with R = 5 had a non-linear correlation (see 
Figure A5.1 in Appendices) indicating that the observed rate constant decreases at high monomer 
conversions. The other experiments all showed a linear correlation, hence a least-squares 
approximation of the data was used. & for the first interval of the CDSB and the SDSB was also 
calculated, as described in Section 4.5.1. Since there were only two data points available for each 
analysis, the average of three trials was taken. The results of the observed rate constant calculations 
were tabulated in Table 4.3. The calculations for & for each of the trials can be found in Appendix 
A5. 
Table 4.3: Observed Rate Constant (&) during RAFT-mediated Polymerization of NVP with XA2 at Different Initial Monomer 














It would appear that the addition of benzene did not affect the initial observed rate constant 
significantly, as noted for the results of the trial with R = 5. Interestingly, the observed rate constant 
for the polymerization where R = 196 correlated well with the polymerizations where R = 20 while 
the polymerization where R = 117 had a much greater observed rate constant. The temperature was 
regulated in all cases by a thermocouple as well as a mercury thermometer and a large oil bath was 
used to dampen temperature fluctuations. The oil bath was allowed to stabilize until the 
temperature remained stable for an hour of frequent, periodic observation. It is unclear why there 
was an increase in the rate of polymerization for the trial with R = 117 but it was suspected that 
adventitious water present during the reaction may have increased £¤.12 Repeating the trial gave a 
similar observed rate constant which stands to question the theory of adventitious water being the 
cause. If it were the case, then it should not only occur for the batch polymerization with R = 117. 
The presence of water was detected during NMR analysis of the reaction mixture for the batch 
polymerizations with R = 117 but its concentration could not be quantified. It was also detected in 
the reaction mixtures during all the other trials.  
 
4.6.2) Polymerization of NVP with XA2 by the Convergent Discrete Semi-Batch Process 
NMR Analysis 
1H-NMR analysis of the crude reaction mixture was used to determine the conversion of monomer 
with time at each interval as well as Mn,NMR as described in Section 3.3.1. Figure 4.9 shows both the 
calculated and experimental monomer conversion profiles for the CDSB. The results fit well with the 
calculations for the first two intervals. A decrease in the rate of propagation was noted for the third 
interval. This could be due to adventitious oxygen being introduced during the reaction sampling and 
reactant feeding without stopping the reaction. From the third interval onwards, there was also a 
consistent increase in the total monomer to RAFT agent ratio by a factor of 1.5 more than the 
amount of monomer that was added. This could not be accounted for as the samples taken for 
analysis were minute and would have less of an effect on the concentrations of the reactants at later 
stages of the polymerization. There was also a noted increase in reaction rate from the third interval. 
The increase in the expected reaction rate could be due to the volume contraction as higher 
molecular weight polymer chains began to form. Another cause could be due to a decrease in £ as 
the viscosity increases. Another reason for this increase could be due to the addition of more AIBN 
than intended due to an error during the weighing of the reagent.   





Figure 4.9: Monomer Conversion Profile for CDSB. 
The fraction of xanthate functionality retained relative to phthalimide functionality was determined 
by 1H-NMR analysis of the crude reaction mixture. However, when the concentration of monomer 
relative to xanthate became too great, the base of the vinyl protons peak became a problem. 
Optimized shimming, presaturation of the 13C nuclei and using a higher field strength instrument 
could have improved the analysis conditions. 
The results of the CDSB analysis are given in Table 4.4. 













125 61% 80% 100 20.7 1700 2000 2200 1.23 
245 61% 95% 100 39.0 2900 3000 2900 1.19 
355 57% 100% ca. 100 59.6 4100 4000 4300 1.21 
435 60% 100% ca. 100 90.1 6300 6300 5800 1.16 
515 60% 100% ca. 100 118.6 8200 8200 7900 1.16 
605 62% 100% 79a 148.2 10500 10100 10600 1.17 
 




The total monomer to initial RAFT agent ratio could be calculated from the NMR data which allowed 
the accurate determination of Mn,theory	at the end of each interval. Mn,theory	correlated well with Mn,NMR	indicating that XA2 had indeed been completely converted to poly-RAFT agent before any 
significant propagation took place. 
 
SEC Results 
SEC analyses of the samples from the CDSB were performed as described in Section 3.2.5. The SEC 
traces were normalized as described in Appendix A1 and plotted according to molecular weight in 
Figure 4.10.A. 
 
Figure 4.10: A) Molar Mass Distributions for the CDSB. B) Comparison of Molar Mass Distributions for the Final Product of 
the CDSB to those for the Batch-Mode Polymerizations Performed in Section 3.2.2 and 3.2.3. 
Figure 4.10.B compares the normalized SEC results for the final product of the CDSB with the SEC 
results for the batch polymerizations described in Sections 3.2.2 and 3.2.3. From Figure 4.10.B, it is 
clear that the product of the CDSB had the lowest Ð. It was 0.07 less for the CDSB than for the batch 
polymerizations at a similar monomer conversion.  
 
4.6.3) Polymerization of NVP with XA2 by the Steady Discrete Semi-Batch Process 
NMR Analysis 
1H-NMR analysis of the crude reaction mixture was used to determine the conversion of NVP and 
XA2 with time as well as Mn,NMR as described in Section 3.3.1. The amount of xanthate relative to 
phthalimide present in the reaction mixture at the end of each interval was also measured using this 




data. The crude reaction mixture samples from the third and fourth intervals were analyzed using a 
600 MHz Unity NMR spectrometer. The higher magnetic field strength provided spectra with better 
resolution between the methylene protons peak of the xanthate end group and the carbon satellites 
of the vinyl protons peak. However, half of the carbon satellite peak still overlapped with the 
methylene protons peak of the xanthate. The results of the SDSB are given in Table 4.5. Figure 4.11 
shows the monomer conversion profile for the SDSB polymerization of NVP with XA2. It appeared as 
though the observed rate constant had increased considerably for the later stages. This could have 
arisen from adventitious water in the reaction mixture, temperature spikes in the oil bath or the 
inaccurate weighing of the initiator added to the reaction at the end of the second interval.  
 
Figure 4.11: Monomer Conversion Profile for SDSB. 
 
The 600 MHz 1H-NMR spectra of the samples taken for the third and fourth intervals of the SDSB are 
superimposed on each other in Figure 4.12. The spectra were normalized by setting the integral for 
the phthalimide protons peak at δ = 7.67 – 7.74 ppm to 2.00. Only half of the carbon satellite of the 
vinyl protons peak (e) overlapped with the methylene protons peak of the xanthate (d). Its 
interference was accounted for by subtracting 0.5×0.55% of the integral intensity of the vinyl 
protons peak (e) from that of the methylene protons peak (d) of the xanthate. 
 




















125 57% 82% ca. 100 20.9 1450 1900 2800 1.12 
245 62% 95% ca. 100 41.0 3000 3300 3300 1.15 
380 64% 99% 85a 76.5 6200 5700 7000 1.19 
530 64% 100% 85a 184.4 14600 13400 16000 1.19 
 
Strangely, there was no change in the fraction of xanthate compared to phthalimide between the 
two 600 MHz NMR spectra – both had an integration intensity of 1.7 after normalization and 
interference subtraction. One reason for this could be that there was no change in the amount of 
xanthate but rather that the longitudinal relaxation time (T1) for the methylene protons of the 
xanthate is longer than that for the phthalimide protons. This would result in a steady state forming 
at a lower relative population for the methylene protons, provided the transient scan time is 
sufficiently short. However, the spectra were recorded with a four second acquisition time and a 2 
second relaxation delay. This is a generally long transient time and most protons should relax to 
their equilibrium population difference. However, T1 has been shown to be dependent on molecular 
size as larger molecules tumble more slowly.  





Figure 4.12: 600 MHz 1H-NMR Spectrum of Reaction Mixture in CDCl3 for (-) 3
rd Interval of SDSB and (-) 4th Interval of SDSB. 
 
SEC Results 
SEC analyses of the samples obtained from the SDSB was performed as described in Section 3.2.5. 
The SEC traces were normalized as described in Appendix A1 and plotted according to molecular 
weight in Figure 4.13.A: 
 
Figure 4.13: A) Molar Mass Distributions for SDSB. B) Comparison of Molar Mass Distributions for the Product of the SDSB 
with those for the Polymerizations Performed in Batch-Mode with R = 117 and R = 196 that had a Similar Mn,SEC. 




Figure 4.13.B is a comparison of the normalized molar mass distributions for the final product of the 
SDSB with those for the batch-mode polymerizations described in Section 3.2.2 and 3.2.3. A 
comparison between the CDSB and SDSB results indicated that there was not much difference 
between the two products in terms of their distribution though an accurate comparison could not be 
made due to the differences in Mn,SEC between the two products. It was much simpler to prepare a 
polymer with the desired molecular weight by the CDSB. Optimizing the stabilizing group on the 




The poor pre-equilibrium kinetics for the RAFT-mediated polymerization of NVP with XA2 were 
improved by optimizing the probability of radical transfer to the phthalimidylmethyl leaving group of 
XA2 from a propagating radical. This was achieved by performing the polymerization using a discrete 
semi-batch process. This process was modelled for two different monomer addition profiles. The 
first profile converged to a continuous semi-batch process and hence was called the convergent 
discrete semi-batch polymerization (CDSB). It resulted in a product with the lowest Ð for a particular Mn. It was also the easiest way to prepare a product with a specific Mn. The second process kept the 
dilution rate of the xanthate functionality constant and did not converge to a continuous semi-batch 
process. This process, called the steady discrete semi-batch process (SDSB), had products with only 
slightly larger Ð than those prepared by the convergent discrete semi-batch polymerization. The 
reaction time was significantly shorter for the SDSB. Also, both the fraction of phthalimide-
functionalized chain ends as well as the fraction of dormant polymer chains were calculated to be 
larger for the SDSB than for the CDSB. The loss of xanthate end-groups compared to phthalimide 
end-groups was found to not increase with time. This suggested that the decomposition was caused 
by a reaction with a trace impurity rather than by a spontaneous decomposition such as thermolytic 
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Deprotection of the Primary Amine α-End-Group on PVP 
 
5.1) Introduction 
As mentioned in Section 3.1, the thiocarbonylthio functional group reacts with amines to form a 
thiol and an O-thiocarbamate. This means that any free amine that forms by deprotection of the 
phthalimide-functionalized chains would react with any xanthate present in the reaction mixture. 
Also, the deprotection methods for the phthalimide group involve either reaction with hydrazine in 
methanol1-4 or borohydride reduction followed by hydrolysis. Hydrazine is more nucleophilic than 
primary amines thus it would react rapidly with thiocarbonylthio groups. Sodium borohydride also 
acts as a nucleophile and attacks the xanthate end-group, converting it to a thiol in most cases. Since 
thiols can undergo oxidation to form disulfides under atmospheric conditions, it is necessary to end-
cap these functional groups to avoid increasing Mn and Đ of the PVP block. While some thiol-
functionalized PVP would be useful for coupling a targeting ligand to the surface of the micelle drug 
delivery system, most of it is not required and should be removed rather than capped. This is 
especially the case if any synthesis steps later on require catalytic hydrogenation because sulfur is 
generally not compatible with noble metal catalysts. Luckily, the xanthate end-group can be 
converted to a variety of different functional groups.5-9 
To determine the amount of amine-functionalized polymer present after deprotection, 
derivatization with 3,5-bis(trifluoromethyl)benzaldehyde (TFBA) in a deuterated solvent (except 
water) and analyzing the sample by 1H-NMR and 19F-NMR was performed as described by Ji et al.10  
α, α, α-trifluorotoluene (TFT) was used as an internal standard. TFBA reacts with primary amines to 
form an imine, as depicted in Scheme 5.1. The fluorine nuclei of the TFBA imine conjugate have a 
different 19F-NMR resonance frequency compared to those of free TFBA and the two peaks are 
resolved even for derivatized polymers. 
 
Scheme 5.1: Imine Formation of TFBA with Primary Amines. 
Derivatization with pentafluorobenzaldehyde was also attempted. 




5.2) Materials and Experimental Methods 
Sodium hydrogen carbonate (NaHCO3, ACS reagent grade), anhydrous calcium chloride, anhydrous 
calcium sulfate, concentrated sulfuric acid (95 – 97%), sodium metal and concentrated hydrochloric 
acid were purchased from Merck and used as received. Benzophenone, hydrazine hydrate (50 – 
60%), 3,5-bis(trifluoromethyl)benzaldehyde (TFBA), pentafluorobenzaldehyde (PFBA), α,α,α-
trifluorotoluene (TFT) and chloroform-d 99.8 atom % were purchased from Sigma Aldrich and used 
as received. 4Å molecular sieves (8 – 12 mesh) were also purchased from Sigma Aldrich, dried in a 
vacuum oven at 165 °C for 5 hours and allowed to cool to room temperature under vacuum before 
use. Methanol, dichloromethane and diethyl ether were purchased from KIMIX. Methanol was 
fractionally distilled before use. Dichloromethane was washed with concentrated sulfuric acid 
followed by 5% sodium bicarbonate solution and finally water before being dried over calcium 
chloride and fractionally distilled from calcium sulfate. Diethyl ether was distilled from sodium and 
benzophenone. Dimethylacetamide (Chromosolv® Plus, for HPLC ≥ 99.9%) was purchased from 
Sigma Aldrich and used as received. Butylated hydroxytoluene (BHT) 99% (GC) was purchased from 
Sigma Aldrich and used as received. Lithium chloride ≥ 98% was purchased from Riedel-de Haën and 
used as is. 0.45 μm Glass fiber prefilters were purchased from PALL Life Sciences. SnakeSkin® Dialysis 
tubing (3500 g/mol nominal molecular weight cutoff) was purchased from Thermo Scientific and 
used as is. 
 
5.2.1) Thermolysis of the Xanthate End-Group 
The general procedure for removal of the xanthate end-group by thermolysis was performed as 
follows. Isolated PVP to be thermolyzed was placed in a petri dish and covered with aluminium foil. 
A few small holes were punched in each cover using a fine needle. The samples were loaded into a 
vacuum oven along with a vial containing about 20 mL of liquid nitrogen and the pressure in the 
oven was dropped to below 1 mbar. Heating was then initiated and the samples were heated at 140 
°C for 8 hours while keeping the pressure below 1 mbar. Afterwards, the heating was stopped and 
the oven was allowed to cool before the pressure was returned to atmospheric pressure. The 








5.2.2) Deprotection of the Primary Amine End-Group 
 Thermolyzed PVP (0.3 g, 2.1×10-5 mol, Mn = 14,000 g/mol) was placed in three separate vials. The 
vials were labeled 1, 2 and 3. A 2.0 M stock solution of hydrazine in methanol was prepared by 
adding hydrazine hydrate (1.3037 g, 2.03×10-2 mol) to 8.7 mL of methanol. Specific aliquots of this 
solution were added to each vial and diluted with methanol. The amount of methanol and hydrazine 
solution added to each vial is depicted in Table 5.1. 
Table 5.1: Hydrazine Stock Solution Dilution with Methanol for the 3 Trials. 
Vial Volume of Hydrazine Solution added (mL) Volume of Methanol added (mL) Molar Excess of Hydrazine 
1 1 0 93 
2 0.5 0.5 47 
3 0.1 0.9 9 
 
The vials were closed and left to react for 16 hours at 25 °C. The samples were then precipitated 
from diethyl ether three times, using dichloromethane as a solvent, and dried under vacuum. The 
isolated products were analyzed by 1H-NMR to determine the degree of phthalimide deprotection. 
 
5.2.3) Dialysis of the Deprotected PVP 
Three samples of deprotected polymer, prepared as described in Section 5.2.2 with a 10 times molar 
excess of hydrazine, were each dissolved in 5 mL methanol. Each sample was placed in a separate 
3,500 molecular weight cut-off (MWCO) dialysis tube and dialyzed with a different solvent. Sample 1 
was dialyzed with three portions of 100 mL methanol, changed every 8 hours. Sample 2 was dialyzed 
with 3 portions of 100 mL de-ionized water followed by 2 portions of 100 mL methanol, changed 
every 8 hours. Sample 3 was dialyzed with 1 portion of 100 mL 0.1 M HCl followed by 3 portions of 
100 mL de-ionized water and finally 2 portions of 100 mL methanol, changed every 8 hours. The 
polymers were isolated from solution by evaporation of the methanol under vacuum followed by 
dissolving the residue in DCM and precipitation from diethyl ether. 1H-NMR spectra of Sample 2 and 
Sample 3 in CDCl3 were recorded. 
 
5.2.4) Derivatization with 3,5-Bis(trifluoromethyl)Benzaldehyde  
0.024 g TFBA (9.9×10-5 mol) and 0.018 g TFT (1.23×10-4 mol) were added to 10 mL CDCl3 to prepare a 
TFBA stock solution. 0.0193 g of the isolated polymer from Sample 2, prepared in Section 5.2.3, was 




added to 1 mL of the TFBA stock solution. 5 beads of 4Å molecular sieves and 0.01 g NaHCO3 were 
added to the sample and it was left to react in a 2 mL amber vial with a Teflon lid for 24 hours. The 
sample was filtered using a Pasteur pipette with a glass wool plug before being placed in an NMR 
tube for analysis. Both 1H as well as 19F NMR spectra were recorded for the sample and the stock 
solution. An acquisition time of 4 seconds and a relaxation delay of 16 seconds were used for 
acquiring the 19F-NMR spectra. These were set to 4 seconds and 1 second, respectively, for the 1H-
NMR spectra. 
 
5.2.5) Derivatization with Pentafluorobenzaldehyde 
0.03 g (2.0×10-6 mol) deprotected PVP (Mn,NMR	=  13,400 g/mol), isolated as described for Sample 1 in 
Section 5.2.3, was dissolved in 1.00 mL CDCl3. 0.007 g (3.6×10
-5 mol) PFBA was added along with 0.02 
g (2.4×10-4 mol) NaHCO3 and a few beads of 4 Å molecular sieves.  The sample was sealed and left in 
a cool, dark cupboard overnight. The solution was filtered through glass wool before 1H-NMR 
analysis. 
 
5.3) Results and Discussion 
5.3.1) Themolysis of the Xanthate End-Group 
NMR Analysis 
The thermolyzed polymer samples were analyzed by 1H-NMR in CDCl3 in order to determine the 
degree of xanthate removal. Figure 5.1 shows the 1H-NMR spectrum of the isolated polymer product 
from the CDSB superimposed on that for the thermolyzed product. The peaks at δ = 4.85 ppm and 
6.95 ppm are characteristic of the internal and terminal vinyl protons of the alkene end-group on the 
thermolyzed product. Using the phthalimide proton peaks as an internal reference, the two spectra 
were normalized. Integration of the region in the 1H-NMR spectrum of the thermolyzed product, 
where the methylene protons of the xanthate should be, indicated that the concentration of 
xanthate in the thermolyzed product was too low to be detected by 1H-NMR. UV analysis could be 
used to get a more accurate measurement as it is a more sensitive technique.9,11 However, due to 
time constraints, further analysis of the thermolysis efficiency was suspended. No byproducts of 
polymer degradation could be detected. 





Figure 5.1: 1H-NMR Spectra for (-) Xanthate-Functionalized PVP Starting Material and (-) Thermolyzed Product. 
 
SEC Analysis 
The thermolyzed PVP was analyzed by SEC in order to ensure that the polymer chains did not 
undergo any degradation during the thermolysis. Samples were prepared as described in Section 
3.2.5. The SEC traces of the initial polymer and the thermolyzed product were baseline corrected 
and normalized as described in Appendix A1. The normalized distributions were plotted as functions 
of molecular weight in Figure 5.2. 
 
Figure 5.2: Comparison of the Normalized Molecular Weight Distributions for the Xanthate-Functionalized PVP and the 
Thermolyzed Product. 




The almost identical molecular weight distributions indicate that there was indeed no degradation of 
the polymer chains. The slight shift in the peak positions could be due to non-linear baseline 
variations that could not be accounted for or a change in the hydrodynamic volume of the PVP due 
to the different end-group. 
 
5.3.2) Deprotection of the Primary Amine α-End-Group and Isolation of the Product by Dialysis 
NMR Analysis 
The 1H-NMR spectrum for vial 3 prepared in Section 5.2.2, with a 10-fold molar excess of hydrazine, 
is illustrated in Figure 5.3. The NMR spectrum of the thermolyzed polymer starting material was 
superimposed on it. The singlet at δ = 4.7 ppm could be due to some adsorbed molecular hydrogen 
that may have formed as a byproduct of hydrazine decomposition.12,13 However, high temperatures 
are required for autothermal decomposition.13 It could also be due to residual hydrazine although no 
references for the chemical shift of hydrazine in CDCl3 could be found. 
 
Figure 5.3: 1H-NMR Spectra for (-) Thermolyzed Polymer. (-) Deprotected Polymer. 
The absence of the phthalimide protons peaks at δ = 7.73 and 7.83 ppm indicated that the 
deprotection was quantitative even with only a 10-fold molar excess of hydrazine (equivalent to 0.2 
M hydrazine and 0.02 M polymer solution). The peaks at δ = 7.81 and 8.25 ppm indicate that some 
residual 2,3-dihydro-1,4-phthalazinedione remained in the sample after precipitation. The spectrum 




also indicated that the alkene end-group was not affected during the deprotection (δ = 6.91 – 7.06 
ppm). 
The 1H-NMR spectra for Sample 2 and Sample 3, prepared in Section 5.2.3, were normalized by 
adjusting the integral for the polymer backbone peak at δ = 2.9 – 4.2 to equal that for the 
normalized thermolyzed polymer backbone peak with the same resonance frequency. Any changes 
in the fraction of alkene end-group between the thermolyzed PVP starting material and the dialyzed 
product was determined by measuring the change in the integral for the vinyl protons at δ = 6.95 
ppm. For Sample 2, the integral intensity of the alkene end-groups changed from 0.81 to 0.74. This 
indicated that 9% of the alkene-terminal PVP chains had lost their alkene functionality, 
corresponding to approximately 7% of all the PVP chains in the sample. This change for Sample 3 
was from 0.79 to 0.67, corresponding to 15% of the alkene-terminal PVP chains and approximately 
12% of all the PVP chains in the sample. These results indicated that the presence of a strong acid 
increases the rate of alkene decomposition. The product formed could be an alkyl halide end-group, 
a hydroxyl end-group or an aldehyde end-group. A deeper investigation of the xanthate and alkene 
end-group hydrolysis is covered in Chapter 6. 
 
SEC Analysis 
The deprotected polymer was isolated from the excess hydrazine, as well as any byproducts of the 
deprotection, by the dialysis procedures described in Section 5.2.3. Figure 5.4.A shows the 
normalized molecular weight distribution for the deprotected polymer isolated from Sample 1 in 
Section 5.2.3. The normalized molecular weight distribution of the thermolyzed polymer starting 
material was superimposed on it. The comparison indicated that the Mn,SEC	decreased by 1,900 
g/mol and Đ increased by 0.03. This would suggest decomposition of the polymer chains by the 
hydrazine. However, it is unlikely that hydrazine could cleave the hydrocarbon backbone. The 
unstable baseline made accurate correction impossible. A change in the hydrodynamic volume for 
PVP due to the different end-group could also play a role. Most likely however, the SEC 
chromatogram of the thermolyzed polymer was inaccurately taken.  The SEC trace for this sample is 
illustrated in Figure 5.4.B. 
The close correspondence of peak intensities in the high molecular weight region indicated that no 
coupling reactions, such as disulfide coupling or imine formation between an aldehyde-
functionalized PVP and the amine-functionalized PVP, had occurred. 
 





Figure 5.4: A) Normalized Molecular Weight Distribution for the (-) Polymer Isolated from Sample 1 in Section 5.2.3 
Superimposed with those for the (-) Thermolyzed Polymer. B) SEC Trace for the Thermolyzed Polymer. 
Figure 5.5.A shows the normalized molecular weight distribution of the deprotected polymer 
isolated from Sample 2 in Section 5.2.3 superimposed with that for its starting material. An increase 
in Mn,SEC by 1,700 g/mol as well as an increase in Đ by 0.05 indicated that some of the polymer chains 
had undergone coupling reactions. A possible mechanism for coupling would be the partial 
hydrolysis of the alkene end-groups of the thermolyzed polymer to aldehydes followed by imine 
formation between the free amine end-groups and the aldehyde end-groups. This deduction is 
complemented by the results of Figure 5.5.A as the original distribution did not broaden but rather 
just decreased in intensity while a high molecular weight shoulder formed. Formation of disulfide 
linkages is unlikely to occur to a significant extent as the xanthate end-group was reduced to a level 
below the detection limit for NMR. Further evidence of conjugation by imine formation was noted 
for the results of Sample 3. Figure 5.5.B shows the normalized molecular weight distribution of the 
deprotected polymer isolated from Sample 3 as well as that for the thermolyzed PVP starting 
material. Comparing the normalized molecular weight distribution for Sample 3 with those for 
Sample 2, it is evident that a larger fraction of polymer chains had undergone coupling for Sample 3. 
For sample 3, Mn,SEC increased by 3,500 g/mol and Đ increased by 0.13. The fact that the major peak 
for the molecular distributions of Sample 2 and Sample 3 did not shift significantly further indicated 
that the change in the molecular weight distribution for Sample 1 was due to an error in the 
measurement caused by the unstable baseline rather than by end-group effects. 
 
 





Figure 5.5: Normalized Molecular Weight Distributions of the Deprotected Polymer Samples (-) Isolated from A) Sample 2 
and B) Sample 3, prepared in Section 5.2.3. (-) Thermolyzed Polymer. 
 
5.3.3) Derivatization with 3,5-Bis(trifluoromethyl)Benzaldehyde 
NMR Analysis 
The 19F-NMR spectrum of the TFBA stock solution, illustrated in Figure 5.6, was used to determine 
the ratio of TFBA relative to TFT. This ratio was 0.795 : 1. 
 
Figure 5.6: Normalized 19F-NMR Spectrum of TFBA Stock Solution Prepared in Section 5.2.4. 




There was an unassigned peak at δ = -63.02 ppm. It was unclear what impurity was responsible for 
this peak but it was suspected that it was the TFBA hydrate. The 1H-NMR spectrum of the stock 
solution, illustrated in Figure 5.7, contained a broad resonance signal at δ = 3.8 ppm. It had the same 
integration intensity, relative to TFBA, as the fluorinated impurity. A resonance in this region is 
characteristic of the carbonyl proton of a hydrate. The electron-withdrawing effect of the meta-
trifluoromethyl functional groups could cause the hydrate of TFBA to be more stable than that for 
benzaldehyde. 
 
Figure 5.7: Normalized 1H-NMR Spectrum of TFBA Stock Solution Prepared in Section 5.2.4. 
The 1H-NMR spectrum of the TFBA-derivatized sample, prepared in Section 5.2.4, is illustrated in 
Figure 5.8. The peaks downfield of δ = 8 ppm are from the excess TFBA. It was used to determine the 
amount of TFT relative to PVP. The spectrum was normalized with respect to the number of PVP 
chains in the sample by adjusting the integral for δ = 2.9 – 4.2 ppm to 393.68. This value is equal to 
the integral for the same region in the 1H-NMR spectrum of the thermolyzed PVP starting material, 
illustrated in Figure 5.9. The difference in the amount of residual diethyl ether absorbed in the 
separate samples was accounted for using a numerical procedure that is described in Appendix A10. 





Figure 5.8: 1H-NMR Spectrum of TFBA-Derivatized PVP Prepared in Section 5.2.4. 
 
Figure 5.9: 1H-NMR Spectrum of Thermolyzed Polymer used as the Starting Material for the Preparation of Sample 2 in 
Section 5.2.3. 




Once the 1H-NMR spectrum of the TFBA-derivatized polymer sample was normalized, the amount of 
TFT relative to the phthalimide-initiated PVP chains in the sample could be determined by dividing 
the integral for the aromatic TFT protons by 5. This gave a value of 11.22. 
The change in the intensity of the TFBA peak in the 19F-NMR spectrum of the TFBA-derivatized PVP 
sample, illustrated in Figure 5.10, could be used to determine the fraction of TFBA that reacted with 
the amine end-groups of PVP. This was calculated according to Equation 5.1. 
o ¥y(q)rqo ¥"(q)rqst!x~.ust!x~.yyst!x~.ust!x~.yy o ¥y(q)rqst!x~.ust!x~.yy = .à.i.à = 0.107                                                                                (5.1) 
Where 
¬(á) = 19F-NMR spectrum of TFBA stock solution 
¬i(á) = 19F-NMR spectrum of TFBA-derivatized PVP sample 
 
Figure 5.10: 19F-NMR Spectrum of TFBA-Derivatized PVP Prepared in Section 5.2.4. 
The fraction of phthalimide-functionalized PVP that had been successfully deprotected and 
derivatized was calculated according to the Equation 5.2. 
o ¥~(q)rqo ¥u(q)rqst!x~.ust!x~.yyst!x~.ust!x~.yy o ¥~(q)rqst!x~.ust!x~.yy × 0.795 × 11.22 = 0.95	                                                                      (5.2) 




This indicated that at least 95% of the phthalimide functionalized chains were successfully 
deprotected and derivatized. This is in close agreement with the lack of any detectable phthalimide 
in the NMR spectra for the deprotected polymer samples as well as the theory that a few percent of 
the PVP chains underwent coupling by imine formation with aldehyde-functionalized PVP. 
 
5.3.4) Derivatization with Pentafluorobenzaldehyde 
NMR Analysis 
In order to normalize the 1H-NMR spectrum of the PFBA-derivatized PVP, the integral for the alkene 
protons in the 1H-NMR spectrum was adjusted to 0.85 – the integral value for this peak after 
normalizing the thermolyzed sample. The interference from the carbon satellite of the chloroform 
peak was taken into account as described in Appendix A11. This was the fraction of xanthate end-
groups in the starting material relative to phthalimide end-groups, as illustrated in Figure 4.12. The 
fraction of PFBA-derivatized PVP relative to phthalimide could then be measured directly from the 
integral of the imine protons at δ = 8.20 to 8.47 ppm, as illustrated in Figure 5.11. 
 
Figure 5.11: 1H-NMR Spectrum for the PFBA-derivatized PVP. 




This gave a value of 0.96, indicating that this procedure is as good as the TFBA derivatization analysis 
for polymers with a molecular weight range around 14,000 g/mol. For higher molecular weight 
polymers, the TFBA derivatization may be preferable as there are 6 equivalent fluorine nuclei per 
molecule as opposed to the single carbonyl hydrogen on PFBA. 19F nuclei have a relative sensitivity of 
83% compared to 1H thus the TFBA derivatization should provide greater sensitivity by a factor of 
0.83 × 6 = 4.98. However, the high chemical shift anisotropy effect for fluorine nuclei causes their 
transverse relaxation to decrease with the magnetic field strength of the instrument.14 This can 
result in a reduced sensitivity from broadening signals when high field strength instruments are 
used. Also, the analysis time for the TFBA derivatization is greater than for the PFBA derivatization as 
three NMR spectra need to be taken and the longitudinal relaxation time of fluorine nuclei is usually 
considerably longer than for hydrogen nuclei.15,16 Hence, the greater sensitivity of the TFBA 
derivatization may only be necessary for analyzing polymers with a much higher molecular weight. 
 
5.4) Conclusions 
The quantitative removal of the phthalimide protecting group from PVP prepared by RAFT-mediated 
polymerization with XA2 was achieved by reacting with hydrazine in methanol. This was confirmed 
by 1H-NMR. The presence of free primary amines on the deprotected, isolated PVP was quantified 
using TFBA and PFBA derivatization procedures. Both showed over 90% of the phthalimide chain 
ends had been converted to phthalimide chain ends. PFBA derivatization proved to be effective and 
simpler for analyzing polymers with a molecular weight range of up to 14,000 g/mol. The xanthate 
end-group had to be removed beforehand as it would react with the hydrazine in solution as well as 
the free amine end-groups. This was quantitatively achieved by thermolysis of PVP in a vacuum oven 
at 140 °C and at a pressure of less than 1 mbar. There was an increase in Mn,SEC and Ð for the 
deprotected PVP compared to the thermolyzed PVP. It was considered that this was occurring due to 
hydrolysis of the alkene end-groups to aldehyde end-groups during dialysis and their subsequent 
conjugation with the amine end-groups to form imine bonds. Dialysis with 0.1 M HCl resulted in a 
greater increase in both Mn,SEC and Ð. 
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Hydrolysis of the Xanthate and Alkene End-Groups on PVP 
 
6.1) Introduction 
In Section 5.3.2, it was proposed that alkene end-groups of the thermolyzed PVP tend to decompose 
into aldehyde end-groups in aqueous media. The hydrolysis of the alkene chain ends to form 
aldehyde chain ends during dialysis of the deprotected PVP with water and with 0.1 M HCl was 
problematic as it resulted in the formation of imine bonds between the amine chain ends and the 
aldehyde chain ends in organic solvents. This could prevent the derivatized amine end-groups from 
acting as initiators for the ROP of L-lysine NCAs. Furthermore, the method of choice for deprotection 
of the Nε-(benzyloxycarbonyl)-L-lysine residues was acidolysis with HBr in a 
dioxane/dichloromethane solvent mixture (see Sections 8.2.2 and 8.3.1). Under these conditions, it 
is likely that any alkene groups would undergo electrophilic addition of HBr. The alkyl bromide could 















































Scheme 6.1: Addition of HBr to Alkene End-Groups of PVP and Subsequent Hydrolysis of the Bromide. 
On the other hand, the free amines on the lysine residues could attack the alkyl halide, resulting in 
the coupling of polymer chains. The hydroxyl-terminated PVP is known to convert to an aldehyde via 
elimination of pyrrolidone,1,2 as illustrated in Scheme 6.2. 
 
 






















Scheme 6.2: Formation of Aldehyde End-Groups via Elimination of Pyrrolidone. 
The presence of an aldehyde functional group on the PVP block of the block copolymer would be 
problematic as it could react with the primary amines of the lysine residues as well as that on the 
daunosamine residue of Doxorubicin. This could affect the micelle self-assembly, architecture or 
drug release profile. Thus it would be best to either protect or remove the aldehyde chain end after 
the acidolysis step or to remove the xanthate end-group via another method. If the xanthate can be 
quantitatively converted to an aldehyde chain end without affecting the phthalimide chain end, it 
could be removed before the amine is deprotected. Reduction or oxidation of the aldehyde are two 
possible methods for its selective removal. Phthalimides are generally insensitive to most oxidizing 
agents that are powerful enough to convert an aldehyde to a carboxylic acid.3 Phthalimides are also 
not deprotected by sodium borohydride but are instead converted to 2-
(hydroxymethyl)benzamides.3,4 These functional groups readily hydrolyze in acidic solutions at 
elevated temperatures, releasing the primary amine.3,5 Thus the primary amine end-group can be 
deprotected via a two-step process, with the aldehyde end-groups being transformed into the more 
stable primary hydroxyl end-groups during the first step. This deprotection procedure is illustrated in 
Scheme 6.3. 
 
Scheme 6.3: Two-Step Removal of Phthalimide Protecting Group with Simultaneous Reduction of Aldehyde End-Groups. 
The mechanism by which the xanthate chain end is converted to a hydroxyl chain end was unclear. 
Three possible mechanisms were considered. The first mechanism involves nucleophilic attack on 




the thiocarbonyl carbon followed by decomposition of the tetrahedral intermediate by elimination 
of the weakest base, as depicted in Scheme 6.4. 
 
Scheme 6.4: Mechanism of Xanthate Hydrolysis by Nucleophilic Attack. 
This mechanism indicates that a thiol chain end will be formed instead of a xanthate. The second 
mechanism involves elimination of xanthic acid, either via a bimolecular or unimolecular process, as 




Scheme 6.5: Mechanism of Xanthate Hydrolysis by Elimination of Xanthic Acid. 
However, the bimolecular process involves hydration of the alkene-terminated PVP. Alkene 
hydration usually does not occur readily at low temperatures without the addition of a strong acid 
catalyst. Hence, a unimolecular elimination mechanism is the most likely process by which the 
xanthate end-group is converted to an alcohol end-group in water. Water is a weak base and would 
be more likely to donate a pair of electrons to the carbocation than to extract a proton. 
The final mechanism considered possible was nucleophilic substitution of xanthic acid with water, as 
depicted in Scheme 6.6. 






Scheme 6.6: Mechanism of Xanthate Hydrolysis by Substitution of Xanthic Acid with Water. 
Formation of a hydroxyl end-group could be more likely to occur in acidic media than formation of a 
thiol end-group since xanthic acid decomposes into carbon disulfide and water under such 
conditions. This would drive the reaction towards the quantitative formation of the hydroxyl end-
group. Four in-situ 1H-NMR kinetic experiments were performed in order to get a better 
understanding of the rates of xanthate conversion to an alcohol, an aldehyde or a thiol under various 
conditions. This would help to optimize the reaction conditions for the conversion of the xanthate 
end-group to an aldehyde in the presence of a phthalimide protecting group. The simultaneous 
reduction of the aldehyde end-group and deprotection of the phthalimide end-group was also 
attempted. 
 
6.2) Materials and Experimental Methods 
Anhydrous calcium chloride, sodium hydrogen carbonate (ACS reagent grade), anhydrous sodium 
carbonate (Na2CO3), concentrated hydrochloric acid (32%), anhydrous calcium sulfate, concentrated 
sulfuric acid (95 – 97%) and D2O were purchased from Merck and used as received. A seven inch long 
Wilmad® quick pressure valve medium wall NMR tube with a 5 mm diameter, benzophenone, 35% 
DCl in D2O, sodium borohydride (98.5%) and chloroform-d 99.8 atom % were purchased from Sigma 
Aldrich and used as received. Methanol, dichloromethane and diethyl ether were purchased from 
KIMIX. Methanol was fractionally distilled before use. Dichloromethane was washed with 
concentrated sulfuric acid followed by 5% sodium bicarbonate solution and finally water before 
being dried over calcium chloride and fractionally distilled from calcium sulfate. Diethyl ether was 
distilled from sodium and benzophenone. Dimethylacetamide (Chromosolv® Plus, for HPLC ≥ 99.9%) 
was purchased from Sigma Aldrich and used as received. Butylated hydroxytoluene (BHT) 99% (GC) 
was purchased from Sigma Aldrich and used as received. Lithium chloride ≥ 98% was purchased from 
Riedel-de Haën and used as is. 0.45 μm Glass fiber prefilters were purchased from PALL Life 
Sciences. SnakeSkin® Dialysis tubing (3500 g/mol nominal molecular weight cutoff) was purchased 
from Thermo Scientific and used as is. 




6.2.1) In-Situ 1H-NMR Kinetic analysis of Xanthate End-Group Hydrolysis 
Two in-situ 1H-NMR experiments were performed in order to study the mechanisms and rates of 
xanthate end-group hydrolysis reactions in D2O and 1 M DCl.  
Xanthate-functionalized PVP (0.01 g, 2.48×10-6 mol), prepared in Section 4.5.2, (Mn,NMR = 4,000 
g/mol) was added to two separate vials.  
0.75 mL D2O was added to the first vial and the solution was placed in a Wilmad® quick pressure 
valve medium wall NMR tube. A vacuum was carefully applied for one minute in order to remove the 
residual organic solvents and the NMR tube was back-filled with nitrogen. The time taken from 
addition of the D2O until the NMR analysis began was measured. A Varian VNMRS 300 MHz 
spectrometer was used for the analysis. A scan of the initial conditions at 25 °C was taken, the 
sample was withdrawn and the temperature in the probe was raised to 40 °C. The sample was re-
inserted, the deuterium feed-back loop was locked and the magnetic field was shimmed before the 
analysis was continued. The time taken to do this was recorded. A spectrum was recorded every 388 
seconds, using 64 scans with an acquisition time and relaxation delay of 4 seconds each, for a total 
acquisition time of 512 seconds and a total analysis time of 13 hours. The PVP was isolated from the 
reaction mixture by evaporation of the D2O under vacuum, dissolving the residue in DCM and 
precipitation from diethyl ether. SEC analysis was performed on the isolated sample. 
For the second vial, the sample was prepared as described for the first vial except that 0.068 mL  
35% (w/w) DCl in D2O (0.085 g, 7.94×10
-4 mol) was added to the NMR tube quickly before analysis. 
The time taken from this addition until the initial conditions could be recorded was measured. The 
analysis was performed on a Varian Inova 400 MHz NMR spectrometer with nitrogen gas being used 
for the VT control. After the initial conditions at 25 °C were recorded, the sample was removed and 
the temperature of the probe was raised to 60 °C before re-inserting the sample, locking the 
deuterium feed-back loop, shimming the magnetic field and continuing with the analysis. The time 
taken to do this was recorded. A spectrum was recorded every 1608 seconds, using 16 scans with an 
acquisition time of 4 seconds and a relaxation delay of 8 seconds, for a total acquisition time of 192 
seconds per spectrum and a total analysis time of 64 hours. The PVP was isolated from the reaction 
mixture by adding sodium carbonate (0.065 g, 6.13×10-4 mol) and measuring the pH (pH = 11), 
evaporation of the D2O, dissolving the residue in DCM and precipitation from diethyl ether. SEC 
analysis was performed on the isolated sample. 
 




6.2.2) In-Situ 1H-NMR Kinetic analysis of Alkene End-Group Hydrolysis 
Two in-situ 1H-NMR experiments were performed in order to study the mechanisms and rates of 
alkene end-group hydrolysis reactions in D2O and 1 M DCl. 
 Thermolyzed PVP (0.01 g, 2.48×10-6 mol), prepared as described in Section 5.2.1 from PVP 
synthesized by the SDSB in Section 4.5.3 (Mn,NMR = 7,000 g/mol), was added to two separate vials.  
0.75 mL D2O was added to the first vial and the sample was prepared as described for vial 1 in 
Section 6.2.1. The kinetic analysis was measured for 64 hours at 65 °C. A spectrum was recorded 
every 3216 seconds, using 32 scans with an acquisition time of 4 seconds and a relaxation delay of 8 
seconds, for a total acquisition time of 384 seconds. The PVP was isolated from the reaction mixture 
by evaporation of the D2O, dissolving the residue in DCM and precipitation from diethyl ether. SEC 
analysis was performed on the isolated sample. 
For the second vial, the sample was prepared as described for vial 2 in Section 6.2.1. The kinetic 
analysis was measured for 15 hours at 65 °C. A spectrum was recorded every 1416 seconds, using 32 
scans with an acquisition time of 4 seconds and a relaxation delay of 8 seconds, for a total 
acquisition time of 384 seconds. The PVP was isolated from the reaction mixture by addition of 
sodium bicarbonate (0.06 g, 7.14×10-4 mol), evaporation of the D2O, dissolving the residue in DCM 
and precipitation from diethyl ether. SEC analysis was performed on the isolated sample. 
 
6.2.3) Reduction of the Aldehyde End-Group with Simultaneous Phthalimide Deprotection 
1 g of the crude PVP reaction mixture, prepared by the CDSB as described in Section 4.5.2, (Mn,NMR = 
10,100 g/mol) was dissolved in 5 mL of 1 M HCl and dialyzed with 1 M HCl at 60 °C for 16 hours. The 
solution was then dialyzed with deionized water until it was neutral. 1 mL of the solution was 
isolated by evaporation of the water under vacuum, dissolving the residue in DCM and precipitation 
from diethyl ether. The isolated polymer was analyzed by 1H-NMR. Another 2 mL of the solution was 
placed in a separate vial and  sodium borohydride (0.02 g, 2.64×10-4 mol) was added. The sample 
was stirred at ambient temperature for 16 hours before being dialyzed with three portions of 100 
mL deionized water. 1 mL of the solution was removed and the PVP was isolated for NMR as well as 
SEC analysis as described above. 0.15 mL 35% HCl was added to the remaining solution and the 
reaction mixture was heated at 60 °C for 8 hours. The solution was dialyzed to neutral pH with 
deionized water and the PVP was isolated for NMR and SEC analysis by evaporating the water under 
vacuum, dissolving the residue in DCM and precipitation in diethyl ether. The product was 




derivatized with PFBA, as described in Section 5.2.5, before NMR analysis in order to determine the 
fraction of free primary amine end-groups. SEC analysis was also performed on the final product. 
 
6.3) Results and Discussion 
6.3.1) Hydrolysis of the Xanthate End-Group 
NMR Analysis 
The 1H-NMR spectrum of the initial conditions for the in-situ NMR experiment performed on vial 1 in 
Section 6.2.1 is illustrated in Figure 6.1. The spectrum was normalized by setting the integral for the 
phthalimide protons at δ = 7.74 – 7.99 ppm to 4. This was cross-referenced with the polymer 
backbone peaks at δ = 2.98 – 4.02 ppm. The fraction of xanthate end-groups remaining during the 
in-situ hydrolysis in D2O was measured from the integral intensity for the α-protons to the xanthate 
at δ = 5.65 – 5.9 ppm. 
 
Figure 6.1: Initial Conditions for the in-situ NMR Experiment Performed on Vial 1 in Section 6.2.1. 
The concentration profiles for the xanthate end-group during hydrolysis in D2O as well as in 1 M DCl 
were plotted in Figure 6.2.  





Figure 6.2: Concentration Profile for the Xanthate End-Group during Hydrolysis in D2O at 40 °C and in 1M DCl at 60 °C. 
The hydrolysis of the xanthate chain ends appeared to occur quite readily in D2O at 40 °C, having a 
half-life of about 3 hours. No aldehyde chain ends were detectable. The major product was the 
hydroxyl end-group, as illustrated in Figure 6.3 (δ = 5.25 – 5.40 ppm). It could not be accurately 
quantified due to the interfering water peak. The peak at δ = 7.41 – 7.66 ppm could not be 
accounted for but was present from the initial measurement and its intensity did not change 
throughout the kinetic analysis. Some alkene end-groups were detected at the end of the analysis (δ 
= 6.78 – 7.02 ppm) as illustrated in Figure 6.3. The integral for the alkene protons was 0.24, 
suggesting that 24% of the xanthate end-groups were converted to alkene end-groups. 
Increasing the temperature and adding DCl increased the rate of decomposition greatly. The half-life 
for xanthate hydrolysis in this case was approximately 9 minutes. Accurate measurement of the 
initial conditions was difficult as time was required for the sample temperature to equilibrate as well 
as to lock and shim the instrument. The phthalimide group was quite stable under acidic conditions. 
Only about 7% had ring-opened after 64 hours at 60 °C and the 2-carbamoylbenzoic acid formed was 
still acting as a protecting group for the amine. The rate of phthalimide ring-opening in H2O may be 
greater, however, due to the kinetic isotope effect.6-8 The aldehyde end-group could not be detected 
under acidic conditions. It was only slightly detectable in D2O due to the partial hydration of the 
aldehyde. This caused some of the carbonyl protons to resonate in the region of the spectrum that is 
dominated by the water resonance. 





Figure 6.3: Conditions at the end of the in-situ NMR Experiment Performed on Vial 1 in Section 6.2.1. 
To determine the amount of aldehyde present, the hydrolyzed PVP was isolated as described in 
Section 6.2.1. It was intended to only raise the pH to 7 by adding 0.75 equivalents of Na2CO3 to DCl 
but the resulting pH was 11. Either some of the DCl had evaporated during the kinetic analysis or 
there was an error in the weighing of Na2CO3 or DCl. The 
1H-NMR spectrum of the isolated sample in 
CDCl3 is illustrated in Figure 6.4.  
The phthalimide protons peak could no longer be used as an internal reference as over 50% of the 
phthalimide end-groups had ring-opened. This is characteristic of phthalimides in alkaline solution. 
Hence, the NMR spectrum was normalized by adjusting the PVP backbone peak to 130.49 – the 
value for the starting material, taking into account the interference from the diethyl ether, as 
described in Section A10. No alkene end-groups could be detected and integration of the aldehyde 
protons peak indicated over 80% of the xanthate end-group was converted to an aldehyde end-
group. The peak at δ = 5.94 – 6.05 ppm indicated that aldol condensation took place. The presence 
of three distinct aldehyde peaks also implies the presence of aldol condensation products as well as 
aldol addition products. Since the concentration of DCl in the reaction mixture could not be 
accurately neutralized with Na2CO3, a milder base should be employed for the neutralization. 
Titration of less than 1 mL of solution would prove difficult and would dilute the concentration of 




polymer in the product solution. That would make end-group analysis by NMR more difficult and less 
accurate. 
 
Figure 6.4: 1H-NMR spectrum of the PVP Isolated after Hydrolysis of the Xanthate End-Group in 1 M DCl at 60 °C. 
The aldol addition and condensation products are each formed by the conjugation of two aldehyde-
functionalized PVP chains. Hence, the initial fraction of aldehyde end-groups relative to xanthate-
functionalized PVP, before any aldol addition or condensation reactions had occurred, was 
calculated to be 1.04 using Equation 6.1.  
χ¡äå = 2 × o ¬(á)¹á + o ¬(á)¹á + 2 ×qÚà.æDqÚà.jqÚà.àqÚà.jà o ¬(á)¹áqÚà.çqÚà.æ                                                  (6.1) 
Thus the conversion of the xanthate end-group to an aldehyde end-group is quantitative under 
acidic conditions and moderate temperatures. The xanthate hydrolysis is also selective in the 
presence of the phthalimide end-group. 
The peak at δ = 6.59 – 6.69 ppm is indicative that the nitrile end-group of the initiator-derived PVP 
chains had hydrolyzed to form a primary amide.9-11 If the hydrolysis was quantitative and no further 
degradation to carboxylic acid had taken place, the integral of the amide protons divided by 2 
indicated that the concentration of initiator-derived PVP chains was 7.5% of the xanthate end-group 




concentration. Thus ÇÈÉwould be 0.93 and ÇÎ  would be 0.96. This is in close agreement with the 
calculations in Section 4.2 
 
SEC Analysis 
The SEC traces for the xanthate-functionalized PVP and its products of hydrolysis in D2O at 40 °C as 
well as in 1 M DCl at 60 °C were normalized, as described in Appendix A1. The normalized 
distributions were plotted in Figure 6.5. 
 
Figure 6.5: Normalized Molecular Weight Distributions for the Hydrolysis of the Xanthate End-Group in D2O and 1 M DCl. 
Mn,SEC for the product of hydrolysis in D2O increased by 300 g/mol and Ð decreased by 0.07. These 
values are quite low and within experimental error. The end-group effects discussed in Section 5.3.2 
may be plausible in this case as Mn,SEC for this polymer is relatively low so the end-group effects 
would be more pronounced. The baseline of the SEC trace was not that stable either. The SEC trace 
for the product of hydrolysis in D2O at 40 °C is illustrated in Figure 6.6. 
Mn,SEC for the product of hydrolysis in 1 M DCl increased by 2,622 g/mol and Ð increased by 0.34, 
indicating that a significant amount of chain coupling had occurred. This result provides further 
evidence towards the theory that aldol addition and condensation reactions had occurred during the 
isolation of the PVP from the reaction mixture. Hence, alkaline conditions should be avoided when 
isolating aldehyde end-functional PVP. 





Figure 6.6: SEC Trace for the Xanthate-Functionalized PVP Hydrolyzed at 40 °C in D2O. 
 
6.3.2) Hydrolysis of the Alkene End-Group 
NMR Analysis 
The 1H-NMR spectra of the alkene-functionalized PVP that was used for the hydrolysis experiments 
in Section 6.2.2 were taken in both D2O and CDCl3. These are illustrated in Figure 6.7. The 
concentration profiles for the alkene end-group during hydrolysis in D2O as well as in 1 M DCl were 
plotted in Figure 6.8.  
Hydrolysis of the alkene end-group did not occur to any measurable extent in D2O, even at 65 °C. In 
contrast, 81% had decomposed after 22 minutes in 1 M DCl at 25 °C (the time taken for sample 
preparation and setting up the initial scan.) Thus, in acidic solutions, the alkene end-group was more 
susceptible towards hydrolysis than the xanthate end-group. However, alkene end-group formation 
is not the most likely intermediate during the hydrolysis of the xanthate end-group in D2O as the 
latter hydrolyzed readily in neutral aqueous solutions. Hence, hydroxyl end-group formation most 
likely follows an SN1 mechanism, as indicated in Scheme 6.5, by E1 elimination followed by hydration 
of the carbocation. 





Figure 6.7: 1H-NMR of Alkene-Functionalized PVP used for the Hydrolysis Experiments Described in Section 6.2.2. 
 
Figure 6.8: Concentration Profiles for the Alkene End-Group during Hydrolysis in D2O as well as in 1 M DCl. 




Some hydroxyl-functionalized PVP was detected briefly while the probe temperature was still 25 °C 
though it rapidly decomposed once the temperature was increased to 65 °C. The 1H-NMR spectrum 
of the alkene-functionalized PVP after hydrolysis in 1 M DCl at 65 °C is plotted in Figure 6.9. 
 
Figure 6.9: 1H-NMR Spectrum of Alkene-Functionalized PVP after Hydrolysis in 1 M DCl at 65 °C. 
The spectrum was normalized by adjusting the PVP backbone peaks to 180.74, the value for the 
same peaks in the NMR spectrum the starting material in CDCl3. The interference from the absorbed 
diethyl ether was accounted for using the procedure described in Appendix A10. According to this 
normalization, the conversion of the alkene end-group on PVP to an aldehyde was quantitative - the 
integral intensity for the Alkene end-groups of the starting material was 0.84 in CDCl3. No alkene, 
xanthate or hydroxyl end-groups could be detected in the product. 
The integrals for the phthalimide protons were significantly larger than expected and this could not 
be accounted for. However, it seems more likely that there was a small interference in the region of 
the phthalimide protons resonance frequencies from an adventitious impurity in the isolated 
product than a large interference in the region of the PVP backbone peaks for the starting material. 
While the conversion of alkene end-groups to aldehyde end-groups was quantitative, the 
concentrations of the alkene and aldehyde end-groups in the starting material and product, 
respectively, were still less than the concentration of the phthalimide end-groups. Extended 




relaxation delays were used when acquiring the spectra so that protons with long T1 relaxation 
times would not lose relative signal intensity with an increase in the number of scans. Thus the loss 
of the xanthate end-group during the synthesis of this polymer sample may have occurred by a 
different mechanism than just thermolysis. 
 
SEC Analysis 
The SEC traces for the xanthate-functionalized PVP starting material, the thermolyzed PVP and the 
product of hydrolysis in 1 M DCl at 65 °C were normalized, as described in Appendix A1. The 
normalized distributions were plotted in Figure 6.10. 
 
Figure 6.10: Normalized Molecular Weight Distributions for the Thermolysis of the Xanthate End-Group and its Hydrolysis 
in 1 M DCl at 65 °C. 
Mn,SEC for the product of hydrolysis in 1 M DCl decreased by 700 g/mol and Ð decreased by 0.01, 
indicating that no chain coupling had occurred. The decrease in Mn,SEC	and Ð could be from the end-
group effects discussed in Section 5.3.2 but it may also be due to experimental error. 
 
 




6.3.3) Reduction of the Aldehyde End-Group with Simultaneous Phthalimide Deprotection 
NMR Analysis 
The 1H-NMR spectrum for the PVP isolated after hydrolysis and dialysis of the crude reaction mixture 
is illustrated in Figure 6.11. 
 
Figure 6.11: 1H-NMR Spectrum of PVP Isolated for Crude Reaction Mixture by Dialysis and Hydrolysis. 
The spectrum was normalized by adjusting the integral of the PVP backbone protons peak at δ = 2.9 
– 4.2 ppm to 290, the value for the same region of the PVP isolated by precipitation. The difference 
in the amount of diethyl ether in the sample compared to the precipitated PVP was accounted for by 
the procedure described in Appendix A10. After normalization, the amount of phthalimide end-
groups was about 6% less than that for the starting product. Some imine protons were also detected 
(δ = 8.5 ppm). Their relative amount was 22% of the amount of phthalimide end-groups present on 
the xanthate-functionalized starting material. These results suggested that some of the phthalimide 
end-groups may have decomposed during the hydrolysis, releasing the primary amine that could 
have formed a Schiff base with the aldehyde end-groups. However, this seems unlikely as the 
phthalimide end-group appeared to be stable under the hydrolysis conditions described in Section 
6.2.1 and the amount of imine protons detected is also greater than the decrease in the amount of 
phthalimide end-groups. The rate of phthalimide hydrolysis may have been slower in DCl due to the 
kinetic isotope effect.6-8 It was considered that some of the NVP oligomerized during the hydrolysis, 




increasing the amount of PVP backbone protons as well as the amount of aldehyde end-groups. This 
is feasible since the crude reaction mixture still contained residual AIBN. Also, the hydrolysis of some 
of the monomer present may have occurred, producing acetaldehyde. This is indicated by the sharp 
peak overlapping with the broad aldehyde protons peak at δ = 9.49 – 9.74 ppm in Figure 6.11. This 
meant that the normalization of the spectrum would no longer be equal to that for the precipitated 
PVP. This is possible if the dialysis was not performed for sufficiently long to allow equilibration to 
occur before changing the dialysis solvent. 
The NMR spectrum for the PVP isolated after reduction with sodium borohydride is illustrated in 
Figure 6.12. The same normalization procedure was used as described above. No aldehyde end-
groups could be detected and all the detectable phthalimide end-groups were converted to 2-
(hydroxymethyl)benzamides. 
 
Figure 6.12: 1H-NMR Spectrum of PVP after Reduction with NaBH4. 
The 1H-NMR spectrum of the reduced PVP after hydrolysis and PFBA-derivatization is illustrated in 
Figure 6.13. The spectrum was normalized as described above. The integral of the imine protons 
peak indicated that over 96% of the phthalimide end-groups had been successfully deprotected by 
the procedure. 





Figure 6.13: 1H-NMR Spectrum of the Reduced PVP after hydrolysis and PFBA-Derivatization. 
 
SEC Analysis 
The SEC traces for the xanthate-functionalized PVP starting material and the product of deprotection 
by hydrolysis and reduction were normalized by the procedure described in Appendix A1 and the 
normalized distributions were plotted as functions of molecular weight in Figure 6.14. 
Mn,SEC of the deprotected product had increased by 1500 g/mol though Ð stayed constant. The 
constant Ð indicated that the increase in Mn,SEC was either due to propagation during the initial 
hydrolysis of the crude reaction mixture that contained both AIBN and NVP or the different end-
groups causing a change in the hydrodynamic volume of the polymer chains rather than coupling 
reactions. Hence, even in the presence of some amine-functionalized PVP, the aldehyde end-group 
can be quantitatively reduced in H2O by NaBH4 without any significant amount of imine bonds being 
formed or reduced. 





Figure 6.14: Normalized Molecular Weight Distributions Obtained by SEC for the Xanthate-Functionalized PVP and the 
Product of Deprotection by Hydrolysis and Reduction.  
 
6.4) Conclusions 
The hydrolysis of the xanthate end-group in D2O leads to the formation of hydroxyl-functionalized 
PVP. The reaction rate is increased dramatically in the presence of a strong acid and further 
decomposition of the hydroxyl end-group to an aldehyde end-group occurs more readily. The alkene 
end-group is more stable towards hydrolysis than the xanthate end-group in D2O but is more readily 
hydrolyzed in the presence of a strong acid. Both the xanthate and the alkene end-groups of PVP 
decompose quantitatively to aldehyde end-groups when hydrolyzed at around 60 °C in 1 M DCl. The 
nitrile end-group of the initiator-derived PVP chains also appeared to hydrolyze when the hydrolysis 
was performed for an extended time at 60 °C in 1 M DCl. The phthalimide end-groups were stable in 
acidic solutions but readily ring-opened under alkaline conditions.  
Some of the primary amine end-groups appeared to be deprotected during the hydrolysis of 
xanthate-functionalized PVP in 1 M HCl at 60 °C. 
More work needs to be performed to fully understand the rates of hydrolysis for the different end-
groups but, from the preliminary results, it appears that the selective hydrolysis of the xanthate and 
alkene end-groups in the presence of the phthalimide protecting group is possible. Studies using HCl 
need to be performed to avoid any kinetic isotope effects. 
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Preparation of Poly(N-vinylpyrrolidone-Block-L-lysine) Copolymers by N-
Carboxyanhydride Ring-Opening Polymerization 
 
7.1) Introduction 
The preparation of block copolymers can be achieved by two approaches. One approach is to 
functionalize the first block with a functional group that can act as a macroinitiator for the monomer 
of the second block. This is essentially what is known as a grafting-from approach in the preparation 
of graft copolymers as well as modified surfaces.1 The other approach is to link the two blocks 
together by a coupling reaction after functionalizing the respective blocks with complementary 
functional groups. This is analogous to the grafting-to approach.1 Both approaches have benefits as 
well as pitfalls and these are usually complementary. For our purposes of preparing poly(N-
vinylpyrrolidone-block-L-lysine) copolymers, a grafting-from approach seems more feasible since 
most coupling reactions between two macromolecules are not very efficient even if the coupling 
reaction is very efficient for small molecules. The main reasons for this are the generally poor 
diffusion coefficients for the end-groups compared to those for small molecules as well as greater 
steric hindrance caused by the polymer backbone. A grafting-to approach would also require three 
preparation and isolation procedures while the grafting to approach would only require two. NCA 
ring-opening polymerization is one of the best ways to prepare a homopolypeptide such as poly(L-
lysine) and it has recently been demonstrated that polymer-peptide block copolymers as well as 
block copolypeptides can be readily prepared by using a macroinitiator for the NCA polymerization.2-
5 Hence it would be a well suited reaction process for the preparation of our desired copolymer. The 
polymerization of Nε-(benzyloxycarbonyl)(L-lysine) NCA by a primary amine-functionalized 
macroinitiator to prepare block copolymers of various molecular weights and architectures has been 
achieved by performing the polymerization at low temperature2 (0 °C), low pressure6 (1×10-5 bar) or 
both.3 Since the best results were obtained by applying both low temperatures and pressures during 
the NCA polymerization, this was the route followed in our research. 
Lysine has two primary amine functional groups, the alpha amino group (Nα) adjacent to the 
carboxyl group and an epsilon amino group (Nε) on the side chain. Thus in order to prepare a stable 
N-carboxyanhydride of lysine (Lys-NCA), the ε-amine must be appropriately protected. This was 
most often achieved with the benzyloxycarbonyl (CBZ) protecting group.2,3,7-11 The α-amine can be 




protected during the reaction that introduces the CBZ protection by forming a Cu(II) complex with 
the α-amine and carboxyl group, as depicted in Scheme 7.1. The copper can be removed from the 
protected amino acid by washing with a solution of EDTA. 
 
Scheme 7.1: Preparation of Nε-(Benzyloxycarbonyl)-L-Lysine. 
N
ε-(benzyloxycarbonyl)-L-Lysine N-carboxyanhydride (Nε-(CBZ)-Lys-NCA) has been prepared by the 
optimized Fuchs-Farthing method2,3,6,9,12 (Scheme 7.2), isolated and polymerized successfully.  
 
Scheme 7.2: Synthesis of Nε-(CBZ)-Lys-NCA by the Fuchs-Farthing Method. 
A modified Leuch’s method (Scheme 7.3) for the preparation of Nε-(CBZ)-Lys-NCA has also been 
reported. It was a one pot protection and cyclization procedure using benzyl chloroformate followed 
by phosphorus pentachloride (PCl5).
13 Purification of the NCAs prepared this way to the level 
required for living polymerization may prove difficult due to the formation of phosphorus oxide 
chloride which has been known to co-crystallize with NCAs.14 





Scheme 7.3: Synthesis of Nε-(CBZ)-Lys-NCA by the Modified Leuch’s Method. 
An article by Kramer et al.8 involving the purification of NCAs by flash chromatography was found. 
However, the NCAs from their group were prepared using either phosgenation or α,α-
dichloromethylmethyl ether as the halogenating agent. Thus it was unclear if this procedure would 
work for NCAs prepared with PCl5 or other halogenating agents such as thionyl chloride, phosphorus 
trichloride or phosphorus tribromide. Some papers have also eluded the decomposition of NCAs 
during aqueous extraction techniques by cooling the water and organic phase to 0 °C during the 
separation and drying stages.7,15  
Removal of the CBZ protecting group from the lysine residues in peptides has been achieved either 
through acidolysis7,9,10,16,17 or  catalytic hydrogenation.7,16,18,19 
 
7.2) Materials and Experimental Methods 
L-lysine hydrochloride was purchased from Wuhan Pharma Chemical Co., Ltd. and used as received. 
Bis(trichloromethyl)carbonate (99%), benzyl chloroformate, dimethyl sulfoxide-d6 (DMSO-d6), 
benzophenone, α-pinene, anhydrous N,N-dimethylformamide (DMF), N,N-dimethylacetamide 
(Chromosolv® Plus, for HPLC ≥ 99.9%), butylated hydroxytoluene (BHT) 99% (GC), calcium hydride 
and basic copper(II) carbonate were purchased from Sigma Aldrich and used as received. 2000 g/mol 
nominal molecular weight cut-off (MWCO) benzoylated dialysis tubing was purchased from Sigma 
Aldrich and soaked in 3 portions of deionized water before use to remove the sodium azide 
preservative. 4Å molecular sieves (8 – 12 mesh) were also purchased from Sigma Aldrich, dried in a 
vacuum oven at 165 °C for 5 hours and allowed to cool to room temperature under vacuum before 
use. Sodium, sodium bicarbonate, sodium carbonate, disodium ethylenediaminetetraacetic acid 
dihydrate (EDTA), anhydrous magnesium sulfate and glacial acetic acid were purchased from Merck 
and used as received. Diethyl ether, n-hexane and tetrahydrofuran (THF) were purchased from Kimix 
and distilled from sodium and benzophenone before use. DCM was purchased from Kimix and 
washed with concentrated sulfuric acid followed by 5% sodium bicarbonate solution and finally 




water before being dried over calcium chloride and fractionally distilled from 4Å molecular sieves. 
Methanol was purchased from Kimix and fractionally distilled before use. Ethanol was purchased 
from Kimix and dried by refluxing with calcium oxide. Dry ethanol was distilled off after 6 hours and 
stored over 4Å molecular sieves. Ethyl acetate was purchased from Kimix and washed with sodium 
bicarbonate solution followed by water before drying with magnesium sulfate and 4Å molecular 
sieves. Dry ethyl acetate was fractionally distilled and stored over 4Å molecular sieves. 1-Octylamine 
was purchased from Sigma Aldrich and was dried as well as distilled from calcium hydride under 
reduced pressure. SnakeSkin® Dialysis tubing (10,000 g/mol and 3,500 g/mol nominal molecular 
weight cutoff) was purchased from Thermo Scientific and used as is. Lithium chloride ≥ 98% was 
purchased from Riedel-de Haën and used as is. 0.45 μm Glass fiber prefilters were purchased from 
PALL Life Sciences. 
 
7.2.1) Synthesis of Nε-(Benzyloxycarbonyl) L-Lysine 
L-lysine monohydrochloride (32 g, 0.1752 mol)  was dissolved in 300 mL deionized water. Basic 
copper(II) carbonate (CuCO3∙Cu(OH)2, 37 g, 0.1673 mol) was added and the solution was refluxed for 
30 minutes before being cooled down to room temperature and being filtered. Sodium bicarbonate 
(17 g, 0.2023 mol) was added and the solution was cooled to 0 °C in a three-neck round bottom flask 
fitted with a dropping funnel and a mineral oil bubbler. Benzyl chloroformate (20 g, 0.1172 mol) was 
dissolved in 150 mL THF and the solution was charged into the dropping funnel. The benzyl 
chloroformate solution was then added dropwise to the lysine copper complex solution while 
maintaining the temperature at 0 °C for two hours. The reaction mixture was then heated at 40 °C 
overnight. The THF was removed by evaporating under vacuum and the precipitate was filtered and 
washed with three 100 mL portions of deionized water. 
EDTA (22 g, 0.0591 mol) and sodium carbonate (8 g, 0.0755 mol) were dissolved in 300 mL deionized 
water and added to the precipitate. The mixture was heated at 60 °C with gentle mixing for 1 hour 
before being cooled to 0 °C and filtered. This procedure was repeated 2 more times to ensure all the 
copper was removed from the product. The precipitate was washed with three 50 mL portions of 
deionized water and dried in a vacuum oven at 60 °C overnight. Product Yield: 22.65 g (69%) IR 
(ATR):20 3334 cm-1 (m, N-H secondary urethane), 2599 cm-1 (w, br, N-H amine), 2131 cm-1 (w, br, N-H 
amine), 1692 cm-1 (s, C=O carbamate), 1522 cm-1 (s, C=O acid). 
 




7.2.2) Synthesis of Nε-(CBZ) Lys-NCA 
N
ε-(Benzyloxycarbonyl)-L-Lysine (4 g, 14.27 mmol) was placed in a 250 mL three-neck round bottom 
flask and 120 mL dry THF was added along with α-pinene (4 g, 29.36 mmol). The round bottom was 
fitted with a dropping funnel, reflux condenser and mineral oil bubbler. The reaction mixture was 
sparged with argon for 10 minutes before heating to 65 °C. Triphosgene (1.64 g, 5.527 mmol) was 
dissolved in 40 mL dry THF and the solution was charged in the dropping funnel. The triphosgene 
solution was added to the reaction mixture dropwise over thirty minutes with vigorous stirring and 
occasional sparging with argon. Initially, a dense slurry formed. However, it would dissolve as the 
reaction progressed provided it was sufficiently broken up by the stirring process. After 90 minutes, 
the reaction mixture was cooled to 0 °C and run through a celite column (5.0 cm × 2.2 cm) that had 
been dried in a vacuum oven at 140 °C. Argon was used to flush the solution rapidly through the 
column. The filtrate was concentrated to ca. 40 mL under vacuum and the product was precipitated 
by adding dropwise to 200 mL of hexane with rapid stirring. The suspension was sealed and left in a 
freezer overnight to ensure complete precipitation of the product before filtering. The product was 
recrystallized from THF and hexane two more times, cooling the THF solution to 0 °C and running it 
rapidly through a dry silica column (2.0 cm × 2.2 cm) each time. Product Yield: 3.42 g (78%) 1H-NMR 
(CDCl3): δ = 7.27 ppm (br, 5H, phenyl hydrogens), 6.84 ppm (br, 1H, N-H carbamate), 5.03 ppm (br, 
2H, benzyl hydrogens), 4.86 ppm (br, 1H, N-H NCA ring), 4.19 ppm (br, 1H, α-hydrogen), 3.13 ppm 
(br, 2H, ε-hydrogens), 2.05 – 1.05 ppm (br, 6H, β, γ and δ-hydrogens.) 
 
7.2.3) Polymerization of Nε-(CBZ) Lys-NCA Using 1-Octylamine 
In order to assure that the NCAs synthesized were sufficiently pure to allow for a controlled ring-
opening polymerization as well as to have a reference of the peaks corresponding to the protons of 
the lysine residues in the 1H-NMR spectrum of the PVP-poly(L-lysine) block copolymer, a 
polymerization was performed using a small molecule primary amine initiator. 1-Octylamine was 
used as an initiator as this amine was not very volatile and hence would remain in a DMF solution at 
0 °C when the pressure is below 1 mbar. The methyl protons on the initiator would also serve as an 
internal reference for the 1H-NMR spectrum of the polypeptide which would allow for the direct 
measurement of the average number of residues in the product. 
A 10% (w/w) stock solution of 1-octylamine was prepared by adding 0.9 g DMF to 0.1 g 1-
octylamine. An aliquot of the stock solution (0.168 g, 1.30×10-4 mol) was added to 7 mL anhydrous 
DMF. The solution was cooled to 0 °C in an ice bath at 0.6 mbar for 15 minutes. Nε-(CBZ) Lys-NCA 




(1.42 g, 4.64×10-3 mol) was quickly added to the reaction and the pressure was reduced to 0.6 mbar 
again. The initiator-to-NCA ratio was 35. The pressure and temperature were maintained for 5 
hours, after which it was noted that the reaction mixture had become a gel. In order to avoid 
excessive loss of solvent, the Schlenk tube was sealed for the remainder of the reaction. The 
reaction was allowed to continue at 0 °C for 24 hours. The product was precipitated from diethyl 
ether, using THF as a solvent. The precipitate was suspended in 10 mL methanol and 1 mL glacial 
acetic acid was added. The dispersion was dialyzed, using 2000 g/mol MWCO dialysis tubing, with 3 
portions of methanol followed by 6 portions of deionized water. The polypeptide was isolated by 
lyophilization and analyzed by 1H-NMR in DMSO-d6. 
 
7.2.4) Polymerization of Nε-(CBZ) Lys-NCA Using Amine-functionalized PVP 
Polymerization was carried out at several different initiator-to-NCA ratios and, due to a limited 
amount of prepared PVP macroinitiator, several different amine-functionalized PVP samples were 
used. Mn,SEC for the various PVP initiator samples was kept within 12 kDa to 17 kDa as PVP with 
molecular weight greater than 25 kDa is known to bioaccumulate within the body.21-23 PVP prepared 
by the semi-batch RAFT polymerizations described in Chapter 4 has a much lower weight fraction of 
polymer chains with a molecular weight greater than 25,000 g/mol than conventional PVP with a K-
value of 17 that is used for parenteral formulations. The added molecular weight of the polypeptide 
block should not pose a problem as polypeptides prepared from NCAs of L-amino acids are 
biodegradable.  
In a typical polymerization, amine-functionalized PVP (prepared as described in Section 4.5.2 and 
deprotected as described in Chapter 5) was dissolved in dry DCM and anhydrous sodium carbonate 
was added (10% w/w compared to polymer) along with 4Å molecular sieves. The mixture was sealed 
and allowed to dry for 16 hours at 4 °C before filtering through glass wool and placing in a Schlenk 
tube. The DCM was carefully removed by evaporation under vacuum and replaced with DMF (10 mL 
per gram of polymer.) The Schlenk tube was placed in an ice bath and the pressure was reduced to 
0.6 mbar for 2 hours. Nε-(CBZ) Lys-NCA (150% of the amount intended to be used) was dissolved in a 
minimum amount of ethyl acetate and eluted through a column of silica (120 × 8 mm for 1.5 g), that 
had been washed with 10 mL ethyl acetate. Ethyl acetate was used as the mobile phase and nitrogen 
gas was used to perform flash chromatography. A beaker containing hexane was used to determine 
when the NCA began to emerge from the column by capturing a drop every few seconds until a 
precipitate was seen to form. This was also used to determine when the NCA had finished eluting. 




The NCA was precipitated from hexane, filtered and dried under vacuum. The required amount was 
added to the reaction mixture rapidly at 0 °C. The pressure in the Schlenk tube was reduced to 0.6 
mbar and left at 0 °C for 5 hours, after which the tube was sealed and kept at 0 °C for 24 hours. The 
product was isolated from the reaction mixture by precipitating from diethyl ether, using THF as a 
solvent. The isolate was further purified by dissolving in methanol and dialyzing, using 10,000 
MWCO dialysis tubing, with three portions of methanol followed by six portions of deionized water. 
The polymer was isolated from the dialysis solution by lyophilization. The isolated sample was 
analyzed by 1H-NMR in DMSO-d6, DMAC SEC, transmission electron microscopy in vitreous ice (cryo-
TEM) and dynamic light scattering (DLS) in H2O as well as DMF. 
 
7.2.5) Preparation of Colloidal Dispersion of PVP-block-poly(Nε-(CBZ)-L-lys) in H2O 
The PVP-block-poly(Nε-(CBZ)-L-lys) was amphiphilic and formed a colloidal dispersion when dialysed 
from methanol into water. Thus a sample of PVP-block-poly(Nε-(CBZ)-L-lys) dispersed in H2O was 
imaged using cryo-TEM to obtain an impression of the size of the micelles formed. 2 mg of the 
isolated block copolymer sample was dispersed in 1 mL deionized water. 1 mL methanol was added 
to the dispersion and the mixture was shaken vigorously until it became homogeneous. The 
methanol was removed by heating gently under vacuum until only about 0.9 mL of solution 
remained. A solution of PVP-block-poly(Nε-(CBZ)-L-lys) in DMF was also prepared at a concentration 
of 2 mg/mL. Both samples were filtered with 0.45 µm glass fiber SEC filters before analysis. 
DLS analysis of the dispersion of PVP-block-poly(Nε-(CBZ)-L-lys) in H2O, as well as the solution in 
DMF, was performed on a Malvern PN3704 Zetasizer S173. The complex refractive index of the 
dispersion was set to 1.59 + 0.01i. This was an approximation as no refractive index measurement 
equipment was available. This is the complex refractive index of a poly(styrene) latex24 and since the 
dispersion of PVP-block-poly(Nε-(CBZ)-L-lys) in H2O resembled this type of latex and contained many 
phenyl functional groups, it was assumed that the complex refractive index of the latex would be a 
close approximation to that for PVP-block-poly(Nε-(CBZ)-L-lys) in H2O. The dispersant refractive index 
was set to 1.330 and its viscosity was set to 0.8872 cP.25 The complex refractive index of the DMF 
solution was set to 1.45 + 0.001i. This is an approximation, assuming the average refractive index 
increment for a protein in DMF solution is about 0.2 mL/g.26 This approximation was considered to 
be closer to the refractive index of PVP-block-poly(Nε-(CBZ)-L-lys) in DMF than that of a polystyrene 
latex. Unfortunately, these approximations are quite speculative and their degree of error cannot be 
determined. However, since no previous work on determining these values could be found, it was 




the only option. Also, the main variable being observed for the DLS experiments was the change in 
the average hydrodynamic diameter due to aggregation or dissociation so accurate values for the 
mean hydrodynamic diameter were not crucial. The solvent refractive index was set to 1.431 and its 
viscosity was set to 0.9200 cP. Three measuremens were taken at 25 °C for both samples. Each 
measurement consisted of 14 scans with an acquisition time of 60 seconds. The average of the three 
measurements was used to construct a particle size distribution of the colloidal suspension and the 
solution.  The data was converted from an intensity distribution to a number distribution for both 
samples. 
cryo-TEM of the dispersion was performed using a Tecnai F20 transmission electron microscope 
operating at 200kV for the field emission gun and fitted with a US 4000 Gatan CCD camera. 
 
7.3) Results and Discussion 
7.3.1) Synthesis of poly(Nε-(CBZ)-L-lysine) 
NMR Analysis 
The 1H-NMR spectrum of poly(Nε-(CBZ)-L-lysine) initiated by 1-octylamine is illustrated in Figure 7.1. 
Using the methyl protons peak at δ = 0.84 ppm as an internal reference and normalizing its 
integration intensity to 3, the average number of lysine residues per peptide chain was calculated by 
measuring the integration intensity of the benzyl protons on the CBZ group at δ = 4.96 ppm and 
dividing the value by 2. This calculation indicated that the degree of polymerization was 
approximately 32. This is well within the desired block size for the DDS and the correspondence 
between the degree of polymerization at that monomer conversion indicated that the 
polymerization was well controlled. If the polymerization was not well controlled, many of the 
oligomers formed would be lost during the dialysis step and DP for the product would not correlate 
with the expected value of 35. 





Figure 7.1: 1H-NMR of poly(Nε-(CBZ)-L-lysine). 
 
7.3.2) Synthesis of PVP-block-poly(Nε-(CBZ)-L-lysine) 
NMR Analysis 
Of the several trials attempted for the NCA ROP using amine-functionalized PVP as the 
macroinitiator, only one was successful at preparing a significantly large peptide block. The 
introduction of water or other impurities, such as residual phosgene or HCl, could have resulted in 
the loss of control of the ROP. That is why all the materials used for the ROP should be as pure as 
possible. An inadequate temperature or pressure regulation could also have led to poorer control. 
This trial used a 15.8 kDa PVP macroinitiator and had a initiator-to-NCA ratio of 50. The 1H-NMR 
spectrum of the isolated block copolymer in DMSO-d6 is illustrated in Figure 7.2. Due to the large 
amount of water in the sample, the water peak was presaturated in order to obtain a better dynamic 
range for the spectrum. Since the water peak overlapped with the PVP backbone peaks at δ = 2.8 – 
4.1 ppm, the PVP backbone peaks at δ = 1.14 – 2.43 ppm were used as an internal reference. The 
interfering peaks for the lysine residues (e) were accounted for using an iterative protocol as 
described in Appendix A12. 





Figure 7.2: 1H-NMR Spectrum of PVP-block-poly(Nε-(CBZ)-L-lys) with Presaturation of the Water Peak. 
After normalization, dividing the integral for the phenyl protons peak (b – Figure 7.2) by 5 indicated 
that the average number of lysine residues per PVP chain was approximately 45. This is close to the 
expected value for the initiator-to-NCA ratio used. Dividing the integral for the benzyl protons peak 
(c – Figure 7.2) by 2 indicated that the average number of lysine residues per PVP chain was 
approximately 38. These are in close agreement and the difference may be due to the precision of 
the integration or differences in T1 as the acquisition time plus the relaxation delay was only 5 
seconds. The integral for amide protons peak would not be useful as chemical exchange with water 
would result in a reduction in signal intensity during the presaturation stage of the NMR spectral 
acquisition. However, its broadness is indicative that the average molecular weight of the molecules 
containing lysine residues must be quite large. 
 
SEC Analysis 
SEC analysis for the PVP-block-poly(Nε-(CBZ)-L-lys) was performed as described in Appendix A1 for 
block copolymers. The normalized molecular weight distributions for the PVP macroinitiator as well 
as the block copolymer product are illustrated in Figure 7.3. 





Figure 7.3: Normalized Molecular Weight Distributions for the PVP-Amine Macroinitiator and the PVP-block-poly(Nε-(CBZ)-
L-lys) Product. 
Mn and Đ for the PVP-block-poly(Nε-(CBZ)-L-lys) were 28300 g/mol and 1.13, respectively. Mn and Đ 
for the PVP macroinitiator were 16800 g/mol and 1.17, respectively. Thus the average molecular 
weight of the polymer had increased by 11500 g/mol. This corresponds to an average increase in DP 
by approximately 44 Nε-(CBZ)-L-lys repeat units. The low dispersity of the product indicates that the 
polymerization was well controlled. The bimodal distribution indicates that not all of the PVP chains 
had initiated ring-opening polymerization of the NCA. This is to be expected since some of the PVP 
chains were initiator-derived. Deconvolution of the molecular weight distribution could aid in 
determining the fraction of initiator-derived PVP chains in the product but, in order to be able to 
perform such a calculation, the distributions of the mono-functional and bi-functional R-group 
functionionalized PVP chains is required. These are the only polymer chains that would be able to 
initiate ROP of the Nε-(CBZ)-L-lys NCA. The degree of deprotection and fraction of amine end-groups 
that successfully initiate ROP of Nε-(CBZ)-L-lys NCA also needs to be accurately known, provided the 
assumption that these fractions are not chain-length dependent is correct. Models of the RAFT-
mediated polymerization and ROP polymerization would then be prepared to fit the respective 
parameters. The distribution models would require the rate constants for the elementary steps of 
the polymerization reaction mechanisms to be determined. Very few of these constants were 
actually found in the literature, as described in Chapter 4, and obtaining some of them would 
require instrumentation that was not available to us. Also, peak-position relative calibration with 
PMMA would introduce substantial errors due to differences in the hydrodynamic volume of the 
block copolymer and PMMA. Hence, either universal calibration or direct molecular weight 




determination, using a static light scattering detector, is necessary for all the SEC analyses. A more in 
depth study is required to accurately determine the fraction of initiator-derived PVP chains. 
 
Cryo-Transmission Electron Microscopy analysis 
The colloidal dispersion prepared in Section 7.2.5 was analyzed by cryo-TEM. A representative cryo-
TEM image is illustrated in Figure 7.4.A. 
 
Figure 7.4: A) Representative Cryo-TEM Image of PVP-block-poly(Nε-(CBZ)-L-lys) Collodial Dispersion. B) Histogram of 
Measured Micelle Diameters. 
The particle sizes were measured in all the images taken using the AxioVision LE 4.4 software 
package and a histogram of the collected data was plotted in Figure 7.4.B. The mean measured 
micelle diameter was 21.5 nm with a standard deviation of 6.5 nm. This indicated that the average 
size of the micelles was within the desired range. Some cylindrical micelles were also present in the 
sample though they appeared to have a different density to the spherical ones. It was unclear why 
two types of micelles were present but it was considered that perhaps block copolymers with low-
molecular weight PVP chains and relatively high molecular weight peptide chains would have a 
larger critical packing parameter and form the cylindrical micelles with a different packing density. 
Due to the variation in perspective with the depth of each particle within the sample, these 









The size distributions obtained from the DLS analysis of the PVP-block-poly(Nε-(CBZ)-L-lys) colloidal 
suspension in H2O as well as the solution of PVP-block-poly(N
ε-(CBZ)-L-lys) in DMF are illustrated in 
Figure 7.5. Comparison of the two distributions indicated that PVP aggregates in H2O to form 
micelles with an average diameter of 57 nm and a standard deviation of 21 nm while the average 
size of each polymer chain in solution is 3.8 nm with a standard deviation of 1.2 nm. Since the exact 
values of the complex refractive index for the solution or the colloidal suspension were not known, 
these values are only an approximation and the results of cryo-TEM may be closer to the actual 
values. 
 
Figure 7.5: DLS Analysis of PVP-block-poly(Nε-(CBZ)-L-lys) in DMF and in H2O. 
 
7.4) Conclusions 
The ring-opening polymerization of (Nε-(CBZ)-L-lys) NCA using a primary amine-functionalized PVP 
was successfully used to prepare the block copolymer PVP-block-poly(Nε-(CBZ)-L-lys) with a relatively 
high molecular weight. NMR as well as SEC analysis confirmed the polymerization was well 
controlled. DLS and cryo-TEM analysis indicated that the block copolymer was amphiphilic and self-
assembled in H2O to form micelles within the desired size range. 
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As mentioned in Chapter 7, there are two main methods of deprotecting the Nε-amine of lysine from 
the benzyloxycarbonyl protecting group. These are acidolysis with hydrobromic acid in 
trifluoroacetic acid1-5 (TFAA) or catalytic hydrogenation (CH) with a palladium catalyst.5-7 Since no 
previous papers dealt with the deprotection of PVP-block-poly(Nε-(CBZ)-L-lys), both methods were 
investigated. Deprotection via CH also offered the advantage of reducing the alkene end-group of 
PVP, preventing aldehyde or alkyl halide end-group formation.  
 
8.2) Materials and Experimental Methods 
Anhydrous calcium chloride, anhydrous calcium sulfate, concentrated sulfuric acid (95 – 97%), 
DMSO-d6, glacial acetic acid sodium hydrogen carbonate (ACS reagent grade), anhydrous sodium 
carbonate, concentrated hydrochloric acid (32%), hydrogen bromide (25% in acetic acid), Celite® 
545, sodium chloride  and sodium metal were purchased from Merck and used as received. 
Benzophenone, pentafluorobenzaldehyde (PFBA), trifluoroacetic acid, 10% Pd/C and chloroform-d 
99.8 atom % were purchased from Sigma Aldrich and used as received. 4Å molecular sieves (8 – 12 
mesh) were also purchased from Sigma Aldrich, dried in a vacuum oven at 165 °C for 5 hours and 
allowed to cool to room temperature under vacuum before use. Dichloromethane, 1,4-dioxane and 
absolute ethanol were purchased from KIMIX. Dichloromethane was washed with concentrated 
sulfuric acid followed by 5% sodium bicarbonate solution and finally water before being dried over 
calcium chloride and fractionally distilled from calcium sulfate. 1,4-Dioxane was distilled from 
sodium and benzophenone. Ethanol was dried by refluxing with calcium oxide. Dry ethanol was 
distilled off after 6 hours and stored over 4Å molecular sieves. SnakeSkin® Dialysis tubing (10,000 
g/mol nominal molecular weight cutoff (MWCO)) was purchased from Thermo Scientific and used as 
is. 
 




8.2.1) Deprotection of the CBZ Group by Acidolysis with HBr in TFAA 
PVP-block-poly(Nε-(CBZ)-L-lys) (0.4 g, 3.2×10-5 mol)  with Mn,NMR of the PVP block equal to 11,000 
g/mol and Mn,NMR of the peptide block equal to 5,300 g/mol was dissolved in 3 mL TFAA. The solution 
was cooled to 0 °C and 1 mL of HBr (25% in acetic acid) was added. The reaction mixture was stirred 
for four hours at 0 °C and then 10 mL of H2O with 3.2 g Na2CO3 was added slowly. The reaction 
mixture was dialyzed, using 10,000 MWCO dialysis tubing, with four 250 mL portions of H2O and the 
polymer was isolated by lyophilization. The product and starting material were analyzed by 1H-NMR. 
The starting material was dissolved in CDCl3 and the product was dissolved in DMSO-d6. 
 
8.2.2.) Deprotection of the CBZ Group by Acidolysis with HBr in a 1,4-Dioxane and DCM Mixture 
1 mL DCM and 1 mL 1,4-dioxane was added to PVP-block-poly(Nε-(CBZ)-L-lysine) (0.05 g, 1.77×10-6 
mol). The solution was cooled to 0 °C in an ice bath and 1 mL HBr (25% in acetic acid) was added. 
The reaction mixture was kept at 0 °C for 3 hours. Na2CO3 (1.0 g, 9.4×10
-3 mol) was dissolved in 10 
mL H2O and this solution was slowly added to the reaction mixture. The DCM and 1,4-dioxane were 
removed by evaporation under vacuum and the solution was dialyzed with four 250 mL portions of 
H2O, using 10,000 MWCO dialysis tubing. The polymer was isolated by lyophilization. 
 
8.2.3) Deprotection of the CBZ Group by Catalytic Hydrogenation 
PVP-block-poly(Nε-(CBZ)-L-lysine) (0.1 g, 4.50×10-6 mol) was dissolved in 4 mL ethanol with gentle 
heating. 1 mL glacial acetic acid and 0.05 g 10% Pd/C was added. The reaction mixture was heated to 
45 °C and sparged with H2 gas for four hours. 1 g NaCl dissolved in 5 mL 0.4 M HCl and this solution 
was added to the reaction mixture. The catalyst was removed by centrifugation at 5000 rpm for 20 
minutes followed by filtering through celite. Sodium bicarbonate (0.2 g, 2.4 mmol) was slowly added 
and the solution was dialyzed with four 250 mL portions of H2O, using 10,000 MWCO dialysis tubing. 









8.3) Results and Discussion 
8.3.1) Deprotection of PVP-block-poly(Nε-(CBZ)-L-lys) by Acidolysis with HBr 
NMR Analysis 
The 1H-NMR spectrum of the PVP-block-poly(Nε-(CBZ)-L-lys) starting material that was deprotected 
by acidolysis with HBr in TFAA (HBr Method 1) was normalized by the procedure described in 
Appendix A12. The average number of lysine residues on the starting material was determined to be 
20.39. The 1H-NMR spectrum of the product was normalized by adjusting the integral for the 
polymer backbone peaks at δ = 0.98 – 2.42 ppm to equal that for the starting material. The degree of 
deprotection achieved by HBr Method 1 was determined by measuring the change in the integral for 
the benzyl protons peak at δ = 4.77 – 5.15 ppm of the normalized 1H-NMR spectra for the starting 
material and the product. This turned out to be 70%. A possible reason for the incomplete 
deprotection could be due to the poor solubility of PVP in TFAA that resulted in the precipitation of 
the block copolymer at 0 °C. The 1H-NMR spectrum of the PVP-block-poly(L-lysine) deprotected by 
HBr Method 1 is illustrated in Figure 8.1.  
 
Figure 8.1: 1H-NMR Spectrum of PVP-block-poly(L-lysine) Deprotected with HBr in TFAA. 




Using the same analytical procedure, the degree of deprotection achieved by acidolysis with HBr in 
the DCM and 1,4-dioxane solvent mixture (HBr Method 2) was determined to be about 100% as no 
benzyl protons peak could be detected. The product was derivatized with PFBA and its 1H-NMR 
spectrum is illustrated in Figure 8.2. After adjusting the integral of the backbone protons peaks at δ = 
0.98 – 2.42 ppm to equal that for the starting material, the integral of the imine protons peak at δ = 
7.95 – 8.68 ppm was equal to 28.72. This was less than the expected value of ca. 40. A possible 
reason for this could be that the acidolysis step resulted in partial hydrolysis of the lysine residues. 
However, a more likely reason is that the presence of water (δ = 3.3) and acetic acid (peaks – g and 
h) were causing an equilibrium to be established, resulting in only a partial imine derivatization. 
 
Figure 8.2: 1H-NMR Spectrum of PVP-block-poly(L-lysine) Deprotected with HBr in a Mixture of 1,4-Dioxane and DCM. 
 
DLS Analysis 
The product of the HBr Method 2 as well as the PVP macroinitiator used to prepare it were analyzed 
by DLS in H2O. The hydrodynamic diameter distributions were plotted in Figure 8.3. The results 
indicated that PVP-block-poly(L-lysine) has a larger hydrodynamic diameter in H2O than the PVP 




macroinitiator but a much smaller one than PVP-block-poly(Nε-(CBZ)-L-lys). Thus PVP-block-poly(L-
lysine) most likely does not self-assemble into micelles in H2O. 
 
Figure 8.3: DLS Results for PVP-block-poly(L-lysine), Deprotected by Acidolysis in the 1,4-Dioxane and DCM Solvent Mixture, 
as well as that of the PVP Macroinitiator Used to Prepare it. 
 
8.3.2) Deprotection of PVP-block-poly(Nε-(CBZ)-L-lys) by Catalytic Hydrogenation 
NMR Analysis 
The 1H-NMR spectrum of the PVP-block-poly(Nε-(CBZ)-L-lys) starting material that was deprotected 
by CH was normalized by the procedure described in Appendix A12. The average number of lysine 
residues on the starting material was determined to be 23.55. The degree of deprotection by CH was 
determined by the same method as described in Section 8.3.1. For CH, the degree of deprotection 
turned out to be 85%. The 1H-NMR spectrum of the PVP-block-poly(Nε-(CBZ)-L-lys) starting material 
and that for the product of deprotection by CH are superimposed on each other in Figure 8.4. 
Though this procedure was generally milder than the acidolysis procedures and more effective than 
the HBr Method 1, it was still not quantitative and it was not possible to remove all of the 
heterogenous Pd catalyst from the product even with our extensive isolation procedure. PVP is 
known to adsorb strongly to the surface of colloidal noble metal particles as it stabilizes their surface 
energy and stabilizes their dispersion through steric hindrance.8,9 It was not possible to remove all of 




the catalyst from the reaction mixture by centrifugation, even when acid and a large amount of 
electrolyte was added. This confirmed that the Pd nanoparticles must be sterically stabilized.10,11 
Filtering over celite also failed to remove all of the catalyst. However, due to time restraints, this was 
only confirmed qualitatively by noting that the solution remained light brown. Thus acidolysis by the 
HBr Method 2 proved to be the simplest and most effective method for deprotecting the lysine 
residues of PVP-block-poly(Nε-(CBZ)-L-lys). 
 




The deprotection of PVP-block-poly(Nε-(CBZ)-L-lysine) was most effective when performed by 
acidolysis with HBr in a 1,4-dioxane and DCM solvent mixture at 0 °C. Though deprotection by 
catalytic hydrogenation was almost quantitative and could be optimized to provide quantitative 
deprotection, complete removal of the noble metal catalyst proved to be extremely difficult due to 
the strong stabilizing interaction of the colloidal metal particles with PVP. 
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Conjugation of Doxorubicin to PVP-block-poly(L-lysine) 
 
9.1) Introduction 
This chapter focusses on the preliminary study of the synthesis as well as self-assembly and stability 
of PVP-block-poly(L-lysine) conjugates with Doxorubicin as well as other compounds via imine 
linkages. Imines form when a primary amine reacts with an aldehyde or ketone, forming a carbon-
nitrogen double bond and eliminating water. They belong to a class of functional groups known as 
Schiff bases. The general mechanism of Schiff base formation is illustrated in Scheme 9.1. 
 
Scheme 9.1: General Mechanism of Schiff Base Formation. 
Schiff bases are usually unstable in aqueous solutions and decompose readily into their starting 
materials.1 However, their stability can be improved if electron-withdrawing groups are attached to 
the nitrogen or carbonyl carbon. Ketones also generally decompose more slowly than aldehydes. 
Due to their tunable hydrolysis rates, Schiff bases are often investigated as acid-labile linkers. Acyl 
hydrazones are among the most well-known of the acid-labile linkers and Etrych et al. have studied 
the conjugation of Doxorubicin via hydrazone bonds to its α-hydroxy ketone extensively.2-5  Some 
research has also been published where the conjugation of Doxorubicin to macromolecules is 
achieved via an imine bond of an aldehyde to its daunosamine residue.6-8 These techniques are 
based on incorporating the hydrolytically-labile imine bond within the hydrophobic domain of a 
hydrogel or micelle.   
 
 




9.2) Materials and Experimental Methods 
Benzaldehyde was purchased from Sigma Aldrich and used as received. Sodium bicarbonate was 
purchased from Merck and used as received. Doxorubicin hydrochloride was purchased from 
Taizhau Crene Biotechnology and used as received. Methanol was purchased from Kimix and 
fractionally distilled before use. 0.45 μm Glass fiber prefilters were purchased from PALL Life 
Sciences. 
 
9.2.1) Synthesis of PVP-block-poly(L-lysine)-Doxorubicin Dispersion in H2O 
PVP-block-poly(L-lysine) (4 mg, 1.94 × 10-7 mol, ca. 7.29 × 10-6 mol of lysine residues) with Mn,NMR of 
the PVP block equal to 15,800 g/mol and Mn,NMR of the poly(L-lysine) block equal to 4,800 g/mol (DP 
= 38) was dissolved in 2 mL methanol. Doxorubicin.HCl (0.010 g, 1.72 × 10-5 mol) was added along 
with NaHCO3 (0.005 g, 5.95 × 10
-5 mol). The solution was left to react at 4 °C in the absence of light 
for 48 hours. 2 mL of H2O was added and the methanol was removed by evaporating under vacuum. 
The sample was filtered through a 0.45 µm glass SEC prefilter, stored in a glass vial and frozen in 
liquid nitrogen for transportation to cryo-TEM analysis. DLS was performed immediately after 
preparation as well as after 24 hours at 25 °C in the absence of light. 
 
9.2.2) Synthesis of PVP-block-poly(L-lysine)-Benzaldehyde Dispersion in H2O 
Benzaldehyde (0.040 g, 3.77 × 10-4 mol) was dissolved in 20 mL methanol. PVP-block-poly(L-lysine) (4 
mg, 1.94 × 10-7 mol, ca. 7.29 × 10-6 mol of lysine residues) with Mn,NMR of the PVP block equal to 
15,800 g/mol and Mn,NMR of the poly(L-lysine) block equal to 4,800 g/mol (DP = 38) was dissolved in 2 
mL of the benzaldehyde solution along with NaHCO3 (0.005 g, 5.95 × 10
-5 mol). The solution was left 
to react at 4 °C in the absence of light for 48 hours. 2 mL of H2O was added and the methanol was 
removed by evaporating under vacuum. The sample was filtered through a 0.45 µm glass SEC 
prefilter, stored in a glass vial and frozen in liquid nitrogen for transportation to cryo-TEM analysis. 








9.2.3) Synthesis of Doxorubicin Dispersion in H2O 
Doxorubicin.HCl (0.010 g, 1.72 × 10-5 mol) was added to 2 mL methanol along with NaHCO3 (0.005 g, 
5.95 × 10-5 mol). The solution was left to react at 4 °C in the absence of light for 48 hours. 2 mL of 
H2O was added and the methanol was removed by evaporating under vacuum. The sample was 
filtered through a 0.45 µm glass SEC prefilter and DLS was performed immediately after preparation. 
 
9.3) Results and Discussion 
9.3.1) Synthesis of PVP-block-poly(L-lysine)-Doxorubicin as well as free Doxorubicin Dispersions 
DLS Analysis 
The complex refractive index of the PVP-block-poly(L-lysine)-Doxorubicin dispersion was set to 1.59 
+ 0.01i. This was the same approximation used in Section 7.2.5 as no refractive index measurement 
instrumentation was available. The dispersant refractive index was set to 1.330 and its viscosity was 
set to 0.8872 cP. The hydrodynamic diameter distributions of the PVP-block-poly(L-lysine)-
Doxorubicin dispersion, measured by DLS, immediately after sample preparation as well as after 24 
hours at 25 °C are illustrated in Figure 9.1. The initial mean hydrodynamic diameter was 194 nm, 
substantially larger than the 57 nm measured for the PVP-block-poly(Nε-(CBZ)-L-lys) dispersion. The 
standard deviation of the distribution was significantly low (83 nm) indicating that the dispersion 
was most likely the result of self-assembly into micelles rather than aggregation into a colloidal 
precipitate.  
 
Figure 9.1: Hydrodynamic Diameter Distributions for the PVP-block-poly(L-lysine)-Doxorubicin Dispersion. 




The increase in particle size could be due to the larger size of the Doxorubicin molecule compared to 
the CBZ protecting group as well as the oligomerization of Doxorubicin on some of the lysine 



































Scheme 9.2: Oligomerization of Doxorubicin on Lysine Residues of PVP-block-poly(L-lysine). 
Both the mean hydrodynamic diameter and the standard deviation of the PVP-block-poly(L-lysine)-
Doxorubicin dispersion increased to 461 nm and 293 nm, respectively, after 24 hours. This was 
indicative of aggregation occurring, resulting in the formation of a colloidal precipitate. The 
formation of a precipitate was visible and sedimented at the bottom of the sample vial after it was 
left standing for a sufficient amount of time. The hydrodynamic diameter distribution of the 
Doxorubicin dispersion measured by DLS is illustrated in Figure 9.2.  
 
Figure 9.2: Hydrodynamic Diameter Distribution for the Free Doxorubicin Dispersion. 
The mean hydrodynamic diameter and the standard deviation of this dispersion were calculated to 
be 602 nm and 251 nm, respectively. This distribution closely resembles that of the PVP-block-
poly(L-lysine)-Doxorubicin dispersion after 24 hours, complementing the theory that the imine 




bonds conjugating Doxorubicin to the PVP-block-poly(L-lysine) were hydrolyzed and the free 
Doxorubicin had aggregated to form a precipitate.  
 
Cryo-TEM Analysis 
Cryo-TEM analysis of the PVP-block-poly(L-lysine)-Doxorubicin dispersion was performed to obtain a 
more accurate measurement of the average particle diameter as well as to visualize the morphology 
of the micelles. A representative image of those acquired is illustrated in Figure 9.3.A. 119 particle 
diameters were measured from 18 images and a histogram of the measured values was plotted in 
Figure 9.3.B. 
 
Figure 9.3: A) Cryo-TEM Image of PVP-block-poly(L-lysine)-Doxorubicin Dispersion. B) Histogram of Measured Particle 
Diameters. 
The average particle diameter measured from the cryo-TEM images was 86 nm with a standard 
deviation of 25 nm. There were many cylindrical micelles observed, indicating that the hydrophobic 
block of the block copolymer had indeed increased in size, compared to that of the PVP-block-
poly(Nε-(CBZ)-L-lys) dispersion, causing an increase in the critical packing parameter.9  
 
9.3.2) Synthesis of PVP-block-poly(L-lysine)-Benzaldehyde Dispersion 
DLS Analysis 
The complex refractive index of the PVP-block-poly(L-lysine)-benzaldehyde dispersion was set to 
1.59 + 0.01i. This was an approximation as no refractive index measurement equipment was 
available. The dispersant refractive index was set to 1.330 and its viscosity was set to 0.8872 cP. The 




hydrodynamic diameter distributions, measured by DLS, immediately after sample preparation as 
well as after 24 hours at 25 °C are illustrated in Figure 9.4. The initial mean hydrodynamic diameter 
was 50 nm with a standard deviation of 16 nm. This indicated that the PVP-block-poly(L-lysine)-
benzaldehyde conjugates would self-assemble in aqueous solution to form micelles as the mean 
hydrodynamic diameter of PVP-block-poly(L-lysine) was 11 nm.  
 
Figure 9.4: Hydrodynamic Diameter Distributions for the PVP-block-poly(L-lysine)-benzaldehyde Dispersion as well as that 
for PVP-block-poly(L-lysine). 
The mean hydrodynamic diameter as well as the standard deviation of the PVP-block-poly(L-lysine)-
benzaldehyde dispersion did not change much after 24 hours at 25 °C (52 nm and 16 nm, 
respectively.) Thus it appeared as though the PVP-block-poly(L-lysine)-benzaldehyde dispersion was 
stable under ambient conditions and at pH ≈ 7.5. This cannot be confirmed by DLS alone and 
quantification of the release of benzaldehyde from the dispersion with time needs to be 
determined. This could be achieved by high performance liquid chromatography (HPLC),10 field-flow 




12 cryo-TEM images of the PVP-block-poly(L-lysine)-benzaldehyde dispersion were taken to study 
the morphology of the micelles as well as to gain a closer approximation of their mean particle 
diameter. A representative cryo-TEM image of the PVP-block-poly(L-lysine)-benzaldehyde dispersion 




is illustrated in Figure 9.5.A. 234 particle diameters were measured and a histogram of the data is 
illustrated in Figure 9.5.B. The average measured particle diameter was 12 nm with a standard 
deviation of 1.1 nm.  
 
Figure 9.5: A) Cryo-TEM Image of PVP-block-poly(L-lysine)-benzaldehyde Dispersion. B) Histogram of Measured Particle 
Diameters. 
The particle morphology was far more uniform – only spherical micelles were observed in all the 
images. This indicated that the hydrophobic block of the PVP-block-poly(L-lysine)-benzaldehyde 
conjugate was smaller in size than that of the PVP-block-poly(Nε-(CBZ)-L-lys), causing a decrease in 
the critical packing parameter. 
The apparent stability and uniform morphology of the PVP-block-poly(L-lysine)-benzaldehyde 
conjugate may be the key to improving the retention of Doxorubicin in the core. Instead of 
conjugating Doxorubicin alone to the PVP-block-poly(L-lysine), a formulation with benzaldehyde 
could be used. Benzaldehyde would also act as a capping agent, preventing the oligomerization of 
Doxorubicin and increasing the hydrophobicity of the peptide block. It could also be used to 
modulate the size of the micelles. The addition of a cross-linking agent, such as terephthalaldehyde, 
may increase the stability of the dispersion further.14-16 
 
9.4) Conclusions 
The conjugation of Doxorubicin and benzaldehyde to PVP-block-poly(L-lysine) via imine bonds 
occurred readily in methanol. These conjugates self-assembled into micelles in aqueous solution. 
PVP-block-poly(L-lysine)-Doxorubicin was not stable in H2O and dissociated into free Doxorubicin, 
that aggregated into a precipitate, and polymer. PVP-block-poly(L-lysine)-benzaldehyde was stable in 




H2O. The stability of the PVP-block-poly(L-lysine)-Doxorubicin conjugates in H2O may be improved by 
preparing a formulation with benzaldehyde, that would act by diluting the concentration of 
Doxorubicin conjugated to the peptide block (allowing control of the micelle size and morphology) as 
well as improving the hydrophobicity of Doxorubicin by capping the free amine of its daunosamine 
residue. This would also prevent the oligomerization of Doxorubicin. A cross-linking agent, such as 
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10.1) Thesis Synopsis 
The RAFT-mediated controlled radical polymerization of NVP, using O-ethyl-S-
(phthalimidylmethyl)xanthate (XA2) as the chain transfer agent, was demonstrated to suffer from 
slow pre-equilibrium phase kinetics as the phthalimidylmethyl radical was less stable than the 
propagating radical. The probability of radical transfer from a propagating radical to the 
phthalimidylmethyl leaving group at a given time during the polymerization was demonstrated to 
increase with a decrease in the ratio of monomer to RAFT agent. The optimization of this transfer 
probability was achieved by designing a semi-batch process for the RAFT polymerization of NVP with 
XA2. This semi-batch process ensured the ratio of monomer to RAFT agent was as low as possible 
while the pre-equilibrium phase was still active, taking into account the increase in reaction time as 
well as initiator-derived and terminated polymer chains. By this process, the effects of the poor pre-
equilibrium phase kinetics were mitigated and an improvement in the main equilibrium phase 
kinetics was also noted.  
A primary amine end-group functional PVP was prepared by reacting the phthalimide end-group 
with hydrazine in methanol. The xanthate end-group had to be removed beforehand to avoid its 
aminolysis. It was converted to an alkene end-group by thermolysis under vacuum. It was found that 
both the xanthate as well as the alkene end-groups were susceptible to hydrolysis in dilute acid 
solutions at ambient temperatures. Both formed an N-(1-hydroxyalkyl)amide end-group that would 
eliminate pyrrolidone at elevated temperatures and form an aldehyde end-group. The simultaneous 
removal of the xanthate and phthalimide end-groups was achieved by a three stage one-pot process. 
It involved the hydrolysis of the xanthate end-group to an aldehyde, reduction of the aldehyde end-
group to a primary alcohol with the simultaneous reduction of the phthalimide end-group to a 2-
(hydroxymethyl)benzamide and the acid hydrolysis of the benzamide to a primary amine. 
The amine-functionalized PVP was used as a macroinitiator for the ROP of Nε-(CBZ)-L-lys NCA to form 
a PVP-block-poly(Nε-(CBZ)-L-lys) block copolymer. The CBZ protecting group was removed by 
acidolysis with HBr in a 1,4-dioxane and DCM solvent mixture at 0 °C. Hydrogenation over a 
palladium catalyst proved promising as a milder alternative deprotection protocol but removal of 




the catalyst after the reaction proved to be extremely difficult due to the stabilizing adsorption of 
PVP to the palladium nanoparticle surface. 
The conjugation of Doxorubicin as well as benzaldehyde to the lysine residues via imine linkages was 
achieved in methanol and these conjugates were shown to self-assemble into micelles when 
dispersed in H2O. The Doxorubicin conjugates were quite unstable in aqueous solution at ambient 
temperatures while the benzaldehyde conjugates appeared to be relatively stable. 
 
10.2) Implications of the Research 
The improvement in the probability of radical transfer, when RAFT-mediated polymerization is 
performed in semi-batch mode, may also be observed for other RAFT agent-monomer systems that 
suffer from slow pre-equilibrium kinetics. The improvement in the probability of radical transfer 
between the propagating and dormant polymer chains of different length during the main 
equilibrium of a RAFT-mediated polymerization may also be observed. However, the degree that this 
effects the measurable parameters may vary, due to the increase in both initiator-derived and 
terminated polymer chains, and has yet to be accurately measured for the NVP-XA2 system. 
The deprotection of a phthalimide end-group was quantitative when hydrazine in methanol was 
used. However, hydrazine is extremely toxic and also can act as an initiator for the ROP of NCAs 
hence needs to be quantitatively removed from the product. This was achieved by extensive dialysis. 
The deprotection of the phthalimide end-group by reduction and subsequent hydrolysis proved to 
be quantitative and avoided the introduction of toxic or potentially interfering compounds, making 
product isolation less stringent. 
While the PVP-block-poly(L-lysine)-Doxorubicin conjugates were not sufficiently stable on their own, 
the observed stability of the PVP-block-poly(L-lysine)-benzaldehyde conjugates may be induced in 
the former by preparing a formulation of Doxorubicin and benzaldehyde with PVP-block-poly(L-
lysine). The benzaldehyde would also modulate the size of the hydrophobic block and prevent the 
oligomerization of Doxorubicin. Cross-linking agents, such as terephthalaldehyde, may also be 
incorporated into the formulation to further improve micelle stability. 
If a formulation of Doxorubicin with benzaldehyde and PVP-block-poly(L-lysine) proves to be 
sufficiently stable under the physiological conditions of blood plasma, the formulation can be 
transformed or enhanced through the substitution or addition of other chemotherapy drugs, such as 




Paclitaxel or Rapamycin, to the conjugate. The only limitation for such changes is that the new drugs 
must contain an aldehyde or ketone functional group. 
 
10.3) Future Research and Developments 
In order to ensure that the proposed drug-delivery system is considered for clinical trials, regardless 
of its efficacy, it needs to be composed entirely of biodegradable or excretable components. While 
the peptide block is biodegradable and should not pose a problem, the PVP block is not and thus 
needs to be below the renal excretion threshold. The PVP block cannot be too short either as this 
would affect the critical packing parameter for micelle morphology. Thus the lengths of the PVP and 
poly(L-lysine) blocks need to be optimized. The PVP block must be removable from the body via 
renal excretion while still providing a sufficiently low critical packing parameter for the block 
copolymer. The poly(L-lysine) block needs to be sufficiently long to induce the desired cell-
penetrating property.  
The work done so far focused on determining the stability of the imine conjugates in H2O. The future 
formulations should have their stability tested under the physiological conditions of blood plasma. 
Once a sufficiently stable formulation is devised, its dissociation sensitivity at endosomal pH (pH ≈ 4 
– 6) needs to be measured and the formulation should then be further optimized to ensure that the 
dissociation is sufficiently rapid. 
Another modification that could be performed to improve the stability of the micelles is to 
incorporate a ternary block to the block copolymer that is composed of a well-established pH-
sensitive polymer. Poly(L-histidine) is one such polypeptide. Since poly(L-histidine) and poly(L-lysine) 
both have relatively stiff backbones, incorporating a short poly(L-histidine) block between the PVP 
and poly(L-lysine) blocks should improve the stability of the imine bonds in the core of the micelle as 
the poly(L-histidine) block would form a shell around the core, preventing direct contact with the 
aqueous phase. Such a synthesis should be relatively simple since the transition between the 
histidine block and the lysine block does not need to be discrete. For instance, a gradient 
copolypeptide could be prepared by initiating the ROP of L-histidine NCAs with an amine end-
functional PVP and after a significant NCA conversion is reached, L-lysine NCAs are added. Ideally, 
the length of the histidine block should be as short as possible to avoid an excessive reduction in the 
cell-penetrating potential of the poly(L-lysine) block. However, studies accessing the effect of the 
poly(L-histidine) block length on the cell penetrating potential of the poly(L-lysine) block should be 
performed to determine the exact effect. 




Since the main reason for developing the imine conjugates as drug delivery systems was to 
incorporate poly(L-lysine) for its cell-penetrating potential, this property needs to be demonstrated 
for the block copolymer PVP-block-poly(L-lysine). If the PVP block prevents the poly(L-lysine) from 
performing non-classical membrane transport, a labile linker needs to be incorporated between the 
two blocks. Since the cell penetrating peptide should only be active within a tumor, an acid-labile 
linker should be used. One such linker is the acyl hydrazone bond that was discussed in Chapter 9. A 
theoretical method for forming an acyl hydrazone bond between the PVP and poly(L-lysine) blocks 
was devised and is illustrated in Scheme 10.1.  
 
Scheme 10.1: Preparation of PVP-block-poly(L-lysine) with an Acyl Hydrazone Bond Between the two Blocks. 
This method involves the formation of a Schiff base between hydrazine and an aldehyde end-
functional PVP, under conditions that ensure minimal cross-linking occurs. This hydrazone end-
functional PVP would then be used as a macroinitiator for the ROP of L-lysine NCAs. Since the 
hydrazone bond is acid-labile, an orthogonal protecting group, such as the 9- 
fluorenylmethyloxycarbonyl protecting group. No literature on such an initiator for NCAs has been 
found hence model studies should be performed to ensure such a reaction is possible. 
The ability of poly(L-lysine) to improve the uptake of chemotherapy drugs within various cancer 
cells, including multi-drug resistant ones, via the reversible imine bonds should also be investigated. 
Even though the imine bonds should be unstable in acidic media, their formation and dissociation is 
reversible and is most rapid at pH = 5 – 6. Hence there should be a certain fraction of drugs that are 
conjugated to the poly(L-lysine) block as it passes through a cell membrane. This type of transport 











A1) Conversion of SEC Traces to Molecular Weight Distributions 
A linear calibration curve was used for the SEC analysis with the following general form: 
log(MN)ln = é + êéd	                                                                                                                      (A1.1) 
Where 
     MN = Molecular weight as a function of elution volume 
PMMA = Poly(methyl methacrylate) 
         d = Elution volume in mL 
é and êé are the calibration constants. 
 
After linear baseline correction, the DRI signal was normalized according to Equation A1.2. 
Æ½O = ¼∑ë¼¼                                                                                                                                             (A1.2) 
Where 
                    O = Baseline-corrected DRI signal at >th data point 
                   NO = Weight of the >th data point = ë¼ë¼°y.ì/«µ                          
                   MNO = Molecular weight corresponding with >th elution volume 
111.14 g/mol = molar mass of the repeating unit for PVP 
 
Weighting Æ½O was performed to take into account the discrete distribution of possible molecular 
weights as well as to account for the biased sampling of the data points, as depicted in Equation 
A1.3. 
ÆO = Æ½O ×NO                                                                                                                                          (A1.3) 





Mn, Mw and Đ were then calculated using Equations A1.4, A1.5 and A1.6 respectively. 
M = ∑ë¼k¼∑k¼                                                                                                                                                  (A1.4) 
Mí = ∑(ë¼)"k¼∑ë¼k¼                                                                                                                                              (A1.5) 
Đ = 
îÌ                                                                                                                                                               (A1.6) 
 
For the analysis of copolymers, NO could not be determined without knowledge of the number of 
polymer chains between each data point. Hence, the data was treated as a continuous distribution. 
O was normalized by computing the integral between each adjacent data pair numerically, using the 
Trapezoidal rule, and adding them up: 
o ¹MN ≈ (ë¼ë¼°y)(¼¼°y)iOO                                                                                                           (A1.7) 
o ¹MN ≈ ∑o ¹MNOODOÚ                                                                                                                       (A1.8) 
ÆO = ¼o rë¼tÌ                                                                                                                                                (A1.9) 
 
Mn, Mw and Đ were then calculated using Equations A1.10, A1.11 and A1.12 respectively. 
M = ∑o MNOÆOOO ¹MN                                                                                                                        (A1.10)                        
Më = ∑o (ë¼)"k¼rë¼¼°y∑o ë¼k¼¼¼°y rë                                                                                                                             (A1.11)                  
Đ = 










A2) Least Squares Approximation of Kinetic Data  
A2.1) Kinetic Data from Section 3.2.4 
Æd = 2.6518  {|y}.~w}w + 0.3861                                                                                                    (A2.1) 
¸ï2 = 0.3627  ~uu}.xu" + 0.1362  y~y{w.w{" + 0.1377                                                            (A2.2) 
The first derivatives for [NVP] and [XA2] were calculated from Equations A2.1 and A2.2: 
rklr = (−3.3914 × 10).iæçà×D!u                                                                                             (A2.3) 
rmnir = (−1.0515 × 10)i.çàçà×D!u − (1.0340 × 10)æ.çàç×D!w                               (A2.4) 
 
A2.2) Kinetic Data from Sections 3.2.2 and 3.2.3 
ÆdzÚæ = 9.0182  yy}|".~|} − 0.0379                                                                                        (A2.5) 
¸ï2zÚæ = 0.0456  x"{.}{y + 4.4536 × 10                                                                            (A2.6) 
ÆdzÚàð = 7.7998  y{}~w.~|~u + 1.2546                                                                                        (A2.7) 
¸ï2zÚàð = 0.0456  x"{.}{y − 1.1693 × 10j                                                                            (A2.8) 
 
A2.3) Comparison of P(T) for XA2 with that for O-ethyl-S-(cyanoisopropyl)xanthate  
The following least squares approximations were made, using the data provided by Pound et al.,1 for 
the RAFT-mediated polymerization of NVP with O-ethyl-S-(cyanoisopropyl)xanthate (X1). 
Ædm,zÚð = 0.8420  "|"uy.xuw + 1.3057                                                                                       (A2.9) 
¸1m,zÚð = 1.3355  u{{x.wwyw − 0.9378                                                                                        (A2.10) 
 
 




A3) Calculating [M] for a Continuous Semi-Batch Process (CSB) 
The rate of initiator decomposition is described by the rate law: 
− rr = £r­                                                                                                                                                 (A3.1)                           
Where 
­ = concentration of initiator (mol.dm-3) 
£r = rate constant for initiator decomposition (s-1) 
C = reaction time (s) 
 
The analytical solution is found by the separation of variables technique: 
r = −£r¹C                                                                                                                                                  (A3.2) 
­ = ­D()                                                                                                                                          (A3.3) 
 
Since this is a unimolecular decomposition: 
­ = ­D()                                                                                                                                                 (A3.4) 
Where 
­ = No. of mols of initiator 
 
The rate of initiator-derived radical formation is given by the rate law: 
− r●r = 2¬£r­                                                                                                                                          (A3.5) 
Where  
­● = concentration of initiator-derived radicals (mol.dm-3) 
¬ = efficiency factor for the initiator in the specific reaction mixture 




The rate of initiation in the absence of alternative radical reaction pathways and in the presence of a 
large excess of monomer can be considered as: 
O = − r●r = 2¬£r­                                                                                                                                (A3.6) 
Where 
O = rate of initiation (mol.dm-3.s-1) 
 
The rate of termination is described by the rate law: 
 = ∑ ∑ 2£O,ññ O●òñ●óO                                                                                                                            (A3.7) 
Where  
 = rate of termination of propagating radicals (mol.dm-3.s-1) 
£O,ñ = rate constant for the termination of propagating chains of length > with chains of length ô 
(dm3.mol-1.s-1) 
 
The rate law can be simplified as follows: 
 = 2£∗●i                                                                                                                                               (A3.8) 
Where 
£∗ = IUPAC average termination rate constant (dm3.mol-1.s-1) 
● = concentration of propagating radicals (mol.dm-3) 
 
Under the steady state approximation, the rate of initiation is equal to the rate of termination: 
O =  
2¬£r­ = 2£∗●i                                                                                                                                     (A3.9) 
 




Since the volume of the reaction mixture does not influence the number of initiator molecules which 
undergo homolytic scission, equation A3.9 can be rewritten as: 
● = ¥  ∗ = ²¥¦! § ∗                                                                                                              (A3.10) 
Where 
d = Volume of reaction mixture (dm3) 
 
The rate of propagation is described by the rate law: 
− rr = ∑ £¤OO O●M                                                                                                                             (A3.11) 
Where 
£¤O  = rate constant for propagation of chains with length > (dm3.mol-1.s-1) 
 
Under a similar analogy to that for the termination rate constant, the rate law can be simplified to 
Equation A3.12. 
− rr = £¤●M                                                                                                                                   (A3.12) 
               = £¤M²¥¦! § ∗                                                                                                                   (A3.13) 
Where 
£¤ = average propagation rate constant (dm3.mol-1.s-1) 
In a semi-batch reactor, the change in concentration of monomer with respect to time can be 
described as follows: 
rr = rr ¶  +  rÓr = rr   + rr ¶  +  rÓr                                                                     (A3.14) 
Where 
MD = initial amount of monomer in the reactor (mol) 




M¥ = total amount of monomer fed into reactor from CD until C (mol) 
M = monomer which has been converted to polymer (mol) 
 
The first term describes the dilution of initial monomer molecules as the volume of the reaction 
mixture is increased. 
rr   = −" rr                                                                                                                                         (A3.15) 
 
The second term describes the change in concentration of the monomer due to propagation (the 
change in monomer concentration due to initiation being considered negligible). 
rr ¶  = −£¤M²¥¦! § ∗                                                                                                                (A3.16) 
 
The third term describes the change in concentration of monomer in the reaction mixture due to the 
monomer feed. The amount of monomer fed into the reactor from CD until C is given by Equation 
A3.17. 
M¥ = «¨                                                                                                                                                     (A3.17) 
Where 
« = Concentration of monomer in the feed (mol.dm-3) 
¨ = total volume of monomer feed added to the reactor from CD until C (dm3) 
 
the rate at which monomer is fed into the reactor is given by Equation A3.18. 
rÓr = « r r                                                                                                                                                 (A3.18) 
 
Substituting Equations A3.15, A3.16 and A3.18 into Equation A3.14 provides a complete explicit 
differential equation for the monomer concentration.  




rr = − ()" rr + ¡¢ r r − £¤M²¥¦! § ∗                                                                                      (A3.19) 
 
Since d = dD + ¨ 
rr = r r                                                                                                                                                          (A3.20) 
Hence 
rr = − ( )" r r + ¡¢( ) r r − £¤M²¥¦! § ∗( )                                                                           (A3.21) 
 
This is a non-linear first-order ordinary differential equation of three functions (M(t) ,	«(C)	and ¨(C)) of one variable (C). Hence two more equations are required to be able to simultaneously solve 
the system of differential equations. For instance, if the monomer concentrations in the reactor and 
the monomer feed are kept constant from CD to C, then the rate of monomer addition to the semi-
batch reactor can be computed from Equation A3.22. 
− ( )" r r + ¡¢( ) r r − £¤²¥¦! § ∗( ) = 0                                                                                   (A3.22) 
Where 
 = the constant concentration of monomer in the reaction mixture (mol.dm-3) 
 
Equation A3.23 expresses Equation A3.22 explicitly with respect to 
r r. 
r r = ®¡¡¢ ¯(°±)²¥
¦! §( ) ∗  ; ¨(0) = 0                                                                                     (A3.23) 
Equation A3.23 provides the rate at which the monomer feed needs to be added to the reactor 
during the reaction. 




Approximate solutions to the initial value problem can be obtained via numerical methods such as 
Euler’s Method, Predictor-Corrector or Runge-Kutta Methods. This will be useful in order to 
determine the concentration of the RAFT agent with time. Knowing that would allow us to calculate Mn,theory.  
 
A4) Calculation of [M] for a Discrete Semi-Batch Process (DSB) 
The rate of propagation for the time interval CO ≤ C < CO between monomer additions can be 
described by the kinetic mechanism for a batch process. 
− rr = £¤M²¥¼¦!( ! ¼)§ ∗¼                                                                                                                 (A4.1) 
Where 
­O = number of moles of initiator in the reaction mixture at time CO 
dO = Volume of reaction mixture at time CO (dm3) 
 
This differential equation can be solved analytically by the separation of variables technique. 
r = −£¤²¥¼¦!( ! ¼)§ ∗ ¹C                                                                                                                   (A4.2) 
M = i® ¥¼ ∗ ( ! ¼)"  + O                                                                                                       (A4.3) 
Where 
O = integration constant 
 
At the beginning of each time interval: 
M(C) = 	 MO                                                                                                                                               (A4.4) 
MO − i® ¥¼ ∗ = O                                                                                                                         (A4.5) 




Hence the concentration of monomer at any given time during the interval can be determined by 
the piecewise function in Equation A4.6. 
M = i® ¥¼ ∗ ( ! ¼)"  − 1% + MO			¬½	CO ≤ C < CO                                                   (A4.6) 
 
A5) Calculating Observed Rate Constants 
The parameters calculated for the determination of & for the polymerization of NVP with XA2 at 
various monomer to RAFT agent ratios are given in Table A5.1. & for the trial with R = 5 was 
computed by computing the slope of each adjacent data pair because although the linear correlation 
coefficient was 0.976, visual examination of the data (plotted in Figure A5.1.A) indicated that there 
was a non-linear correlation of the data at high monomer conversions. 
 
Figure A5.1: Plots of    versus   ( ! )"  − 1% for the Polymerizations Performed in Sections A) 3.2.4, B) 
4.5.1, C) 3.2.3 and D) 3.2.2. 




Table A5.1: Parameters for the Calculation of & for the Polymerization of NVP with XA2 at Various Monomer to RAFT Agent 
Ratios. 
(9*9  Time (s) [M] I0 (mol) V (dm
3
) @3  ((9% ² '9;<W¾4;<(009) % − õ¿ b 
5 0 3.033 5.48079E-05 0.00089 0 0 N/A 
5 664.992 2.80246 5.48079E-05 0.00089 -0.079054626 -0.376796789 0.209807058 
5 3664.98 2.04601 5.48079E-05 0.00089 -0.393660674 -2.044316744 0.188667036 
5 6665.004 1.49849 5.48079E-05 0.00089 -0.705094294 -3.660147789 0.192738976 
5 9664.992 1.14548 5.48079E-05 0.00089 -0.973728466 -5.225854571 0.171573742 
5 12664.98 0.91494 5.48079E-05 0.00089 -1.198449018 -6.743010473 0.148119618 
5 15665.004 0.75645 5.48079E-05 0.00089 -1.38867107 -8.213138373 0.129391499 
5 18664.992 0.64838 5.48079E-05 0.00089 -1.542830563 -9.637661827 0.10821829 
5 21665.016 0.56914 5.48079E-05 0.00089 -1.673181058 -11.01802865 0.094431779 
5 24665.004 0.5043 5.48079E-05 0.00089 -1.794136179 -12.35557548 0.090430569 
5 27664.992 0.46107 5.48079E-05 0.00089 -1.883757632 -13.65164643 0.069148571 
5 30665.016 0.43946 5.48079E-05 0.00089 -1.931760807 -14.90754245 0.038222253 
5 33665.004 0.41064 5.48079E-05 0.00089 -1.999590589 -16.12447965 0.055738112 
5 36664.992 0.38903 5.48079E-05 0.00089 -2.053651046 -17.30368095 0.045844978 
20 0 8.033625543 5.48079E-05 0.00112 0 0 N/A 
20 7500 3.133113962 5.48079E-05 0.00112 -0.94160854 -3.655655212 0.257575861 
20 0 8.033625543 5.48079E-05 0.00112 0 0 N/A 
20 6600 3.454458984 5.48079E-05 0.00112 -0.84397007 -3.23202437 0.261127 
20 0 8.033625543 5.48079E-05 0.00112 0 0 N/A 
20 7500 3.454458984 5.48079E-05 0.00112 -0.84397007 -3.655655212 0.230867 
117 0 8.998 2.07052E-05 0.002 0 0 N/A 
117 3000 6.92846 2.07052E-05 0.002 -0.261364764 -0.688499111 0.379615253 
117 6600 5.21884 2.07052E-05 0.002 -0.544727175 -1.486575066 0.355056946 
117 11100 3.50922 2.07052E-05 0.002 -0.94160854 -2.442668663 0.41510723 
117 14700 2.60942 2.07052E-05 0.002 -1.237874356 -3.17567458 0.404179297 
196 0 8.998 1.82693E-05 0.002 0 0 N/A 
196 7400 6.659 1.82693E-05 0.002 -0.301033007 -1.559172272 
0.193072 
196 14400 4.409 1.82693E-05 0.002 -0.713354424 -2.92663743 
0.301522 
196 20700 3.869 1.82693E-05 0.002 -0.844006255 -4.074303639 
0.113841 
 
A6) Calculating the Feed Times for the CDSB 
For the first interval, the time it would take for the reaction to reach 60% monomer conversion can 
be computed by Equation A5.1. 
C − CD = − i ln	¾1 + ln	(0.4) i®  ∗¥¿                                                                                           (A5.1) 
 




The following parameters were set: 
     MD = MDdD = MO    (No. of moles of monomer at C = 0)                                                            (A5.2) 
     M = MdD = M¥ = 0.4MD    (No. of moles of monomer at C = C)                                         (A5.3) 
Mrr = Mrr ödD (No. of moles of monomer added at the end of each interval)                       (A5.4) 
      ­D = ­O (No. of moles of initiator at the beginning of each interval.)                                             (A5.5) 
If the concentration of the monomer solution being added is that of the undiluted monomer and the 
reaction is done in the absence of solvent: 
Mrr ≈ MD                                                                                                                                              (A5.6) 
For the second interval, the concentration of monomer in the reaction mixture after addition of the 
monomer feed is: 
MiO = D.¯ÃyÃ = D.
yÃyÃ MD                                                                                                    (A5.7) 
Where 
ö is the volume fraction of monomer added relative to dD. The constant b can be considered 
as the dilution factor for monomer additions during the discrete semi-batch processes. 
The concentration of monomer after the second reaction interval is complete will be: 
Mi¥ = 0.4MD                                                                                                                                           (A5.8) 
Hence the reaction time for the second interval can be computed by: 
Ci − C = − i lnÁ
Â1 + i®² ∗
yÃ¥  ¾0.4 ÷ D.
yÃyÃ ¿Ä
Å                                                                 (A5.9) 
               = − i lnÁ
Â1 + i®² ∗
yÃ¥  ¾D.
"wÃD.yÃ¿Ä
Å                                                                       (A5.10) 
               = − i lnÁ
Â1 + i®² ∗
yÃ¥  ¾ 
yÃ w"Ã¿Ä
Å                                                                          (A5.11) 
For the third interval: 




MjO = D.yÃ¯Ã"Ã = D.
yÃyÃ"Ã MD =
D. {"Ã%"Ã MD                                              (A5.12) 
Mj¥ = 0.4MD                                                                                                                                        (A5.13) 
Ci − C = − i lnÁ
Â1 + i®² ∗
"Ã¥  Ô0.4 ÷ D.
{"Ã%"Ã ØÄ
Å                                                        (A5.14) 
               = − i lnÁ
Â1 + i®² ∗
"Ã¥  ¾ 
"Ã {"Ã¿Ä
Å                                                                          (A5.15) 
Suppose that for a certain reaction interval C − C: 
C − C = − i lnÁ
Â1 + i®² ∗
Ã¥  ¾ 
Ã~°""Ã ¿Ä
Å                                                                   (A5.16) 
Then for the interval Ci − C: 
M(£+1)> = 0.4M01+£êd0+M0d0Ã1+£êd0+1Ãd0 =
0.41+£ê+1Ã1+£+1ê  M0 =
0.41+2£+52ê %1+£+1ê  M0 =
0.41+2(£+1)+32ê %1+£+1ê  M0           (A5.17) 
M(£+1)¥ = 0.4MD                                                                                                                                   (A5.18) 
Ci − C = − i lnÁ
Â1 + i®² ∗
Ã¥  Ô0.4 ÷ 0.41+
2(£+1)+32ê %1+£+1ê  ØÄ
Å                                          (A5.19) 
                       = − i lnÁ
Â1 + i®² ∗
°yÃ ¥  ¾ 
°yÃ ~°"(°y)"Ã ¿Ä
Å                                                         (A5.20) 
Thus, by mathematical induction: 
CO − CO = − i lnÁ
Â1 + i®² ∗
¼Ã¥  ¾ 
¼Ã~°"¼"Ã ¿Ä
Å                                                                     (A5.21) 
 




A7) Calculating the Reaction Time as well as χ for R-group and Xanthate-
Functionalized Chains for the CDSB 
 
Considering Equation A3.4, the number of initiator-derived propagating radicals that are formed 
from CO to CO (Æ­>) can be calculated by equation A6.1. 
Æ­> = 2¬­>(1 − ¦−£¹(C>+1−C>§)                                                                                                                   (A7.1) 
The fraction of ω-xanthate functionalized chain ends can be computed as follows: 
Termination by combination is described by the rate law in Equation A3.8. By the steady-state 
approximation, ● can be calculated using Equation A3.10. 
Since every pair of radicals which undergo termination by combination form one terminated 
polymer chain, the formation of terminated polymer chains can be described as follows: 
rlÏr = −0.5 rl● ø¶r = 0.5 × 2£∗●i                                                                                                    (A7.2)     
Í = £∗ o ¥¦! § ∗ ¹C                                                                                                                         (A7.3) 
         = ¥ o ()¹C                                                                                                                             (A7.4) 
         = − ¥ (() − ())                                                                                                               (A7.5)      
   Í = −¬­D(() − ())                                                                                                              (A7.6) 
 
Thus the number of terminated chains that form during the interval CO − CO  is: 
ÍO = ¬­D(1 − ((¼°y¼)))                                                                                                                    (A7.7) 
 
The fraction of dormant chains after n intervals can be computed by: 
ÇÎ = m(∑ lÏ¼)Ì¼t m                                                                                                                                       (A7.8) 
Where 




Í> = the number of terminated chains formed during interval >   
 
A8) Calculating the Reaction Time as well as χ for R-group and Xanthate-
Functionalized Chains for the SDSB 
The first interval was kept identical to the CDSB.  The initial rate of dilution will also be the same. 
Hence, the change in [M] is: 
MiO = D. = .i MD = 0.7MD                                                                                       (A8.1) 
This translates to a decrease in the monomer conversion from 60% to 30%. Thus 
"Ó"¼  for the second 
interval will be: 
"Ó"¼ = D.D.æ = 0.5714                                                                                                                              (A8.2) 
For the third interval, 
~Ó~¼  will be the same as for the second interval. Hence, the amount of 
monomer needed to make MjO = 0.7MD can be calculated as follows: 
0.7MD = D.×iùiù                                                                                                                         (A8.3) 
0.7MD(2dD + Ù) − 0.4MD × 2dD = ÙMD                                                                                        (A8.4) 
0.6MDdD = 0.3ÙMD                                                                                                                                (A8.5) 
Ù = 2dD                                                                                                                                                           (A8.6) 
It would seem that the volume added at the end of each interval is twice that which was added at 
the end of the previous interval. To prove this, suppose the following relation is true: 
ÙO = 2ÙO                                                                                                                                                      (A8.7) 
Then for interval >: 
0.7MD = D.×¼!yù¼¼!yù¼                                                                                                                      (A8.8) 
 0.7MD(dO + ÙO) − 0.4MD × dO = ÙOMD                                                                                  (A8.9) 
0.3MDdO = 0.3ÙOMD                                                                                                                         (A8.10) 




0.3MDdO = 0.3ÙOMD                                                                                                                         (A8.11) 
ÙO = dO                                                                                                                                                       (A8.12) 
For interval	> + 1 
0.7MD = D.×(i¼!y)ù¼°yi¼!yù¼°y                                                                                                            (A8.13) 
0.7MD(2dO + ÙO) − 0.4MD × (2dO) = ÙOMD                                                                (A8.14) 
0.6MDdO = 0.3ÙOMD                                                                                                                     (A8.15) 
ÙO = 2dO = 2ÙO                                                                                                                                    (A8.16) 
Thus, by mathematical induction: 
ÙO = 2ÙO							∀	> > 1, > ∈ ℕ						(ÙD = 0, Ù = dD)                                                                              (A8.17) 
The length of each reaction interval after the first can be determined by: 
CO − CO = − i  Ô1 + Õ¼ (0.5714)Ø                                                                                     (A8.18) 
Where 
dO = dD + ∑ ÙOÚD                                                                                                                                       (A8.19) 
 
A9) Calculating the Reaction Time as well as χ for R-group and Xanthate-
Functionalized Chains for the s-CSB 
The rate of formation of initiator-derived chain ends Æ­ can be computed by solving the equation: 
− rkr = 2¬£r­D                                                                                                                                             (A9.1) 
Æ­(C) = 2¬£r­D(C + CD)                                                                                                                              (A9.2) 
ÇÈÉ  can be calculated by: 
ÇÈÉ = mmi¥()                                                                                                                                   (A9.3) 
The number of radicals at any time during the reaction can be computed by: 




● =  ¥ ∗( )                                                                                                                                          (A9.4) 
Thus 
rlÏr = (dD + ¨) × £∗  ¥ ∗( )%
i = ¬£r­D                                                                                            (A9.5) 
Thus 
Í = ¬£r­D(C + CD)                                                                                                                                      (A9.6) 
ÇÎ  can be calculated by Equation A9.7. 
ÇÎ = mm¥()	                                                                                                                                    (A9.7) 
 
A10) Determining the Amount of Diethyl Ether in a Polymer Sample with a 
Known Mn,NMR 
The difference in the amount of residual diethyl ether absorbed in two PVP samples that were 
derived from the same polymer but were isolated independantly can be accounted for by using the 
relation shown in Equation A10.1. This is especially useful if there is no longer a detectable end-
group to use as an internal reference for one of the samples and the backbone resonance at δ = 2.9 
– 4.2 ppm needs to be used. 
o ¬(á)¹áqÚ.iqÚi.à − ijo ¬(á)¹áqÚ.iqÚ. = o ¬i(á)¹áqÚ.iqÚi.à − ijo ¬i(á)¹áqÚ.iqÚ.                                   (A10.1) 
Where 
¬(á) = the 1H-NMR spectrum of the PVP sample that has a detectable end-group. 
¬i(á) = the 1H-NMR spectrum of the PVP sample without a detectable end-group. 
 
To normalize the 1H-NMR spectrum obtained for the sample prepared in Section 5.2.4 with respect 
to number of PVP chains for the sample prepared in Section 5.2.1, the left-hand side (LHS) of 
Equation A10.1 was computed and found to be equal to 377.46. Hence, Equation A10.1 can be 
reduced to Equation A10.2. 




o ¬i(á)¹áqÚ.iqÚi.à = ijo ¬i(á)¹áqÚ.iqÚ. + 377.46                                                                                     (A10.2) 
A numerical iterative procedure was performed to approximate this integral.  The first data set in the 
iteration is given below. 
o ¬i(á)¹áqÚ.iqÚi.à  = o ¬(á)¹áqÚ.iqÚi.à = 398.16  
o ¬i(á)¹áqÚ.iqÚ. D = o ¬(á)¹áqÚ.iqÚ. = 31.04  
This approximation assumes that the amount of diethyl ether in both cases was the same. The 
integral for the methyl protons of diethyl ether at the first normalization iteration was measured and 
the difference between the initial assumption and the first iteration was computed. 
o ¬i(á)¹áqÚ.iqÚ.  = 24.6  
o ¬i(á)¹áqÚ.iqÚ.  − o ¬i(á)¹áqÚ.iqÚ. D = −6.44 = ε  
ε < 0 Indicates that there was less residual diethyl ether in the PVP sample that was being 
normalized than in the PVP sample with a detectable end-group.  
The iteration was repeated until it converged to a value for ε that was lower than the precision of 
the NMR data. The procedure is given below. 
o ¬i(á)¹áqÚ.iqÚi.à  = o ¬i(á)¹áqÚ.iqÚi.à  + ij × ε  
o ¬i(á)¹áqÚ.iqÚ.  	>Ò	Òû½¹  











The results of the iterations are tabulated in Table A10.1. 
Table A10.1: Results of Iterative Procedure for Normalizing the 1H-NMR Spectrum obtained for the sample prepared in 
Section 5.2.4 with respect to number of PVP chains for the sample prepared in Section 5.2.1. 




0 N/A 31.04 N/A 
1 398.16 24.6 -6.44 
2 393.87 24.33 -0.27 
3 393.69 24.32 -0.01 
4 393.68 24.32 0.00 
 
A11) Normalizing the NMR Spectrum of the PFBA-Derivatized PVP using the 
Peak for the Vinyl Protons 
The fraction of xanthate-functionalized chains before thermolysis of the PVP sample was determined 
in Section 4.6.3 to be 0.85 compared to phthalimide chain ends. Since thermolysis quantitatively 
converts the xanthate end-group to an alkene, the fraction of alkene end-groups compared to 
phthalimide chain ends should also be 0.85. Hence the 1H-NMR spectrum for the PFBA-derivatized 
PVP can be normalized using the alkene protons peak at δ = 6.75 – 7.01 ppm. The interference from 
the carbon satellite of the chloroform peak has to be taken into account. This interference can be 
computed using Equation A11.1. 
o ¬(á)¹áqÚæ.DqÚð.æ − D.Di o ¬(á)¹áqÚæ.jjqÚæ. = 0.85                                                                                  (A11.1) 
Where 
¬(á) = the 1H-NMR spectrum of the PFBA-derivatized PVP sample. 
 
A first approximation assumed that there was no interference from the carbon satellite.  
o ¬(á)¹áqÚæ.jjqÚæ. D = 0.00  
o ¬(á)¹áqÚæ.DqÚð.æ D = 0.85  
o ¬(á)¹áqÚæ.jjqÚæ. was then measured and found to be equal to 3.05 




The error in the first approximation for o ¬(á)¹áqÚæ.jjqÚæ.  was computed 
ý = o ¬(á)¹áqÚæ.jjqÚæ. D − o ¬(á)¹áqÚæ.jjqÚæ.   
o ¬(á)¹áqÚæ.DqÚð.æ  could then be calculated using the general iterative procedure: 
o ¬(á)¹áqÚæ.jjqÚæ.  is measured and ý is computed using 
ý = o ¬(á)¹áqÚæ.jjqÚæ.  − o ¬(á)¹áqÚæ.jjqÚæ.   
o ¬(á)¹áqÚæ.DqÚð.æ  = o ¬(á)¹áqÚæ.DqÚð.æ  − D.Di ý  
 
The results of the iteration are shown in Table A11.1. 
Table A11.1: Results for the Iterative Procedure, Described in Appendix A11. 
3 ¾ü 8õ(7)<77Úþ.7Úþ.õ ¿3 ¾ü 8õ(7)<7
7Úþ.9õ
7Ú.þ ¿3 
0 0 0.85 
1 3.05 0.87 
2 3.12 0.87 
 
A12) Normalizing the 1H-NMR Spectrum of PVP-block-poly(Nε-(CBZ)-L-lysine) 
The PVP backbone peaks of the 1H-NMR spectrum for PVP-block-poly(Nε-(CBZ)-L-lysine) at δ = 1.14 – 
2.43 ppm were used as an internal reference. There are 6 hydrogen atoms on the lysine residues 
that also resonate in the region of interest. Since the benzyl hydrogens peak of the lysine residues 
are resolved from any interferences, their integration intensity can be used to determine the 
integration intensity of the interfering hydrogen peaks. This was achieved using Equation A12.1. 
o ¬(á)¹áqÚi.jqÚ. − 3o ¬(á)¹áqÚ.qÚ.ææ = 2o ¬i(á)¹áqÚ.iqÚi.à                                                                  (A12.1)  
Where 
¬(á) = the 1H-NMR spectrum for PVP-block-poly(Nε-(CBZ)-L-lysine)   
¬i(á) = the 1H-NMR spectrum of the thermolyzed PVP used to prepare the macroinitiator 




The first data set in the iteration was: 
o ¬(á)¹áqÚi.jqÚ.  = 2o ¬i(á)¹áqÚ.iqÚi.à = 2 × 426.17 = 852.98  
o ¬(á)¹áqÚ.qÚ.ææ  = 59.52  
The error in the first approximation for o ¬(á)¹áqÚi.jqÚ.  was computed using Equation A12.2. 
o ¬(á)¹áqÚi.jqÚ.  − 3o ¬(á)¹áqÚ.qÚ.ææ  = 2o ¬i(á)¹áqÚ.iqÚi.à + ý                                            (A12.2) 
ý = −178.56  
The subsequent data sets were computed using the following general iterative formulae. 
o ¬(á)¹áqÚi.jqÚ.  = o ¬(á)¹áqÚi.jqÚ.  − ý  
o ¬(á)¹áqÚi.jqÚ.  normalized to o ¬(á)¹áqÚi.jqÚ.   
o ¬(á)¹áqÚ.qÚ.ææ  measured from spectrum  
ý = o ¬(á)¹áqÚi.jqÚ.  − 3o ¬(á)¹áqÚ.qÚ.ææ  − 2o ¬i(á)¹áqÚ.iqÚi.à   
The results of the iterative procedure are tabulated in Table A12.1. 
Table A12.1: Results of Iterative Procedure for Normalizing the 1H-NMR Spectrum for PVP-block-poly(Nε-(CBZ)-L-lysine). 




1 852.98 59.52 -178.56 
2 1031.54 71.98 -37.38 
3 1068.92 74.59 -7.83 
4 1076.75 75.14 -1.65 
5 1078.40 75.25 -0.33 
6 1078.73 75.28 -0.09 
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